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 ABSTRACT 
The American University in Cairo 
 
Development of Honey/Chitosan Nanofibrous Scaffolds Loaded with Natural 
Materials and Bacteriophages: Evaluation of their Antimicrobial and Wound 
Healing Activities. 
BY: Wesam Awad Ahmed Sarhan 
Under the Supervision of Prof. Hassan M.E. Azzazy 
 
Non-healing wounds represent a serious health care burden with major socioeconomic impacts. 
Bacterial infection of the wound site further complicates the healing process as it stimulates the 
immune system which in turn prolongs tissue inflammation thus further delaying the healing 
process. Moreover, wound associated bacterial contamination usually develops resistance to 
commonly used antibacterials leading to increased risk of systemic infections. Treatment of 
infected wounds is being achieved via different kinds of dressings in association with 
antibacterials, antiseptics and wound healing materials. Currently, however there has been a 
noticeable shift towards advanced antimicrobial wound care as a possible solution for the problem. 
Advanced antimicrobial wound care are dressings that can be loaded with either antibiotics or 
antiseptics and are able to reduce or eliminate the bacterial load at the wound site. However, one 
of the major challenges associated with such dressings is the continuous emergence of antibiotic 
resistant strains as well as the observed damage of healthy tissues in case of antiseptics. Moreover, 
it has been argued that the antimicrobial efficacy alone of an advanced dressing is insufficient and 
other properties that enhance the wound healing process are also required. To help provide a 
solution for this challenge, this study aims to investigate the development of a novel series of 
advanced antimicrobial wound dressings that are based on honey and chitosan and fabricated in 
the nanofibrous form. Honey and chitosan are well known for their wound healing and antibacterial 
properties. Moreover, developing the dressings in the nanofibrous structure allows enhancement 
of the wound healing process. Electrospinning technique was adopted to fabricate novel 
nanofibrous wound dressings based on high honey and chitosan concentrations (HPCS). Natural 
extracts namely: Cleome droserifolia (CE) and Allium sativum (AE) and apitherapeutics namely: 
bee venom (BV) and propolis  (Pr) as well as bacteriophages (PS1) were loaded within the 
fabricated honey chitosan based nanofibrous dressings to enhance their antibacterial activity and 
extend it against resistant bacterial strains as well as increase their wound healing abilities. The 
fabricated series of nanofibrous dressings, HPCS, HPCS-AE, HPCS-CE, HPCS-AE/CE, HPCS-
BV, HPCS-Pr and HPCS-BV/PS1 demonstrated enhanced wound healing abilities and variable 
antibacterial effects against the examined bacterial strains as compared to the commercial wound 
dressing Aquacel Ag. Most importantly, the developed series of nanofibrous dressings 
demonstrated enhanced biocompatibility as compared to the Aquacel Ag that demonstrated 
noticeable cytotoxicity. Thus, the developed series of nanofibrous wound dressings that are based 
on natural materials represent competitive candidates to be used as effective wound dressings. 
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 1. BACKGROUND AND LITERATURE REVIEW 
1.1Wounds; Serious Health Care Burden 
Non-healing wounds represent a significant health care burden with a major socioeconomic impact 
of over $25 billion as the cost of complicated and delayed wound healing (Sen et al., 2009). That 
is in addition to the mortality and morbidity risk posed to mankind due to chronic wound 
complications (Kirketerp-Møller et al., 2011). Chronic non-healing wounds are those that do not 
follow the normal physiological process in healing staying opened for several weeks reaching to 
months. The most commonly encountered chronic wounds include diabetic foot ulcers, arterial leg 
ulcers, pressure ulcers, venous leg ulcers and burns (Siddiqui & Bernstein, 2010). Pressure ulcers 
were found to affect nearly one-third of the population undergoing treatment in a critical care unit 
with an annual total treatment cost reaching to $11 billion in the United States. Moreover, $2.3‒
$3.6 billion are spent by the National Health Service (NHS) for the treatment of pressure ulcers 
and the cost per each case of pressure ulcer treatment ranges from $5,000 to $65,000 per case. 
Diabetic foot ulcers which are a leading cause of foot amputations, are considered among the most 
commonly encountered complications with diabetes affecting nearly 15% of the diabetic 
population. The prevalence of diabetes is expected to reach 333 million by 2025, from which 10% 
are expected to suffer from diabetic ulcers according to the International Diabetes Federation. 
Diabetic foot ulcers are considered one of the most serious chronic wounds leading to major 
socioeconomic implications as it takes about 12 to 14 weeks for a diabetic wound to heal. It was 
concluded from a recent study conducted in Sweden that the costs per case for the treatment of 
diabetic foot-ulcer associated complications range from $16,500 for patients suffering from 
severely impaired circulations to nearly $63,000 with patients undergoing amputation (Abrigo et 
al., 2014). 
Healing of normal or acute wounds proceeds via a series of physiological phases that end up in 
functional and anatomic skin restoration (Figure 1). Normally, the wound healing process follows 
four distinct phases: hemostasis, inflammation, proliferation and tissue remodeling (Werner & 
Gorse, 2003). The hemostasis phase involves an immediate vascular and cellular response to the 
disruption of the skin surface. The arterial vessels constrict rapidly under the effect of various 
vasoactive mediators (norepinephrine, epinephrine, prostaglandins, serotonin and thromboxane) 
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 which lead to hypoxia and acidosis. Moreover, the exposed sub endothelium activates the 
aggregation of the platelets leading to clot formation. Platelet aggregation results in their activation 
which enables them to release growth and chemotactic factors as proteases, platelet-derived growth 
factor (PDGF) and other vasoactive agents (eg, histamine, serotonin). Consequently, this mediates 
a reflex vasodilation and increase in the vascular permeability which facilitates the entrance of the 
inflammatory cells and the beginning of the inflammatory phase in the healing process (Hunt, 
1988). The cellular components of the inflammatory phase include macrophages, lymphocytes and 
neutrophils. Neutropills are the predominant cell type at the beginning of the inflammatory phase, 
and while it is not essential to the wound healing process, its importance originates in its ability to 
cleanse the wound site from bacteria and necrotic matter. Macrophages on the other hand, are 
essential components in the early phase of the process of wound healing as they phagocytose 
bacteria and debris and release elastases, collagenases and PDGF which stimulates proliferation 
and chemotaxis of fibroblasts and cells of the smooth muscle. Additionally, macrophages produce 
substances that attract endothelial cells and stimulate their proliferation at the wound site to 
mediate angiogenesis. T lymphocytes play an important role in production of antibodies as well as 
cellular immunity (Broughton et al., 2006). 
 The proliferation phase involves the formation of granulation tissue which includes fibroblasts, 
neovascular and inflammatory cells within a matrix of collagen, fibronectin, proteoglycans and 
glycosaminoglycans. Additionally, the proliferation phase involves epithelization, fibroplasia, 
angiogenesis and contraction. Epithelialization involves the formation of epithelium which acts as 
a seal between the environment and the wound. Moreover, the epidermal cells secrete collagenases 
which stimulate plasmin production that promotes the dissolution of the clot. Migrating epithelial 
cells promote the keratinocyte adhesion in order to guide such cells across the base of the wound. 
In the fibroplasia phase, fibroblast and mesenchymal cells differentiate, moreover fibroblasts 
produce collagen, fibronectin, elastin, proteases and glycosaminoglycans. Fibroblasts grow and 
proliferate with the reduction in the number of inflammatory cells.  Angiogenesis which is 
promoted via the endothelial growth factor basic fibroblast growth factor, is important to sustain a 
blood supply to the formed tissue, which in turn lead to increased perfusion of various healing 
factors. As a final step in the proliferative phase the wound edge contract facilitating the closure 
of the skin defect at the wound site (Kirsner & Eaglstein, 1993). 
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 Tissue remodeling represents the final phase of the wound healing process, during which collagen 
undergoes increased organization. This proceeds via gradual disappearance of fibronectin and 
replacement of hyaluronic acid and glycosaminoglycans with proteoglycans. Type I collagen 
replaces type III collagen and water resorbtion occurs from the scar. This allows collagen 
crosslinking and decreasing the thickness of the scar (Hunt, 1988).  
Both acute and chronic wounds pass through the previously demonstrated phases, however chronic 
wounds exhibit delayed healing. In chronic wounds the normal series of physiological processes 
involved in healing is interrupted by the presence of persistent inflammatory stimuli. Such 
inflammatory stimuli result in increased production of metalloproteinases (MMPs) which lead to 
degradation of the extracellular matrix which in turn decreases the migration of cells and reduce 
the deposition of new connective tissue. Most importantly, such MMPs lead to the degradation of 
the growth factors, such growth factors that are essential and very important mediators for the 
normal series of mechanisms that are involved in all phases of the wound healing process. Thus, 
eventually leading to the disruption of the wound healing process (Bjarnsholt et al., 2008; Chen et 
al., 1999). This problem is overcomplicated by the increased level of contamination of chronic 
wounds by different kinds of bacteria. Such bacterial infection stimulates the immune system 
which in turn prolongs tissue inflammation thus further delaying the healing process. Moreover, 
chronic wound associated bacterial infection usually develops resistance to commonly used 
antibacterials showing great difficulty and resistance to be treated with common antibiotics and 
antibacterials, thus, leading to increased risk of systemic infections (James et al., 2008) 
A bacterial wound infection demonstrates various clinical symptoms that include edema, pain, 
erythema and purulent exudates (Robson et al., 1990). The quantity of bacteria at the wound site 
has been correlated to infection, where it has been suggested that bacterial counts of more than 105 
CFU/g may be indicative of infection at the wound site. However, this varies according to the type 
of the organism, its virulence and pathogenicity, as well as the interaction of the organism with the 
surrounding microflora and the hosts’ immune response (Bowler, 2003). Generally, the wound 
microbiology could be described in different phases: contamination, colonization and infection 
which could spread and lead to invasive infection and septicemia (Figure 2). Contamination of the 
wound site means presence of bacteria that are not replicating, whereas, colonization is the 
presence of bacteria that are replicating at the wound site without associated tissue damage. An 
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 infected wound is often associated with clinical signs of infection as well as tissue damage 
(Edwards & Harding, 2004). Therefore, wound infection results in delay in the process of wound 
healing. 
Different kinds of bacteria are involved in the process of wound healing, and they may be present 
at the wound site either as single bacterial species or as a polymicrobial load of two or more 
bacterial species. It was observed that the most common bacterial isolates were Staphylococcus 
aureus, Pseudomonas aeruginosa, Escherichia coli, Corynebacterium spp and Proteus mirabilis. 
Whereas, the most common species that are found in a polymicrobial infection were S. aureus, P. 
mirabilis, and P. aeruginosa with the most predominant associated combination between S. 
aureus/P. aeruginosa (Bessa et al., 2015). 
It was reported that Staphylococcus aureus was the most common Gram positive bacteria (40-60% 
of the total load of bacteria) isolated from variable kinds of wounds (Bowler, 2003; Brook & 
Frazier, 1998; Gjødsbølet al., 2006; Davies et al., 2004; Urbancic-Rovan et al., 2000; Korber et 
al., 2010).  Whereas, P. aeruginosa was the most predominant Gram negative isolate (Gjødsbøl et 
al., 2006; Davies et al., 2004; Halbert, 1992; Madsen, 1996; Burmølle, 2010). It has been observed 
that both P. aeruginosa and S.aureus produce destructive virulence factors that were found 
responsible for infection prolongation and delay in the wound healing process (Bessa et al., 2015). 
The production of different virulence factors as clumping-factor A, coagulase, leuocidines and 
catalase by S.aureus has been linked to clinically significant wound infections (Dissemond, 2009). 
Similarly, P.aerugionsa elastase has been linked to its pathogenicity at the wound site 
(Schmidtchen, 2003). Additionally, it was observed that a relevant percentage of the isolated 
S.aureus (Bessa et al., 2015) were methicillin resistant S.aureus (MRAS), and that MRSA is 
becoming a more prevalent wound pathogen (Demling & Waterhouse, 2007) thus further 
complicating the problem  of an infected wound. This is because a chronic wound infected with 
MRSA represents a source of a resistant nosocomial infection, additionally the presence of MRSA 
in a wound increases the risk further complication of the wound infection to septicemia (Demling 
& Waterhouse, 2007).  
Thus, the success in managing bacteria in wounds is of outmost importance. Generally, treatment 
of chronic wound infections is achieved via antimicrobial therapeutics either systemic or topical 
(Lipsky & Hoey, 2009). It was observed that ˃ 60% of chronic wound patients received antibiotic 
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 treatments for a long periods of time (Howell-Jones et al., 2005; Tammelin et al., 1998). Although 
antibiotic therapy revolutionized wound care, the increased and continuous emergence of resistant 
bacterial strains together with the marked decrease in the discovery of new antibiotics has 
necessitated the need to discover alternative antimicrobials (Cooper, 2004).  Thus, the use of 
topical antiseptic treatments has increased leading to reduction of antibiotic use in chronic wound 
treatments. The commonly used wound dressings in the treatment of chronic wound infections are 
traditional gauzes and bandages which are considered the most primitive and simple kinds of 
dressings that generally work only on achieving wound protection from trauma and bacterial 
contamination. Such traditional dressings are usually used in chronic wounds in association with 
other antibacterials, antiseptics and wound healing materials.  Currently, chronic wound treatment 
is witnessing an increasing shift towards advanced wound dressings. Advanced wound dressings, 
are dressings that aid and accelerate the wound healing process via exudate management, the 
ability to control infections and providing essential growth factors that enhance the healing process 
(Frost & Sullivan, 2014).  
Among the advanced wound dressings, antimicrobial wound dressings stand as an important sector 
that is most beneficial in the treatment of chronic wound infections (Abrigo et al., 2014). Such 
antimicrobial advanced wound dressings allow the sustained release of the loaded antimicrobials 
thus allowing the realization of their antibacterial activity while maintaining a healthy 
concentration to the healing tissues (Vowden et al., 2011).  
The most commonly available antimicrobial wound dressings are dressings loaded with antiseptics 
such as, as silver and iodine. Silver-based dressings stand as one of the most common and effective 
antimicrobial dressings used. However, despite their enhanced broad spectrum of activity, 
development of resistance has unfortunately been reported together with some undesirable side 
effects of silver (Lansdown, 2002). Thus, research into development of effective antimicrobial 
wound dressings based on effective antimicrobials that are more biocompatible and able to be 
effective against resistant bacterial strains is of great necessity. 
Among the advanced wound dressings nanofibrous advanced wound dressings stand as an 
important emerging sector (Zahedi et al., 2010). Nanofibrous based dressings allow pronounced 
wound healing ability as compared to other traditional dressings due to the high surface to volume 
ratio, morphological resemblance to the extracellular matrix (ECM) in the skin and thus promoting 
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 cell adhesion, proliferation, and migration. Additionally, nanofibrous dressings exhibit 
haemostasis capability and increased ability to absorb exudates as well as enhanced cell respiration 
due to high porosity. Most importantly, nanofibrous based dressings are easily loaded with 
different materials as extracts, drugs, antiseptics or others thus allowing enhancement of their 
wound healing and antibacterial abilities (Zahedi et al., 2010; Zhang et al., 2005; Kanani & 
Bahrami, 2010). 
1.2 Electrospun Nanofibers; Emerging Advanced Wound Dressings.  
Nanofibers are a class of nanobased materials with different and broad applications in different 
fields including environmental engineering, optical electronics, nanocatalysis, defense and 
security as well as pharmaceutical and biomedical applications. Nanofibers demonstrate multiple 
advantages that allowed it to be of great interest in different applications. Nanofibers exhibit 
increased surface to volume ratio, increased porosity, in addition to the ease of fabrication of the 
nanofibers from multiple polymers either natural, synthetic or combination of both and the 
feasibility of loading the nanofibers with different materials alone or in combinations (Cui et al., 
2006; Ramakrishna et al., 2006; Luu et al., 2003; Welle et al., 2007; Subbiah et al., 2005). 
Electrospinning represents a facile, cost effective and versatile technique for fabrication of 
nanofibers compared to other nanofiber fabrication techniques (i.e. phase separation or self-
assembly). In the electrospinning process, the polymeric solution is contained in a capillary, 
subsequently a droplet of the polymer solution forms at the capillary tip under a certain flow rate. 
A high voltage is then applied to the polymeric droplet and the droplet gets electrified leading to 
accumulation of charge at the droplet surface. At a certain applied voltage the electrostatic forces 
are able to overcome the polymeric solutions’ surface tension and the accumulated charge at the 
droplet surface causing the deformation of the formed droplet into a cone (Taylor cone), from 
which an ultrafine polymer jet is produced from the tip. The polymeric solutions’ charged jets 
travel towards the used collector and the solvent evaporates rapidly followed by the collection of 
ultra-fine dry fibers on the collector (Altstädt et al., 2008).The morphology of the collected fibers 
can be controlled via the adjustment of the different parameters of the electrospinning process (Teo 
& Ramakrishna., 2006). A detailed illustration of the electrospinning process as well as the 
different parameters affecting the fabricated nanofibers was provided via Bhardwaj and Kundu 
(Bhardwaj & Kundu., 2010). The basic setup for the electrospinner is shown in figure 3, whereas, 
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 Sahay et al and  Migliaresi et al provided a detailed review for more complex electrospinner set-
ups (Sahay et al., 2011 & Migliaresi et al., 2012). 
Currently, one of the main drivers in the wound dressing field is developing wound dressings in 
the nanofibrous form (Zhang et al., 2005). Nanofibrous wound dressings exhibit a number of 
intrinsic properties that make them of particular interest in wound healing applications. An ideal 
wound dressing should be capable of mimicking the natural extra-cellular matrix (ECM). The 
ECM is non-cellualar constituent present in all tissues, during wound healing it acts as a scaffold 
that allow cell attachment, differentiation and proliferation (Martins et al., 2007). Nanofibers due 
to their nanometer size in addition to their random alignment within the nanofibrous mesh mimic 
the architecture of the ECM. Thus, wound dressings in the nanofibrous form provide the cells with 
an artificial ECM  (Figure 4) promoting healing by encouraging tissue growth and leading to 
reduction in scar tissue formation as well as the required time for healing (Bhattarai et al., 2005). 
Moreover, the nano-pore sizes also assist in protecting injured tissues from bacteria and the high 
porosity and surface area enhance the absorption of fluids and the hemostasis. The nanofibrous 
mats exhibit high interconnected porosity (60-90%) (Kanani & Bahrami, 2010) thus, allowing 
high-gas permeation and cell respiration which prevent the dehydration of wounds (Zhang et al., 
2005).  The high surface area provided by the nanofibrous structure enhance the delivery of wound 
healing and antimicrobial agents, thus, eventually encourages wound healing (Diegelmann & 
Evans, 2004; Bhardwaj & Kundu, 2010). 
Electrospun nanofibers for wound healing applications have been fabricated from synthetic and 
natural polymers as well as combinations of both of them (Zahedi et al., 2010). Synthetic polymers 
facilitate the process of electrospinning and enhance the mechanical properties of the developed 
nanofibrous mats, whereas, natural polymers increase the biocompatibility of the resulting 
nanofibrous mats and enhance the ability of the nanofibers to interact with the biomolecules that 
are involved in the wound healing process (Gunn & Zhang, 2010).  
Initially, research involving development of nanofibrous wound dressings focused on optimizing 
the parameters of the process of electrospinning for fabrication of wound dressings with suitable 
mechanical, morphological and physico-chemical properties for providing dressings with suitable 
barrier properties that allow tissue protection and maintain the moisture level of the wound bed, 
such dressings that were referred to as passive dressings according to Abrigo et al (Abrigo et al., 
7 
 
 2014). Within this context, different types of nanofibers were fabricated from poly (urethane) (Khil 
et al., 2003), poly (vinyl alchol) (Phachamud & Phiriyawirut, 2011) and hyaluronic acid (Uppal et 
al., 2011), and both the morphological characterization and the invivo testing demonstrated their 
potential application as wound dressings. The hyaluronic acid nanofibers were proved to be more 
beneficial in treating full thickness wounds as compared to commercial wound dressings (Uppal 
et al., 2011).  
More recent developments in nanofibrous wound dressing research involved development of 
nanofibrous dressings that are capable of accelerating the wound healing process and treating or 
preventing bacterial infection. Abrigo et al., referred to such dressings as interactive dressings that 
are able to combine the optimal physical and morphological requirements needed for wound 
healing and the value-added ability to limit the proliferation of bacteria and address the optimal 
environment for cell proliferation and migration (Abrigo et al., 2014). Such dressings were 
achieved via developing the nanofibrous wound dressings from a combination of polymers of 
synthetic origin and biopolymers that have antibacterial ability and enhanced affinity towards the 
wound environment. A wide variety of reports could be found in literature addressing the use of 
synthetic and natural combinations in the fabrication of nanofibrous wound dressings. Kim et al, 
developed nanofibrous meshes from a combination of polyurethane and gelatin that demonstrated 
their potential effectiveness as wound dressings (Kim et al., 2009). Similarly, nanofibrous meshes 
from keratin and poly (hydroxybutylate-co-hydroxyvalerate) have been fabricated and were 
proved to enhance the process of wound healing (Yuan et al., 2015). Cheng et al., developed 
nanofibrous mats from the combination of poly (ethylene oxide), type I collagen and chitosan. 
Such dressings demonstrated enhanced wound healing ability invivo compared to traditional 
wound dressings (Chen et al., 2008). Additionally, different reports demonstrated fabrication of 
nanofibrous meshes as potential wound dressings from combinations of synthetic polymers and 
natural materials as honey, natural extracts and essential oils (Jin et al., 2013). Further development 
within the nanofibrous wound dressing research involves loading of such interactive dressings with 
antimicrobials, drugs and wound healing agents to further enhance the wound healing and 
antibacterial properties of the developed wound dressings, such dressings that were referred to as 
advanced interactive wound dressings (Abrigo et al., 2014) were reported in a detailed review via 
Meinel et al., (Meinel et al., 2012). Despite that advanced interactive wound dressings are able to 
control bacterial infection at the wound bed, initial burst release of the loaded antibiotics and drugs 
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 causes toxic effects to the healing tissue (Sill & von Recum, 2008; Agarwal et al., 2008). Thus, 
development of advanced interactive wound dressings that demonstrate no toxic effects to the 
healing tissues as well as enhanced antimicrobial and wound healing ability is of great demand. 
 
1.3 Honey and Chitosan; Powerful Wound Dressing Materials 
 
Honey and chitosan, two natural materials that possess a variety of favorable effects and exhibit 
particular importance in pharmaceutical and medical applications. Chitosan [(1–4)-linked 2-
amino-2-deoxy-D-glucopyranose], is a natural polymer that is derived from chitin which is 
considered as one of the most abundant polysaccharides found in nature (Ohkawa et al., 2004; 
Prashanth & Tharanathan, 2007; Sun & Li, 2011). Chitosan is a biocompatible, biodegradable 
polymer with wound healing and antibacterial capabilities (Schiffman & Schauer, 2007), that’s in 
addition to its ability to promote tissue regeneration and help achieve hemostasis (Zhou et al., 
2007). Such properties allowed chitosan to be the ideal polymer in different fields and industrial 
applications (Schiffman, & Schauer, 2007) as food (Tripathi et al., 2009), paper coatings 
(Vartiainen  et al., 2004), textiles (Lim & Hudson, 2003), ophthalmology (Alonso & Sánchez, 
2003), agriculture (Hanshou et al., 2000) as well as different biomedical applications (Jayakumar 
et al., 2010). Thus, numerous studies have electrospun chitosan into fibers with diameter of 
∼100 nm (Zhou et al., 2007). However,   the main drawback with such fibers was the inability to 
electrospin chitosan from its aqueous solution because of its high viscosity in addition to the strong 
hydrogen bonds forming in 3D networks and thus preventing the movement of the polymeric 
chains of chitosan under the influence of the electrical field (Homayoni et al., 2009; Zhou et al., 
2007). Such a character that forced either the use of toxic solvents to allow spinning of chitosan in 
considerable high concentrations reaching to 7% (Geng et al., 2005) upon using (90%) 
concentrated acetic acid, or reaching 3% upon using trifloroacetic acid and dichloromethane 
(Ohkawa et al., 2004). Residues of such solvents are not favorable especially in applications where 
totally biocompatible material is required as drug delivery, wound dressings and tissue 
engineering. To decrease the toxicity of the solvents (Charernsriwilaiwat et al. 2010, 
Charernsriwilaiwat et al., 2011) prepared chitosan in aqueous salt as CS–hydroxybenzotriazole 
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 /PVA and CS–ethylenediaminetetraacetic acid /PVA, however the amount of incorporated 
chitosan did not exceed 1%. 
Another approach for spinning chitosan was through co-spinning with other easily spun polymers 
in more biocompatible solvents. Among them, the composite Poly (vinyl alcohol)/chitosan has 
received great scientific interest either alone (Chuang et al., 1999; Paipitak et al., 2011; Zhang et 
al., 2007) or loaded/mixed with different materials to alter their characters to be suitable for 
different applications (Liao et al., 2011; Yan et al., 2012). Still such approach did not allow 
spinning of high chitosan concentrations.  
Chitosan nanofibrous mats have demonstrated enhanced antibacterial and wound healing effects 
via different studies. Chen et al., demonstrated that electrospun chitosan, collagen type I and 
poly(ethylene oxide) nanofibrous mats exhibited enhanced wound healing activity as compared to 
traditional dressings (Chen et al., 2008).  Spasova et al. utilized chitosan for coating poly(L-lactide) 
and composite poly L lactic acid/poly(ethylene glycol)  nanofibrous mats which resulted in 
enhanced antibacterial activity against S.aureus and well observed hemostatic ability, thus 
demonstrating the developed nanofibrous mats as possible wound dressings (Spasova et al., 2008). 
Chitosan has also been electrospun with silk fibroin and presented a possible candidate for wound 
dressing due to the demonstrated antibacterial effects and the ability of the developed nanofibrous 
mat to enhance fibroblast proliferation (Cai et al., 2010). Chitosan is commonly chosen for 
fabrication of nanofibrous wound dressings because it accelerates the wound healing process via 
its activation to the polymorphonuclear cells, its hemostatic and antibacterial abilities, in addition 
to its ability to promote fibroblast proliferation (Li et al., 2012; Chen et al., 2008; Duan et al., 
2006).  . 
Honey is another natural material of striking medical importance that has always played an 
important role in traditional medicine and is now seriously witnessing a revival in modern care 
medicine.  
Honey is a viscous hypersaturated sugar liquid mainly composed of fructose and glucose in 
addition to other compounds, especially phenolic compounds. Honey is a natural source of micro- 
and macro-nutrients with profound medicinal and nutritional properties (Khan et al., 2007). 
Honeys’ composition varies according to the floral source, season as well as other environmental 
factors. Honey exhibits anti-inflammatory, antioxidant and antimicrobial properties. Moreover, 
honey has strong wound healing activity (Molan, 2006) this is because of its debriding, 
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 deodorizing, antioxidant, antimicrobial and anti-inflammatory properties (Vandamme et al., 2013). 
Additionally, honey exhibits acidic nature that provides the optimal environment for fibroblast cell 
proliferation (Bardy et al., 2008). Currently, the therapeutic protocols undertaken in wound care 
depend on the use of silver. Such therapeutic protocols are considered useful in limiting the 
bacterial infections, however, due to the presence of excessive concentrations of ionic silver at the 
wound site, undesirable side effects have been recorded. Thus, this has initiated a new approach 
in wound healing that depends on the use of natural antimicrobials in everyday clinical practice. 
Consequently, despite its traditional daily use, honey is now licensed as a medical device either 
combined with a sterile dressing or sterile tubes (Dai et al., 2014). 
Unfortunately, electrospinning natural materials like honey is not possible as the process will result 
in either elctrospraying at low concentrations or spinneret occlusion at high concentrations of the 
electrospun materials (Lin et al., 2013). Such natural materials are only electrospun into nanofibers 
when they are blended with other polymers.  
In 2013, Maleki et al. were able to fabricate honey/polyvinyl alcohol nanofibers. Unfortunately, 
the maximum concentration that could be incorporated within the electrospun nanofibers was 
2.25% honey of the total weight of the nanofibrous mat (Maleki et al., 2013). Recently, Wang and 
He, worked on fabrication of high honey concentration nanofibers, however, the maximum 
concentration of included honey was 9% with 10% polyvinyl alcohol of the total weight of the 
nanofibrous mat (Wang & He, 2013). This is because of the decreased viscosity of the honey/PVA 
solution where increasing the concentration of honey results in remarkable decrease in viscosity, 
making it quite difficult to electrospin because the degree of chain entanglements is not high 
enough to tolerate the columbic stretching force that the charged jet is subjected to during 
electrospinning so results in bead formation and at higher honey concentrations inability for fiber 
formation (Maleki et al., 2013). Thus, there is a need to fabricate nanofibers composed primarily 
of high honey concentrations. Such concentrations will maximize the therapeutic and nutritional 
benefits of honey nanofibrous formulations in smaller dosage forms. 
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 1.4 Poly (Vinyl Alcohol); Biocompatible Synthetic Polymer for Co-
Electrospinning. 
Poly (vinyl alcohol) (PVA) is an artificial polymer that has been widely used in commercial, food, 
medical and industrial sectors. PVA is made via the hydrolysis of polyvinyl acetate resulting in a 
biodegradable, biocompatible polymer (Gaaz et al., 2015). PVA is a semi crystalline, hydrophilic, 
nontoxic polymer that has acquired increased attention due to its enhanced thermal stability, good 
resistance to chemicals, cost effectiveness and biocompatibility. Additionally, PVA readily forms 
a three-dimensional networks in aqueous media due to its hydrophilic nature, thus increasing its 
swelling capabilities (Supaphol & Chuangchote, 2008). 
PVA exhibits the extra advantage of excellent electrospinnability. Through the past few years, 
extensive literature have studied electrospinning PVA nanofibers and the different parameters that 
affect the electrospinning process (Zhang et al., 2005). 
Due to its advantageous properties PVA has been extensively used in co-spinning natural 
polymers, synthetic polymers, natural materials and biomolecules. Recently,   Li and  Yang have 
fabricated wool keratin /PVA blend nanofibers, which exhibited good interactions and better 
mechanical properties (Li & Yang, 2014). Similarly, silk fibroin protein and curcumin were made 
into nanofibers via co-electrospinning with PVA (Lin et al., 2015). Chitosan is a polymer that 
exhibits difficulty in electrospinning, thus it was electrospun with PVA in different studies in 
different ratios that affected the properties of the fabricated nanofibrous mats. Alhosseni et al., 
electrospun (PVA)/chitosan nanofibrous mats that exhibit large pore sizes for its application in 
nervous tissue engineering and observed that the fabricated mats exhibited the most optimum 
properties required to meet the main requirements for nerve cell proliferation (Alhosseni et al., 
2012). 
1.5 Natural Materials for Enhancing the Wound Healing and Antibacterial 
Properties of the Nanofibrous Wound Dressings. 
1.5.1 Natural Plant Extracts: Cleome Droserifolia and Allium Sativum. 
Recent research has realized the extent of dependence of the developed world on medicinal plants, 
where quarter of the prescriptions dispensed in the USA usually contains one or more ingredients 
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 derived from medicinal plants (Lewington, 1993). Plants exhibit a broad spectrum of activities 
making them useful in the treatment of different kinds of diseases. According to the WHO 80% of 
the health problems of worlds’ population could be treated by herbal medicinal drugs (Etkin 1981; 
WHO, 2003).  
Cleome droserifolia (Forssk.)Del. is a plant belonging to the Cleomaceae family and is plant of 
striking medical importance and a long history of ethnomedecinal use (Rahman et al., 2004; 
Muhaidat et al., 2015). Different species of this family are of considerable interest for the human 
health and nutrition (Jeruto et al., 2008; Gupta & Rao, 2012). Cleome L. (Cleomaceae), is a genus 
of ca. 200 perennial and annual herbs (Simpson, 2010) among them nine species are found in 
Egypt (Ezzat & Motaal, 2012). Cleome droserifolia which is an aromatic herb having orbicular 
sticky leaves, is the most famous member of the Cleome genus in Egypt (Boulos, 1999). Cleome 
droserifolia is traditionally widely used in Egypt by the Bedouins in the treatment of diabetes. The 
antihyperglycemic effects of the plant has been proven through different studies (El-Khawaga et 
al., 2010; Abdel-Kawy et al., 2000). Cleome droserifolia is also traditionally used for treating 
rheumatism, scabies and inflammation (Hussein et al., 1994)  that’s in addition to its proven 
antioxidant activity (El-Shenawy & Abdel-Nabi, 2004). The phytochemical studies revealed 
enrichment of Cleome droserifolia with different beneficial compounds including phenolics, 
flavonoids, terpenoids and alkaloids (Aboushoer et al., 2010; Abdel-Monem, 2012; Jane and Patil, 
2012). Cleome droserifolia has also demonstrated cytotoxic effects against different cancer cell 
lines (Ezzat & Motaal, 2012). However, studies regarding Cleome biological activity as well as its 
phytochemistry are still far from being complete (Muhaidat et al., 2015). 
Cleome droserifolia has recently been characterized for its antibacterial activity, Muhaidat et al, 
demonstrated the antibacterial activity of Cleome droserifolia oil against a wide range of bacteria 
(Muhaidat et al., 2015). The wound healing ability of Cleome droserifolia has been realized and 
utilized by the Bedouins who use a decoction of the herb and apply it to the wound site. However, 
no research studies have yet been conducted to evaluate the wound healing ability of Cleome 
droserifolia. 
Allium sativum (Garlic) is another medicinal plant that has been extensively explored and linked 
historically via different societies to its ability to treat different health problems (Durairaj et al., 
2009). Allium sativum has been used for different medicinal uses since about 5000 years ago, and 
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 was included in Chinese medicine from nearly 3,000 years. Moreover, Allium sativums’ medicinal 
value was recognized by different civilizations as the Greeks, Egyptians, Babylonians and 
Romans. In 1858, Allium sativums’ antibacterial activity was observed by Pasteur, additionally it 
was utilized as an antiseptic during World War I and II to prevent gangrene (Singh et al., 2008; 
Londhe, 2014). Allium is a genus that comprises more than 500 species that belong to family 
liliaceae (Pazyar & Feily, 2011). Allium sativm mainly contains enzymes, sulfur-containing 
compounds, minerals and amino acids. Other constituents as oligosaccharides, selenium, arginine 
and flavonoids are also found in Allium sativum (Aviello et al., 2009). The sulfur compounds found 
in Allium sativum are responsible for a large number of its medicinal properties (Pazyar & Feily, 
2011). 
 Allium sativum is currently well known for its use in different medicinal purposes and these 
include lowering of the blood pressure and cholesterol, prevention and treatment of cardiovascular 
diseases, antimicrobial activity as well as protective agent from cancer. (Cutler & Wilson, 2004; 
Tsao & Yin, 2001; Bakri & Douglas, 2005; Iwalokun et al., 2004). Such therapeutic effect of 
Allium sativum is mainly attributed to the water soluble and oil soluble organosulfur compounds. 
Allium sativums’ antimicrobial activity has been addressed extensively in literature against wide 
range of bacteria (Benkeblia, 2004; Ankri & Mirelman, 1999; Cellini, 1996; Ekwenye & Elegalam, 
2005). Such antibacterial activity is essentially important in wound healing due to the harmful 
effects of bacterial infection on the wound environment leading to delay in the process of wound 
healing. 
Despite the huge literature on Allium sativums’ different medicinal effects, its role as a topical 
treatment in wound healing was just recently investigated. In 2006, Sidik et al, have examined the 
effect of aqueous extracts of Allium and honey on the wound healing rate in rats. Their results 
demonstrated the enhanced wound healing rates upon application of the Allium and honey 
combination as compared to the use of honey only, thus elucidating the effect of Allium sativum 
on enhancing the wound healing rate. According to our knowledge this was the first investigation 
on the effect of Allium sativum on the wound healing process (Sidik et al., 2006). The effect of the 
concentration of the Allium sativum aqueous extract on the wound healing process was investigated 
via examination of the wound closure rate and subsequent histological examination of the wounds. 
The results demonstrated that 10% extract allowed enhanced wound healing rate compared to 5% 
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 extract and the positive control solcoseryl jelly, whereas, the histopathological examination 
revealed that the 10% extract and the solcoseryl jelly allowed enhanced tissue regeneration (Rokik 
et al., 2009). Aged Allium sativum extract was also investigated for the mechanism of its wound 
healing activity on skin wound on chicken and it was observed that Allium sativum increases the 
re-epithelialization process and allows for a profuse dose-dependent neovascularization (Ejaz et 
al., 2009). Thus, scientific evidence is introducing Alium sativum as a new frontier in wound 
healing agents which exhibits enhanced wound healing ability in addition to well observed 
antibacterial ability against different kinds of bacteria. 
It was observed that none of Cleome droserifolia and Allium sativum, have been co-spun into 
nanofibers. And with the enhanced medicinal properties of both materials such an approach should 
be investigated in different medicinal applications.  
1.5.2 Apitherapeutics: Bee venom and Propolis. 
Apitherapy involves the use of different bee products in the treatment of different human diseases. 
Apitherapeutics include honey, royal jelly, pollen, propolis, beeswax and bee venom. The use of 
apitherapeutics in human treatment dates back to thousands of years ago, and it was mentioned in 
different religious texts as the bible and the Quran, as well as several historical medical documents 
as the papyrus of Ebers (1550 BC) (Gupta et al., 2014). Propolis and beevenom stand as two of 
the most important apitherapeutics that have been used in the treatment of different diseases in 
traditional medicine and their biomedical value is now documented via different research studies. 
Bee venom is produced via the venom glands associating the sting apparatus of both the queens 
and the workers. Storing of the produced venom occurs in the reservoir of the bee venom and 
injection of the venom during the stinging process occurs through the sting apparatus (Schmidt & 
Buchmann., 1999). It was observed that approximately 0.15 – 0.30 mg of beevenom is injected via 
the bees’ stinger (Schumacher et al., 1989). Bee venom was recognized as being safe for human 
therapies, where the median lethal dose (LD50) is 2.8mg of venom per Kg of body weight for the 
adult human (Ali, 2012).  
 Bee venom contains several pharmacologically and biochemically active compounds, with some 
of them well studied and their mechanism of action elucidated (Bellik, 2015). Beevenom is mainly 
a mixture of enzymes, peptides and amines. It was observed that bee venom stimulated the immune 
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 system (Ali, 2012; Ram et al., 2014).  Melittin represents the major component of beevenom and 
was found to block neutrophil superoxide production (Somerfield et al., 1986) and suppress the 
inflammation via inhibition of the activity of the phospholipase enzyme (Saini et al., 1997). Such 
enzyme that is extensively released in severe inflammatory disorders and was found to cause 
degradation of tissues and organs (Mihelich & Schevitz, 1999). Bee venom is utilized in the 
treatment of different diseases as rheumatoid arthritis, lupus, sciatica, arthritis, multiple sclerosis, 
cancerous tumors, low back pain and others (Ali, 2012; Kwon et al., 2002; Kim et al., 2013). 
Additionally, bee venom exhibits antimicrobial, analgesic and antioxidant effects, thus suggesting 
that it could be a successful candidate for enhancement of the wound healing process (Khatun & 
Mukhopadhyay, 2013). Amin et al., have observed accelerated wound healing rates due to 
application of chitosan blend film containing bee venom on wounds which was related to the anti-
inflammatory activity of bee venom (Amin et al., 2008). Similar results were observed via Han et 
al., who compared the wound healing process in full thickness wounds after application of bee 
venom cream and the commercial silver sulfadiazine. The results demonstrated that the bee venom 
cream exhibited wound healing rates similar to that of the commercial silver sulfadiazine, 
moreover, the bee venom cream demonstrated enhanced anti-inflammatory effect (Han et al 2012). 
The wound healing effects of bee venom was also extended to diabetic foot infections. A hydrogel 
based on poly(vinyl alcohol) and chitosan and loaded with bee venom was tested on diabetic rats 
and the results showed accelerated rate of wound healing as compared to the negative control and 
similar anti-inflammatory effect to diclofenac gel (Amin & Abdel-Raheem, 2014).  Despite the 
favorable effects observed for bee venom on the wound healing process, developing combination 
nanofibrous wound dressings loaded with bee venom was not yet explored. 
Propolis is the generic name of a combination of resinous materials collected by the honey bees 
from plants, exudates and buds, then mixed with the bee enzymes and bee wax. The term propolis 
was coined by Aristotle from the Greek words pro meaning before and polis meaning city, which 
refers to before the city or defender of the city (Abu-Seida, 2015). Propolis is normally used by 
the bees to protect the bee hive via coating the inner walls, which provides a shelter against rain 
and wind and against the entrance of different intruders as insects, lizards and snakes and also 
prevents the bacterial and fungal growth. The amount of propoils collected via a bees’s colony in 
one year ranges from 150 to 200 g of propolis (Martinotti & Ranzato, 2015).  The major 
components of propolis include 50% resin, 30% bee wax, 10% aromatic and essential oils. 5% 
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 pollen and 5% other substances (Burdock, 1998). With the realization of advanced identification  
techniques as high-performance liquid chromatography (HPLC), gas chromatography (GC), and 
mass spectroscopy (GC-MS) numerous compounds have been characterized in propolis (Huang et 
al., 2014) including aromatic and aliphatic acids, esters, aldehydes, ketones, carbohydrates, 
vitamins and others. Among the different compounds found in propolis flavonoids stand as one of 
the most important compounds that possess increasing research interest (Marcucci, 1995). 
However, the composition of propolis varies according to the phyto-geographic character of the 
surroundings of the bee hive (Alves de Souza, 2013). 
Propolis exhibits different biological activities with respect to the human body that allowed it to 
be useful in the treatment of different diseases. Propolis is considered non-toxic to humans with 
safe concentration of approximately 1.4 mg/kg day or 70 mg/day (Wagh, 2013) Propolis content 
of polyphenols allowed it to exhibit strong antioxidant activity (Gulcin, 2012; Olczyk et al.,, 2013; 
Castaldo, 2002)  as well as anti-inflammatory activity in both acute and chronic inflammatory 
processes (Kuropatnicki et al., 2013; Sawicka et al.,2012). Propolis demonstrated strong ability to 
inhibit the development of different kinds of cancer (Xuan et al., 2014; Szliszka et al., 2011). 
Moreover, anti-hyperglycemic effect of propolis was observed in different studies (Matsui et al., 
2004; Fuliang et al., 2005). The antibacterial, antiviral, antifungal effects of propolis have also 
been documented (Tosi et al., 1996; Grange & Davey, 1990; Marcucci et al., 2001). Propolis also 
exhibits antiseptic, astringent, spasmolytic, anesthetic, antiulcer, and immunomodulatory effects 
(Kuropatnicki et al., 2013). 
Propolis has also demonstrated strong wound healing abilities where it allows a favorable 
environment for re-epithelization (Olczyk et al., 2014) it enhances skin cell proliferation (Sehn et 
al., 2009) and it was recently observed to be able to quench free radicals, thus allowing its safe 
application in burn treatment (Olczyk et al., 2013). Propolis was also observed to speed up the 
repair of burned tissue via stimulating the remodeling of the wound bed matrix, which could be 
linked to propolis flavonoid content which reduces lipid peroxidation and prevents cell necrosis 
(Olczyk et al., 2014). Additionally, invitro immunomodulatory and immunostimulatory effects on 
macrophages has been observed (Toreti et al., 2013). Another important property of propolis that 
enhances the wound healing process is its antibacterial activity. Different studies revealed the 
strong antibacterial activity of propolis, especially against Gram positive bacterial strains (Grange 
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 & Davey, 1990) Such antibacterial activities could be due to the synergistic activities of the 
different compounds found in propolis the most important of which is propolis flavonoid content 
(Abu-Seida, 2015).Thus, propolis role in enhancing the wound healing process could be attributed 
to its anti-inflammatory, antimicrobial and immumonodulatory properties (Castaldo., 2002). 
McLennan et al, demonstrated that a single topical application of propolis increases the wound 
healing rate of a full thickness cutaneous wound in a diabetic rodent model (McLennan et al., 
2008). Abu-Seida et al, observed enhanced healing of full thickness skin wound in dogs after 
application of propolis (Abu-Seida, 2015). 
Recently, propolis was electrospun into polymeric nanofibers via electrospinning polyurethane 
and propolis solution, and the results demonstrated that the inclusion of propolis within the 
nanofibrous mats allowed enhanced cell compatibility and increased hydrophilicity and 
antibacterial activities (Kim et al., 2014). Similarly, Sutjarittangtham et al fabricated nanofibers of 
polycaprolactone and ethanolic extracts of propolis via electrospinning (Sutjarittangtham et al., 
2012). Propolis was also electrospun with polylactic acid forming nanofibers that exhibited 
bactericidal activity (Sutjarittangtham et al., 2014). Recently, Adomavičiūtė et al., combined 
propolis and silver nanoparticles in poly (vinyl pyrrolidone) nanofibers and demonstrated the 
enhanced antibacterial activities of the developed nanofibers against a wide range of bacteria 
(Adomavičiūtė et al., 2016). This illustrates that propolis has been electrospun into nanofibers with 
different polymers, however none of the developed nanofibers were tested for their wound healing 
activities despite the previously reported enhanced effect of propolis on wound healing. 
1.5.3 Bacteriophages; Viruses Killing Bacteria 
Bacteriophages (phages), (Figure 5) are viruses that infect and rapidly destroy bacteria (Brüssow 
& Hendrix, 2002). Phages are considered as the most abundant microorganisms with an average 
number of 1030-1032 particles of bacteriophages. Humans are continuously exposed to phages via 
unprocessed food and water. Additionally, phages are found in the saliva, dental plaque and the 
intestinal tract. One milliliter of unpolluted water contains about 2 x 108 bacteriohage particles 
(Endersen et al., 2014). 
Felix d’Herelle introduced the term bacteriophage in 1917 and was the first to examine phage 
therapy. d’Herelle used phages against infections of livestock and even examined phages’ 
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 antibacterial therapeutic efficiency on himself. It was then noticed that Twort described the same 
phenomenon in 1915 and also Hankin in 1896 against Vibrio cholerae in the Ganges River (Twort, 
1915). In the 1920s, d’Hérelle utilized bacteriophages to fight different bacterial infections 
introducing new discipline that was defined as “phage therapy”. 
Phage therapy was utilized in different countries as the major antibacterial. Additionally, different 
pharmaceutical companies including E.R. Squibb & Sons (Princeton, NJ, USA), Swan-
Myers/Abbott laboratories, and Eli Lilly (Indianapolis, IN, USA) produced different bacteriophage 
commercial preparations (Monk et al., 2010). However, due to the poor understanding of phage 
properties in addition to the limited knowledge about different human diseases, variable outcomes 
were associated with phage therapy and thus their benefit was questioned via many specialists. It 
was in the 1940s when the utilization of bacteriophage ceased especially in Western countries with 
the introduction of the miracle antibiotics (Monk et al., 2010). However, with the alarming and 
continuous rise in bacterial resistance during the last two decades, together with the decrease in 
the introduction of new antibiotics, interest in phage therapy has been revived. An interest that has 
resulted in a number of companies in different countries for phage based products in food, 
diagnostics, agriculture, and therapeutics. 
Bacteriophages were proved efficient antibacterials through numerous studies and against different 
kinds of bacteria, they were also proven to be more efficient than potent antibiotics in the market 
as vancomycin, linzolid, ampicillins and trimethoprim (Smith & Huggins, 1982; Smith & Huggins, 
1983; Smith et al., 1987; Chibani-Chennoufi et al., 2004; Soothill, 1992).  Additionally, the studies 
revealed that phages therapeutic efficiency is extended also against resistant bacterial strains as 
vancomycin-resistant Enterococcus faecium strain (Biswas et al., 2002) and methicillin- resistant 
S. aureus (MRSA) (Matsuzaki et al., 2005).   
Bacteriophages were proved effective in enhancing the wound healing process via their ability to 
treat persistent bacterial infections in chronic wounds. Mendes et al., observed that the application 
of a topical bacteriophage cocktail to a wound in a diabetic animal model resulted in noticeable 
decrease in bacterial count and subsequent enhancement in the wound healing process (Mendes et 
al., 2013). Similar results were observed upon application of bacteriophages for the treatment of 
pseudomonas infections in burn wounds (Soothill, 1994; Ahmad, 2002). Bacteriophages were also 
efficient in eradication of bacterial biofilms in wound (Seth et al., 2013), this is considered very 
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 important as biofilms represent communities of surface associated bacteria that are enveloped in a 
hydrated extracellular matrix. Thus, they are considered as a source of persistent infection to the 
wound site particularly because of their resistance to conventional antibiotics. 
Due to the increased role of bacteriophages in human life there is a need for better storage 
techniques that will enable more stable and effective formulations for bacteriophage storage and 
transportation. Currently, freeze drying represents the most effective method for long term storage 
of bacteriophages (Miyamoto-Shinohara et al., 2000). However, freeze drying was found to be 
expensive and time consuming (Dai et al., 2014).   Electrospinning of bio-composite nanofibers 
was utilized as a novel technique for storing bacteriophages (Korehei & Kadla, 2013; Salalha et 
al., 2006; Lee & Belcher, 2004). However, none of the electrospun bio-composite nanofibers 
loaded with bacteriophage was further tested in different biomedical applications. 
Despite the promising research results of bacteriophages and despite the approval of the FDA for 
the utilization of phage in food preservation, different challenges are still facing the regulatory 
approval of bacteriophage based therapeutics. Among these challenges bacteriophages narrow host 
range stands as an important challenge that calls for innovative solutions. Each phage strain infects 
only one bacterial type (Sulakvelidze, 2011). In most situations cocktails of bacteriophages are 
utilized to broaden the host range and enhance the therapeutic efficiency. Nevertheless, approval 
of phage cocktails via the regulatory bodies is problematic, where they are more likely to approve 
a single phage strain thus other methods have also to be developed. 
Thus, there is a need to develop broad spectrum bacteriophage formulations that are not based on 
phage cocktails. Within this context developing a broad spectrum bacteriophage wound dressing 
will satisfy an urgent need of developing bacteriophage preparations that could achieve approval 
of different regulatory bodies. 
 
 
 
 
 
20 
 
 2. AIM & OBJECTIVES 
The aim of this study is to develop biocompatible nanofibrous antimicrobial wound dressing based 
on natural materials and to load the developed nanofibrous wound dressing with different natural 
materials (natural extracts, apitherapeutics and bacteriophages) for the aim of achieving enhanced 
biocompatibility and  wound healing activity as well as enhanced broad spectrum antimicrobial 
activity as compared to existing antimicrobial wound dressings. The objectives of the project are 
as follows: 
1-Electrospinning of uniform nanofibers based on high concentrations of honey and chitosan via 
biocompatible solvents. Evaluation of the effect of changing the honey concentration on the 
properties of the developed nanofibers.  
2-Fabrication of electrospun honey/chitosan based nanofibrous mats loaded with natural extracts 
to enhance the wound healing and antibacterial properties of the developed nanofibers. 
3-Fabrication of electrospun honey/chitosan based nanofibrous mats loaded with apitherapeutics 
to enhance the wound healing and antibacterial properties of the developed nanofibers. 
4-According to the results of objectives 2 and 3, one of the fabricated nanofibrous dressings will 
be further loaded with bacteriophages to achieve enhanced, broad spectrum antibacterial activity. 
At the same time, this will allow developing a broad spectrum bacteriophage formulation as a 
solution to one of the challenges of phage based therapeutics. 
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 3. MATERIALS AND METHODS 
3.1 Materials 
Chitosan (Mw, 240 kDa and DDA of 84%, Chitoclear, cg110, TM 3728) was purchased from 
Primex, Siglufjordur, Iceland. Fresh bulbs of Allium sativum (AE) were purchased from a local 
vendor. Cleome droserifolia (CE) were collected from the mountains of Sinai, Egypt. Poly (vinyl 
alcohol) (85,000 Da Mwt), ethanol (absolute, ≥99.8%), gluteraldehyde (25% in H2O) and 
Polyethylene glycol (6000 Da Mwt) were purchased from Sigma Aldrich (St. Louis, USA). Acetic 
acid (glacial, 99-100% purity) was supplied from Merck (Wadeville, South Africa). Muller Hinton 
broth, Nutrient broth, Nutrient agar, Luria-Bertani broth and agar-agar, were supplied from Oxoid 
(Basingstocke, UK). Aquacel ® Ag (ConvaTec Inc) was purchased from local pharmacy in Egypt. 
Fetal bovine serum (FBS), thiazolyl blue tetrazoliumbromide–MTT (M2128-1G), Phosphate 
buffered saline (PBS), Dulbecco’s modified eagle medium (DMEM) and triton X were supplied 
from Sigma Aldrich (St. Louis, USA). Honey (clover) (H) [viscosity: 15,300 mPas, total soluble 
solid content: 81%], Bee venom (BV) [amino acid content (histidine; 12.6%, alanine; 7.9%, 
cysteine; 6.44%, glutamic; 3.81%, tyrosine; 3.28%, valine; 3.02%, leucine; 2.87%, and 
methionine; 2.69%) protein and peptide content (Milittin; 51.6%, phospholipase A2; 15.4%, 
mastocyte degranulating peptide; 3.5%, apamin; 3.3%, minimine; 3.2%, hyaluronidase; 2.5%, 
adolopin; 1.6% and unkowns; 18.9)(Ahmed, 2006)] and propolis (Pr) [Total flavonone and di 
hydroxyl flavonal; 1.330 ± 0.140, total flavones and flavonals; 3.200 ± 0.162, total phenolic 
content 30.847 ± 0.064, Phenolic content (mg/100g) (phenol; 37.57, parahydroxy benzoic acid 
9.18, p.coumaric acid; 1.25, chrysin; 67.03, galangin; 70.13, daidzin; 42.97, acacetin; 48.32)  
total insoluble content (41.03 ± 0.16) and volatile substances content (4,10 ± 0.10) (Aly, 2012)] 
were provided from the faculty of Agriculture, Cairo University (Egypt).  
 
3.2 Methods 
3.2.1 Preparation of Aqueous Extracts of Allium sativum (AE), Cleome droserifolia (CE), and 
propolis (Pr). 
Bulbs of fresh AE were extracted according to the method of Al-Astal (Al-Astal, 2003). Fresh 
bulbs of AE (10 g) were peeled, washed with distilled water several times, then the AE was 
homogenized aseptically using a sterile mortar and a pestle. Subsequently, a Whatman No. 1 paper 
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 was used to filter the homogenized mixture. The obtained filtrate was then directly used in the 
preparation of the electrospinning solutions. On the other hand, dried leaves of CE were extracted 
according to established protocols (Ezzat & Motaal, 2012). The air dried aerial parts of CE were 
powdered and extracted via boiling in distilled water for two minutes and then allowed to stand 
for ten minutes before filtration. Whatman No. 1 paper was used to filter the boiled mixture. 
Subsequently, a rotary evaporator was used to remove the water and the remaining extract was 
dried in a vacuum oven at 40°C (Jeiotech, OV-11, South Korea) until a dry powder of CE extract 
was obtained. The powder was weighed and stored until further use. 
Aqueous extracts of propolis were prepared via covering propolis (500 g) with 1 liter of 20% 
aqueous ethanol solution as the solvent and placed in an amber glass container. The mixture was 
allowed to stand at room temperature for two weeks with periodic agitation. Subsequently, the 
mixture was filtered via Whatman No.1 filter paper. Dry propolis powder was achieved via 
incubating the filtrate at 70 °C. The dry powder achieved represents the water soluble propolis 
utilized in this study (Sosnowski, 1983). 
 
3.2.2 Preparation of the electrospinning solutions  
Different solutions were prepared with the aim of incorporation of the highest honey and chitosan 
concentrations using biocompatible solvents. Different weight ratios of PCS and HP as well as 
HPCS were prepared as follows: PCS (7%:1.5%, 7%:2.5% and 7%:3.5%); HP (20%:10%and 
30%:10%), and HPCS (30%:7%:1.5%, 30%:7%:3.5%, 30%:5%:5.5%, 30%:5%:4.5%, 
20%:7%:3.5%, and 40%:7%:3.5%). Solutions were prepared in 1% acetic acid. The HPCS 
solutions incorporating high honey and chitosan concentrations exhibited very high viscosity at 
the time of preparation thus they were aged at room temperature for different time intervals. 
Subsequently, HPCS solutions with different honey concentrations were prepared for studying the 
effect of changing the honey concentration on the prepared nanofibers. The solutions were 
prepared using the following weight% ratios; (10:7:3.5), (20:7:3.5), and (30:7:3.5) of honey, 
poly(vinyl alcohol), and chitosan, respectively dissolved in 1% acetic acid. Then, the as-prepared 
solutions were allowed to age at room temperature. 
For enhancing the antibacterial and wound healing activities of the fabricated nanofibers, natural 
extracts, namely Allium sativum (AE) and Cleome droserifolia (CE) and apitherapeutics, namely 
bee venom and propolis were loaded within HPCS nanofibers.   
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 Blend solutions of honey/poly (vinyl alcohol)/ chitosan/bee venom (HPCS-BV) and honey/poly 
(vinyl alcohol)/ chitosan/ aqueous propolis extract (HPCS-Pr) were prepared in the following 
concentrations weight % ratios (30:7:3.5:0.01) and (30:7:3.5:10) respectively.  The HPCS-BV and 
HPCS-Pr blend solutions were prepared in 1% acetic acid. Solutions were allowed to age at room 
temperature. 
Various blend solutions of honey/poly (vinyl alcohol)/ chitosan/ Allium sativum extract (HPCS-
AE), honey/poly (vinyl alcohol)/ chitosan/ Cleome droserifolia extract (HPCS-CE), and 
honey/poly (vinyl alcohol)/ chitosan/Allium sativum extract/ Cleome droserifolia extract (HPCS-
AE/CE) were prepared. In the preparation of the blend solution of (HPCS-AE), AE was used as 
50% of the solvent to which honey (30 w/v), chitosan (3.5 w/v) and poly (vinyl alcohol) (7 w/v) 
were dissolved. Both the blend solutions of HPCS and HPCS-AE were prepared in 1% of aqueous 
acetic acid. Both solutions were allowed to age at room temperature for 1 week. Cleome 
droserifolia dry powder extract (CE) (10 w/v) was added to both the as-prepared HPCS and HPCS-
AE blend solutions before electrospinning and stirred for 1h to form the blend solutions of HPCS-
CE (30:7:3.5:10 w%) and HPCS-AE/CE(30:7:3.5:10 w%) in 50% AE as the solvent, respectively. 
During preparation of all blend solutions, poly(vinyl alcohol) was dissolved separately in half the 
volume of the solvent at 100°C with stirring followed by addition of the remaining volume of the 
solvent with the other constituents to the cooled solutions to avoid any degradation of the active 
constituents due to exposure to elevated temperatures. 
 
3.2.3 Viscosity measurements.  
The viscosity of the poly(vinyl alcohol) (7%), PCS (7%:3.5%), HP (30%:7%), and HPCS 
(30%:7%:3.5% and 10%:7%:3.5%) samples were determined. The aqueous AE extract replaced 
50% of the solvent of the HPCS blend solution, thus, its effect on the viscosity of the blend solution 
had to be examined. The viscosity of the HPCS-AE (30%:7%:3.5%:50%) blend solution was 
determined using a viscometer (Myr; VR-3000, Viscotech Hispania, Tarragona, Spain). The 
solutions were aged for a week and the viscosity was determined at different time intervals (0, 24, 
48 h and 1 week). The average value of three measurements was reported as mean ± SD. 
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 3.2.4 Electrospinning of the as-prepared solutions 
The as-prepared solutions were loaded in a 5ml plastic syringe attached to a stainless steel needle 
(22 gauge) as the nozzle for electrospinning (E-spin, NanoTech, Kalyan-pur, India). Two 
electrospinners were utilized (NANON-O1A, MECC, Japan & E-spin, NanoTech, Kalyanpur, 
India). The nozzle was connected at a high electric potential and the distance between the nozzle 
and the collector, the flow rate and the voltage that allowed the most uniform nanofiber 
deposition were selected. A ground collector wrapped with aluminum foil and cotton gauze were 
used for collection of the samples.   
 
3.2.5 Cross-linking of fiber mats                                                                                                    
Physical and chemical methods were used to crosslink the nanofibrous mats of HPCS. 
Glutaraldehyde (GA) was used for chemical crosslinking. The fiber mats were placed in a closed 
desiccator that was saturated with GA vapors (40 ml). Exposure of the nanofibrous mats to the 
GA vapors was done for different time intervals (30, 60,120 and 180 min as well as 48 h and 72 
h). Subsequently, enhancement of the crosslinking reaction and removal of unreacted (GA) were 
done via heating the nanofibrous mats in an oven under vacuum at 40◦C for 24 h. Physical 
crosslinking was performed by freezing/thawing and heating techniques. Freezing and thawing 
was performed via freezing the fiber mats for 15 min in liquid nitrogen followed by thawing at 
room temperature for 15 min for three successive cycles. Heating was carried out under vacuum 
in an oven (Jeiotech, OV-11, South Korea) at both 110◦C, 100◦C for 15 min and 80◦C for 25 min 
as well as at 70◦C for 24 h. 
3.2.6 Characterization and measurements 
The morphologies of the electrospun nanofibers were observed using scanning electron 
microscopy (FESEM, Leo Supra 55, Zeiss Inc., Oberkochen, Germany) and transmission electron 
microscopy (Jeol, Musashino, Akishima, Tokyo, Japan). Image-J software was used for 
measurement of the diameters of the collected nanofibers. From three different images 100 fibers 
were measured for each of the developed nanofibrous mats. Subsequently, the average diameter 
and diameter distribution were determined. Fourier transform infrared spectroscopy (FTIR) was 
performed for the raw poly(vinyl alcohol) and chitosan and the HPCS nanofibrous mats 
(30%:7%:3.5%) using FTIR (Thermoscientific, Nicolet 380, USA). The transmission mode with 
KBr pellets was used for bulk chitosan and poly(vinyl alcohol) as well as and HPCS nanofibrous 
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 mats. The X-ray diffraction patterns of the HPCS nanofibers (30%:7%:3.5%) with increasing 
honey concentrations (10%H, 20%H & 30% H) were obtained using an XRD diffractometer 
(Bruker  4040, Karlsruhe, Germany) with a wavelength, λ=0.154 nm at 40 kV, 150 mA, and at a 
scan speed of 4° per minute in the 2θ range of 5°–80°.  Moreover, thermogravimetric analysis of 
the nanofibers was performed with a TGA analyzer (TGA Q50, TA Instruments). Samples were 
heated in a platinum pan under nitrogen atmosphere (60ml/min) up to 700 ºC, at a heating rate of 
10ºC/min. The stability of the nanofibrous structure was evaluated via SEM examination of the 
morphology of the crosslinked and non-crosslinked samples after storage for 1 year on shelf. 
Crosslinking of the stored samples was performed via exposure of the nanofibers to GA vapours 
for 1h and 3h followed by heating at 40ºC under vacuum. 
 
3.2.7 Evaluation of swelling and weight loss capabilities of the HPCS nanofibers                                
The swelling and weight loss abilities of the developed HPCS nanofibrous mats with increasing 
honey concentrations; 10:7:3.5, 20:7:3.5, and 30:7:3.5 (W%) as well as the HPCS nanofibers 
loaded with the natural extracts and apitherapeutics were evaluated. The mats were placed in 
phosphate buffered saline, PBS of a pH 7.4 at 37°C.  The following relationships were used for 
determination of the swelling ability of the nanofibrous mats at 1, 4 and 24 h, and their weight 
loss at 24 h: 
Degree of swelling (%) = [M-Mi / Mi] × 100              (1) 
 Weight loss (%) = [Mi-Md / Mi] ×100    (2) 
Where M is the weight of the swollen nanofibrous mats after plotting their surface with filter 
paper, Md is the weight of the dried nanofibrous mats after being removed from the phosphate 
buffer saline. The swollen nanofibrous mats were dried in an oven at 40°C until constant weight 
was achieved. Mi is the initial dry weight of the electrospun nanofibrous mats. 
 
3.2.8 Evaluation of the Antibacterial activity 
The viable cell count technique was used for the evaluation of the antibacterial properties of the 
developed nanofibrous mats.  The collected nanofibrous mats were sterilized via exposure to the 
UV for 20 minutes except for the bacteriophage loaded nanofibers that were aseptically collected 
and stored. Both of the developed nanofibrous mats and the Aquacel Ag (0.05 gm) were added to 
3ml sterile Muller Hinton broth. Subsequently an overnight bacterial suspension (30 ul) from each 
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 of the tested bacteria that was adjusted to 0.5 McFarland standard (1x 108 c.f.u. /ml ) was added to 
them. The tubes and a negative control were incubated at 37°C with agitation at 100 rpm for 24 h. 
Following the 2h incubation 10 ul from each treated bacterial suspension as well as the positive 
and negative controls were subjected to serial dilution. From every dilution 50 ul were added to 
nutrient agar plates and incubated for 24 h at 37°C. The surviving colonies on the nutrient agar 
plates were then recorded in plates that allowed counting from 10 to 150 CFU.  The experiment 
was repeated three times and the mean value of CFU was determined (Gallant‐Behm et al., 2005).  
Aquacel Ag (ConvaTec Inc) was evaluated for its antibacterial activity and utilized as the positive 
control. 
The antibacterial activity of the developed HPCS nanofibers with different honey concentrations 
were evaluated against Escherichia coli, Staphylococcus aureus at two different bacterial counts 
(1x 108 cfu /ml & 1x 107 cfu /ml). Upon loading the HPCS nanofibers with natural extracts, 
apitherapeutics and bacteriophages, the antibacterial activity was evaluated against Escherichia 
coli, Staphylococcus aureus, and resistant bacterial strains: Methicillin resistant Staphylococcus 
aureus (MRSA) and Multi drug resistant (MDR) Pseudomonas aeruginosa  at the bacterial count 
of  (1x 108 cfu /ml). 
 
3.2.9 In vivo wound healing studies 
The wound healing abilities of the developed nanofibrous mats were evaluated invivo on male 
mice weighing 25g. All animals were anaesthetized with a mixture of ketamin HCl (50mg/kg) and 
xylene HCl (20mg/kg) and their backs shaved followed by creating a 9 mm wound on the back of 
every mice using a biopsy puncher. The tested nanofibrous mats were UV sterilized for 20 min 
before placing them on the wound site except for the bacteriophage loaded nanofibers that were 
aseptically collected. Aquacel Ag (ConvaTec Inc) was utilized as a positive control, whereas 
untreated wounds covered with a cotton gauze were utilized as a negative control. The change in 
the wound size was evaluated at 3, 5, 7, 10 and 12 days. The wound area (%) that remained exposed 
represented the ability of wound healing for each of the examined samples. Three mice were 
evaluated for each of sample and the controls and the mean value for three measurements was 
recorded.  
Wound area (%) = [W (3, 5, 7, 10, 12)/W (0)] × 100 
Where W (0) and W (3, 5, 7, 10, 12) represents the exposed wound areas of the wounds on days 0 
and 3, 5, 7, 10 and 12 respectively. 
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3.2. 10 Histological examination and the scoring system used for the histologic outcomes  
The wound site and the surrounding skin and muscle were cut and fixed with buffered formalin 
(10%) then the samples were put in paraffin followed by sectioning. Five mice were treated with 
each sample and the positive control as well as five mice untreated. Tissue samples were taken 
from each mice at eaxh time interval. The collected samples were subsequently stained via 
Hematoxylin and Eosin (H&E) staining and Masson’s Trichrome staining (MT).  Samples 
collected on days 3, 5,7,10 and 12 were subjected to H&E staining whereas the MT staining was 
performed for samples collected on day 10. The stained tissue sections were evaluated according 
to the following histological outcomes: necrosis, hemorrhage, granulation tissue, amount of 
inflammatory infiltrates, epithelization and thickness of the epidermis and collagen deposition. A 
histologic scoring system was utilized to evaluate every parameter and a 0-3 score was assigned 
for every sample. Necrosis, inflammatory infiltrates, hemorrhage, epithelization, epidermis 
thickness and collagen deposition were graded as 0 (none), 1 (scant), 2 (moderate) and 3 
(abundant). Inflammation severity was scored as follows: 0 – (no inflammatory cells) no 
inflammation; 1– (scant inflammatory cells) 2 – (moderate inflammatory cells) 3 – (abundant 
inflammatory cells). The maturation of the granulation tissue was graded as: 0 (immature), 1 (mild 
maturation), 2 (matured), 3 (fully matured with collagen deposition). Collagen distribution (based 
on the distribution of the collagen fibers in the microscopic fields) was graded as: 0 (no collagen 
distributed), 1(non-uniform distribution), 2 (mild uniformity in distribution), 3 (uniform 
distribution) (Xie et al., 2013) 
 
3.2.11 Cell viability assay 
The developed nanofibrous mats as well as the commercial dressing Aquacel Ag as a positive 
control were evaluated for their cytotoxicity. The nanofibrous samples were sterilized for 30 min 
using the UV and then washed and soaked in PBS solution. The extract solutions of the tested 
samples were then filtered via sterile disposable filters (0.20 mm, Merck, Darmstadt, Germany). 
DMEM media was then used to make several dilutions of the extract (0, 25, 50 and 100%). Human 
fibroblast cells (HFD4, ATCC; crl-2522) (1x104 cells per well) were incubated for 24 h in a 96 
well plate. The different dilutions of the extract solutions were added to the plate followed by 
incubation at 37°C in a CO2 incubator. After 24h, the human fibroblast cells were incubated with 
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 the extract solution for 48 h.  Subsequently, 20 μl of the MTT [MTT: 3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide)] solution was added to every well and incubated for 4h. To 
evaluate the viability of the cells, the formazan crystals formed were dissolved in 200 μl DMSO 
and the optical density was recorded (595 nm). The results of the examined samples and the 
positive control were compared to those of an untreated control (Son et al., 2016). 
3.2.12 Cell proliferation.                                                                                                                                                
The effect of the developed nanofibrous mats as well as Aquacel Ag (positive control) on cell 
proliferation ability was evaluated. The human fibroblast cells (HFD4, ATCC; crl-2522) 
(1x104 cells/well) were seeded on the examined samples followed by incubation for 1 and 3 days. 
At every time point the examined samples were taken from the original plate to another 24 
culture plate containing 1 ml fresh media and 100 μl MTT solution per well and then incubated 
for 4h. The formed dark blue formazan crystals were dissolved in DMSO and the optical density 
was measured at wave length 595 nm (Son et al., 2016). 
3.2.13 Bacteriophage isolation, purification and characterization 
According to the previous antibacterial evaluation one of the examined bacteria was selected and 
used for enriching and isolating a virulent bacteriophage. Briefly, sewage samples were collected 
from different Egyptian hospitals and used for bacteriophage isolation. Samples (5 gm) were 
suspended in Luria-Bertani broth (30 ml) and 30 ul from an overnight culture of the selected 
bacteria was added and incubated with the mixture for 6h at 35°C with constant shaking in order 
to enrich the bacteria specific bacteriophage. Subsequently, choloroform drops were added to the 
mixture that was allowed to stand for 15 min and then filtered via Whatman No.1 filter paper to 
remove any solid particles. Bacterial cells and debris were removed via centrifugation of the filtrate 
for 5 min at 11,000 g. For amplification of the isolated bacteriophage, polyethylene glycol 6000 
(PEG 6000) (10%) and sodium chloride (1M) were put on the supernatant followed by incubation 
of the solution overnight at 4 °C  and then centrifugation at 11,000 g for 20 min. The pellet was 
dissolved in PBS (1ml) and then filtered via 0.22 μm filter for removal of the residual bacterial 
cells. Phage plaque assay was performed via mixing the amplified bacteriophage solution with 
exponential growth culture of the selected bacteria and allowing them to stand for 15 mins and 
then plating them with semi-solid agar medium (0.6%) followed by incubation at 35 °C for 4h. 
From the resulting plates a single plaque was selected and used for purification and amplification 
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 (Stenholm et al., 2008; Carey-Smith et al., 2006). This resulted in the collection of a concentrated 
phage stock solution (109-1010 PFU mL -1) 
For characterization of the isolated bacteriophage, an aliquot of the amplified phage suspension 
was put on a copper EM grid (400 mesh size) having a nitrocellulose surface backed with carbon. 
After 10 s of incubation, the copper grid was blotted using filter paper and 2% uranyl acetate and 
lead-citrate were used for staining. Subsequently, the copper grid was blotted again and then dried 
in air. Samples were observed via a Plus Transmission Electron Microscope (Jeol, Musashino, 
Akishima, Tokyo, Japan). 
 
3. 2.14 Electrospinning and antibacterial evaluation of the bacteriophage loaded nanofibers 
According to the antibacterial results of the HPCS nanofibers loaded with natural extracts and 
apitherapeutics, one of the nanofiber solutions is selected for subsequent loading with the isolated 
bacteriophage. The bacteriophage stock solution (1ml) was added to the selected nanofiber 
solution (9 ml) and agitated at 70 rpm for 1h. Subsequently, the mixture was subjected to 
electrospinning. The applied voltage, flow rate as well as the distance between the needle and the 
collector were selected based on the values that allowed the most uniform nanofiber deposition. 
The collected nanofibres were then subjected to antibacterial evaluation together with the 
nanofibers without the bacteriophage and Aquacel Ag as a positive control. The viable cell count 
technique was utilized to evaluate the antibacterial activity. The same steps followed in the 
previous antibacterial evaluation were undertaken.  
 
2.2.15 Statistical Analysis  
The results of the quantitative data are presented as mean ± standard deviation (SD). For in vitro 
experiments, average values were reported from three independently prepared samples. Results 
were evaluated statistically using students t-test was and a p-value of less than 0.05 was considered 
significant. 
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4. RESULTS & DISCUSSION 
 
4.1 Fabrication of Uniform Electrospun Nanofibers Based on High 
Concentrations of Honey and Chitosan (Sarhan & Azazzy, 2015a).  
4.1.1 Preparation of the electrospinning solutions  
Solutions of poly(vinyl alcohol)/chitosan (PCS), honey/poly(vinyl alcohol) (HP) and 
honey/poly(vinyl alcohol)/chitosan (HPCS) were prepared and tested for viscosity at different time 
intervals as shown in table 1. At zero time, the (HP; 30%:7%) exhibited very low viscosity (175 
mpas) and the (PCS; 7%:3.5%) exhibited extremely high viscosity (85,440 mpas) making both 
solutions impossible to spin. Whereas, the combination of (HPCS; 30%:7%:3.5%) exhibited at day 
zero 34,000 mpas. However, such viscosity value was still above the optimum viscosity needed 
for electrospinning. Consequently, the HPCS solutions were allowed to age for one week at room 
temperature.  
Interestingly, it was observed that the viscosity of the HPCS solutions decreased noticeably upon 
aging. This was unlike the PCS and the HP solutions that demonstrated increased viscosities after 
aging (Table 1). The decrease in viscosity with time that was observed with the HPCS solutions 
could be attributed to enzymatic degradation of chitosan by the enzymes that are found in honey. 
Honey contains small amounts of enzymes, including enzymes that are able to transform 
polysaccharides into smaller products as amylase. Such enzymes most likely degrade chitosan into 
its oligosaccharides (Xie et al., 2011). Additionally, hydrogen peroxide, which is a major 
component of honey, may have contributed to the enzymatic degradation of the chitosan backbone 
(Brudzynski, 2006). Interestingly, it was observed that increasing the honey concentration within 
the HPCS mixtures allowed further reduction in the viscosity of the solutions as demonstrated in 
table 1. 
4.1.2 Electrospinning and characterization of the morphology and functional groups of the 
developed nanofibers.  
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 Different concentrations of the PCS, HP and HPCS were electrospun (E-spin, NanoTech, Kalyan-
pur, India). For the PCS combinations, the highest concentration of chitosan that could be 
electrospun with polyvinyl alchol using 1% acetic acid, was 1.5% at 20 kV, 10ul/min as the flow 
rate and 15 cm distance between the collector and the needle. On the other hand, for the 
combinations of HP, the highest honey concentration that could be electrospun with polyvinyl 
alcohol was 20% honey (Figure 6a) at 22 kV, 10ul/min as the flow rate and 15 cm distance between 
the collector and the needle. However, clusters were observed within the electrospun nanofibers, 
which are most probably honey clusters that could not be included within the HP nanofibers. 
Remarkably, upon addition of 3.5% chitosan to the same combination of HP, uniform nanofibers 
were achieved (Figure 6b). This is attributed to the favorable effect of chitosan on solution 
viscosity, allowing it to reach to the optimum degree required for chain entanglements needed to 
form uniform nanofibers. However, upon increasing the concentration of honey to 30% within the 
HP combination, the clusters of honey increased extensively even after changing the parameters 
of electrospinning (Figure 6c). This indicates that the poly(vinyl alcohol) polymer is incapable of 
incorporating higher honey concentrations even at increased concentrations of poly(vinyl alcohol), 
where the reduction in viscosity imparted by honey on the HP combinations could not be overcome 
by increasing the poly(vinyl alcohol) concentration. On the other hand, increasing the 
concentration of chitosan within the PCS combinations resulted in extremely viscous solution that 
was impossible to electrospin (Table 1). Interestingly, aging the combination of HPCS 
(30%:7%:3.5%) for more than 2 days allowed it to reach to the optimum viscosity required for 
easy electrospinning and collection of uniform nanofibers at 24 kV, 10ul/min as the flow rate and 
15 cm distance between the collector and the needle (Figure 6d). The combination of HPCS 
allowed for the first time the fabrication of biocompatible nanofibers containing high honey and 
chitosan concentrations using biocompatible solvents.  
Realizing the synergistic effect of the combination of chitosan and honey on the HPCS solutions’ 
viscosity, attempts were made to increase incorporated honey and chitosan concentrations. 
Electrospinning 35% and 40% honey within the PCS (3.5%: 7%) combination was successful 
(Figures 7a and b). Moreover, electrospinning 4.5% and 5.5% chitosan within the HP combinations 
containing 30% honey was achieved (Figures 7c and d). However, the concentration of 
incorporated P was decreased to 5% because of the increased viscosity of the solution due to the 
increased concentration of incorporated chitosan.  
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In previous attempts to fabricate nanofibers with high concentration of honey, the maximum 
concentration of honey that was electrospun with poly(vinyl alcohol) was 9% (Wang & He, 2013). 
This is due to the remarkable decrease in the solution viscosity upon increasing the honey 
concentration, thus making it impossible to electropsin. This is the first report to fabricate 
nanofibers with concentrations of honey reaching to 40% of the weight of the nanofibrous mats. 
Furthermore, the favorable effect of honey on the chitosan solution viscosity upon aging allowed 
for incorporating higher chitosan concentrations reaching to 5.5% for the first time via 
biocompatible solvents. 
Despite the success achieved in electrospinning HPCS nanofibers containing 35% and 40% honey, 
the electrsopinning rate of such nanofibers was very slow leading to an increase in the collection 
time of the nanofibrous mats, especially with the single needle prototype electrospinner utilized in 
this study. Thus, the HPCS nanofibers with 30% honey were selected for completing the study due 
to the feasibility of their collection with the current electrospinner. However, with the advancement 
witnessed with multi-needle, needless and large scale electrsopinners, collection of nanaofibers 
with 40% and more honey should be feasible. On the other hand, HPCS nanofibers with 3.5% 
chitosan were selected for completing the study, because of the longtime of aging required for the 
5.5% chitosan solution to allow it to reach to the viscosity optimum for electrospinning, in addition 
to the slow electrospinning rate. 
The FTIR spectra of the powders of CS and P as well as the HPCS nanofibers were analyzed. 
Chitosan showed characteristic bands at 3429 cm−1and 1655 cm−1corresponding to both the OH 
and the amide O C NH2 groups. The CH3and CH3O groups showed bands between 1000 and 
2000 cm−1 (Paipitak et al., 2011). Poly(vinyl alcohol) exhibited bands at 3429 cm−1, 2923 
cm−1,and 1444 cm−1 corresponding to the characteristic bands of OH, CH2, and CH OH groups 
(Yan et al., 2012). 
The previous characteristic bands observed for both P and CS were preserved in the resulting 
HPCS nanofibers. However, it was realized that the absorption peak at 3429 cm−1and 1655 cm-1 
corresponding to both the OH and amide O C NH2 groups shifted to a lower wave number in the 
hybrid HPCS nanofibers. The characteristic peak observed in the HPCS nanofibers at 1058 cm−1 
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 could be attributed to the C O C symmetric stretching and C O H bending vibrations of the proteins 
found in honey. Whereas, the amide band of the protein found in honey could be realized at 1641 
cm−1 (Philip, 2009). Moreover, the peaks observed between 900 cm−1 and 750 cm−1 were 
attributed to the anomeric region, which is characteristic of the saccharide configuration of honey 
(Jaganathan & Mandal, 2009; Philip, 2010). 
4.1.3 Crosslinking and characterization of the morphology of the nanofibers before and after 
cross-linking treatment.  
It was observed that the HPCS nanofibrous mats lost their nanofibrous structure upon being in 
contact with aqueous media. Thus, different crosslinking techniques were undertaken, in order to 
achieve sufficient crosslinking degree without jeopardizing the nanofibers’ biocompatibility. 
During crosslinking care was taken not to expose the nanofibers to temperatures exceeding 110◦
C to avoid the reduction in the quality of honey with increase in the hydroxymethylfurfural content 
upon exposure to elevated temperatures (Tosi et al., 2004). It was reported that exposure of honey 
to 40◦C for up to 96h does not affect any of the biomolecules found in honey (Molan, 1992). 
The fabricated nanofibers were chemically crosslinked via exposure to the GA vapors for different 
time intervals followed by heating at 40◦C for 24 h under vacuum to enhance the crosslinking 
efficiency and remove any unreacted residues of the GA.  Figure 9 illustrates the images of the 
nanofibers that were chemically cross-linked after being immersed in PBS for 15 min. It was 
observed that the nanofibers subjected for three days to GA vapors demonstrated superior 
crosslinking (Figure 9a) where their original shapes were maintained with no swelling observed. 
Whereas, the nanofibers exposed for two days to GA vapors demonstrated similar results, however 
slight swelling was noticed (Figure 9b). Interestingly, it was realized that the nanofibrous structure 
could still be maintained with some swelling observed after exposure to GA vapors to three hours 
(Figure 9c). Meanwhile, upon reduction of the exposure time to GA vapors for 1 h (Figure 9d) 
lower crosslinking efficiency could be realized (Figure 9d), where partial degradation of the 
surface layers of the nanofibers began together with noticeable swelling of the nanofibers. It is 
worth mentioning, that the crosslinking efficiency noticeably decreased upon reducing the 
exposure time to the GA vapors for thirty minutes, where the nanofibrous morphology of the 
surface layers was nearly lost, probably because of the increased percentage of degraded fibers.   
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 The different physical crosslinking procedures undertaken were heating at different temperatures 
for different periods of time and different cycles of freezing and thawing in liquid nitrogen for 
different time intervals.  It was observed that crosslinked nanofibers were achieved upon heating 
the nanofibrous mats at 110◦C for15 min (Figure 9e), with noticeable swelling realized. 
Meanwhile, heating for 24 h at 70◦C demonstrated partial degradation of the swollen nanofibers 
(Figure 9f). Heating causes induction of the crystallization of the polymers forming the nanofibers 
(Kang et al., 2010). On the other hand, freezing and thawing did not allow maintaining of the 
nanofibrous structure. It is worth noting that the physical crosslinking techniques employed made 
the nanofibrous mats brittle and easily liable to cracking. Moreover, heating resulted in a color 
change from white to light brown. The same effect was realized upon storage of the nanofibrous 
mats for several month. Such change in color may be attributed to possible interactions between 
the amino groups in chitosan and the GA aldehyde group. 
 
4.1.4 Evaluation of the stability of the nanofibrous structure of the crosslinked and 
noncrosslinked nanofibers. 
 
The developed HPCS (30%:7%:3.5%) were evaluated for the stability of their nanofibrous 
morphology before and after crosslinking. Samples were crosslinked via exposure to GA vapors 
for 1h and 3h followed by heating at 40ºC for 24h. The crosslinked and non-crosslinked samples 
were placed in petri dishes closed with parafilm and stored on shelf at room temperature for 1 year 
and then the stability of the nanofibrous structure was examined via SEM. 
As seen in figure 10, the nanofibrous structure could still be realized in both the crosslinked and 
non-crosslinked samples after 1 year, however, the crosslinked samples allowed better 
preservation of the nanofibrous structure. In the non-crosslinked samples the outer layer of the 
nanofibrous mat seem to have degraded and the nanofibrous structure of the underlying layers 
could be observed beneath the upper degraded layer (Figure 10a & 10b). In the crosslinked 
samples, degradation of the outermost layer was not observed, however, significant swelling of 
the nanofibers could be observed. The degradation of the outermost layer in the non-crosslinked 
sample and the swelling observed in the crosslinked sample could be attributed to the adsorption 
of moisture from the surrounding environment. 
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 It is of note that the increase in the crosslinking time from 1h to 3h exposure to GA vapours did 
not result in a noticeable change in the morphology of the stored nanofibers.  
4.2 Evaluation of the effect of changing the honey concentration on the 
properties of the developed HPCS nanofibers (Sarhan et al., 2016a).                 
 
Novel honey/chitosan/ poly(vinyl alcohol) (HPCS) electrospun nanofibers based on high 
concentrations of honey reaching to 40% were successfully fabricated. Thus, honey is considered 
the major component of the developed HPCS nanofibers. Consequently, the effect of changing the 
honey concentration on the properties of the developed nanofibers was studied. Increasing 
concentrations of honey (10%, 20% & 30%) were included within the PCS (7%:3.5%) nanofibers 
and examined for the effect of changing the honey concentrations on the morphology, crystallinity, 
thermal behavior, swelling, degradation and antibacterial abilities of the developed HPCS 
nanofibers. 
4.2.1 Effect of changing the honey concentration on the morphology of the electrospun HPCS 
nanofibers. 
As apparent from Figure 11, it was noted that increasing the honey concentration led to increasing 
the diameter of the nanofibers. For instance, the HPCS nanofibers with 10% honey exhibited a 
mean fibre diameter of 284 ± 97 nm (Figures 11a & 11b) which increased to 371 ± 110 nm, and 
464 ± 185 nm upon increasing the honey concentration to 20% (Figures11c &11d), and 30% 
(Figures 11e & 11f), respectively.  
 
The increase in the fiber diameter is a direct consequence for increasing the amount of honey 
loaded within the nanofibers as can be observed from Figure 12a & 12b, where it is apparent that 
honey is embedded within the chitosan/poly(vinyl alcohol) nanofibers. It was also observed that 
the amount of honey loaded within the nanofibers influences the fiber diameter distribution. As 
seen in Figure 11d, addition of 20% honey to the chitosan/poly(vinyl alcohol) nanofibers allowed 
for the most focused fiber diameter distribution, as most of the nanofibers exhibited diameters 
between 300 nm and 450 nm (Figure 11d). Whereas, the addition of 10% and 30% honey to the 
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 chitosan/polyvinyl alcohol nanofibers resulted in broad distribution of the diameters of the fibers 
(Figures 11b & 11f). 
 
4.2.2 Evaluation of the effect of changing the honey concentration on the crystallization of the 
HPCS nanofibers 
The XRD diffraction patterns of pure poly(vinyl alcohol) and chitosan have been previously 
reported (Nakane et al., 1999; Samuels, 1981). Moreover, the XRD patterns of polyvinyl 
alcohol/chitosan (PCS) nanofibers and films were reported by Jia et al., who observed that 
nanofibers of the PCS exhibited deteriorated crystalline structure compared to the films (Jia et al., 
2007). 
Figure 13, illustrates the XRD diffraction patterns of the prepared HPCS nanofibers with 
increasing honey concentrations. The HPCS nanofibers exhibited an amorphous microstructure 
with a single broad peek around 2θ= 20°. Such XRD patterns are in coherence with those observed 
for the previously prepared poly(vinyl alcohol)/chitosan nanofibers (Jia et al., 2007). Thus the 
addition of honey did not affect the diffraction model of the poly(vinyl alcohol)/chitosan 
nanofibers and consequently the increase in the honey concentration within the HPCS nanofibers 
had no effect on their diffraction pattern.  The deterioration of the crystalline structure of the 
electrospun nanofibers was previously reported (Deitzel et al., 2001; Zong et al., 2002). Such 
deterioration could be attributed to the fast deposition and drying of the elongated electrospun 
nanofibers thus hindering the crystallization (Jia et al., 2007). 
 
4.2.3 Evaluation of the effect of changing the honey concentration on the thermal stability of 
the HPCS nanofibers 
Thermogravimetric analysis (TGA) analysis of the HPCS nanofibers with increasing honey 
concentrations (10%, 20% and 30%) was performed.  As observed in figure 14, the examined 
samples demonstrated similar thermal degradation process that takes place in several steps. The 
first step of weight loss is attributed to moisture elimination which resulted in loss of less than 
10% of the weight of the examined nanofibers below 120 ºC. 
 
It is of note that at 120 ºC the HPCS nanofibers having 10% honey exhibited the highest weight 
loss of ~8% whereas the weight loss decreased by increasing the amount of honey within the HPCS 
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 nanofibers to ~6% and ~3% with the 20% and 30% honey, respectively. This indicates that the 
HPCS nanofibers with higher honey concentrations exhibited higher initial moisture content, 
which is result of the hygroscopic nature of honey. The second and major weight loss of 
approximately 50% of the weight occurred after 120 ºC till 400ºCand is mainly attributed to the 
thermal decomposition of the polymer structure as well as degradation of the honey components 
followed by carbonization of the honey content (Figure 14).  In the final step of the thermal 
decomposition at temperatures above 500ºC, the polymer backbone has been ruptured in addition 
to the oxidation of the organic matter found in honey. Similar observations have been previously 
reported (Chauhan et al., 2014; Felsner et al., 2004). The thermogravimetric analysis clearly 
demonstrates that the fabricated HPCS nanofibers with different honey concentrations exhibit 
good thermal stability below 120ºC. 
 
4.2.4 Evaluation of the effect of changing the honey concentration on the swelling and weight 
loss abilities of the nanofibers.  
 
Honey and chitosan nanofibrous mats represent top candidates for wound dressing applications 
and determining their swelling capabilities would allow prediction of their exudate management 
ability (Li et al., 2013). The effect of changing the honey concentration was studied at two mild 
crosslinking degrees. These include exposing the nanofibers to GA vapours for 1h and 3h with 
subsequent heating at 40°C to enhance the crosslinking and remove any residual GA. 
As observed in figure 15, increasing the honey concentration within the nanofibers decreased its 
swelling ability at both the tested crosslinking degrees (Figures 15a & 15b).  It could be observed 
from the figures that the HPCS nanofibers with 10% honey and 1h of crosslinking with the GA 
vapours exhibited superior swelling capabilities reaching to 520% at 1h and 300% after 24 h 
(Figure 15a). 
On the other hand, the effect of the crosslinking time on the swelling capabilities of the HPCS 
nanofibers varied according to their incorporated honey concentration. For the HPCS nanofibers 
with 10% honey, increasing the crosslinking time from 1h to 3h decreased their swelling 
capabilities noticeably from 520% to 273%. Whereas, HPCS nanofibers with 20% honey exhibited 
increased swelling ability with the increase in the crosslinking time from 1h to 3h. Noticeably, the 
HPCS nanofibers with 30 % honey demonstrated the lowest swelling ability at both crosslinking 
times. Although honey is known for its high water uptake ability (MohdZohdi et al., 2011), it also 
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 has high water solubility. Such high water solubility results in increasing the degradation rates of 
the nanofibers and consequently losing their compact porous structure that can hold in water 
(Wang et al., 2012). Thus, this eventually results in massive decrease in swelling ability. This was 
observed by the very low swelling abilities of the HPCS nanofibers with 30% honey. Interestingly, 
the increase in the crosslinking efficiency by increasing the exposure time to the GA vapours 
allows the nanofibers to maintain a more compact nanofibrous structure (Li et al., 2013; Kim et 
al., 1992) thus, the percent of released and solubilized honey decreases. This allows the honey to 
be maintained within the nanofibers for longer periods of time, and thus its water uptake 
capabilities could be realised.  
On the other hand, the increase in the crosslinking degree decreases the swelling ability as it 
hinders the intermolecular motion and chain disentanglements within the nanofibrous scaffold. 
These two opposite effects on the swelling abilities of the nanofibrous scaffolds could be observed 
in the results presented in figures 15a & 15b. 
In the HPCS nanofibers with 10% honey, the amount of honey within the nanofibers is small thus 
the effect of the swelling hindering due to crosslinking was more pronounced than the water uptake 
ability of the maintained honey. Whereas, when the concentration of honey increased to 20%, the 
water uptake ability of the maintained honey in this case exceeded the hindering effect of 
crosslinking on swelling which allowed the HPCS nanofibers with 20% honey to exhibit a 
noticeable increase in swelling ability even at 24 h by increasing the crosslinking time to 3h. The 
HPCS nanofibers with 30% honey however showed slight decrease in the swelling ability with 
increasing the crosslinking time after 24h. This is because at such high concentration of honey 
such crosslinking treatments could not overcome the increased solubility of the HPCS nanofibers 
with 30% honey which affects the compact structure of the nanofibrous scaffold. Such results were 
confirmed with the weight loss results of the HPCS nanofibers with increasing honey 
concentrations (Figure 15c), where the increase in the honey concentration within the nanofibers 
resulted in increased weight loss at both the tested crosslinking degrees. 
These results reveal the importance of optimization of the crosslinking degree as well as the honey 
concentrations within the developed HPCS nanofibers to adjust the water uptake ability as well as 
the weight loss according to the desired application.  
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4.2.5 Effect of increasing the honey concentration on the antibacterial activity of the developed 
HPCS nanofibers 
It is the aim of the current study to develop nanofibers that could be utilized as effective 
antimicrobial wound dressings, thus, the antibacterial activity of the fabricated HPCS nanofibers 
was screened against Gram positive; S.aureus and Gram negative; E.coli as they are two of the 
most common pathogens found in infected wounds (Bessa et al., 2015). Moreover, two different 
bacterial counts were utilized to study the efficacy of the developed nanofibrous mats in inhibition 
of high bacterial loads. 
Both honey and chitosan exhibit antibacterial activity. Honey exerts its antibacterial activity via 
its acidity, high sugar content as well as its ability for hydrogen peroxide production (Vandamme 
et al., 2013). Whereas, the polycationic nature of chitosan allows it to interact with the negatively 
charged membranes of bacteria leading to loss in the permeability of the membrane with 
subsequent cell leakage and death (Muzzarelli et al., 1990).                 
The effect of changing the honey concentration within the HPCS nanofibers on the antibacterial 
activity of the developed nanofibers was investigated as shown in figure 16 The increase in the 
honey concentration within the HPCS nanofibers enhanced their antibacterial activities against 
both S.aureus and E.coli at 1 × 107 CFU/ml (Figures 16a & 16b). However, upon increasing the 
bacterial count to 1 × 108 CFU/ml the increase in the honey concentration resulted in an increase 
in the antibacterial activity against S.aureus, whereas nearly no antibacterial effect was realized 
against E.coli. These results are in agreement with No, et al (2002) who demonstrated the weak 
antibacterial activity exhibited by chitosan against Gram negative bacteria (No et al., 2002). The 
nanofibrous structure allowed enhancement in the antibacterial activity of the components 
included within the nanofibers. The examined samples (0.05 g) contain chitosan less than 10 ppm 
and ~ 0.0875% honey and demonstrated pronounced antibacterial effect against S. aureus 
compared to no antibacterial effect at the same concentrations for both chitosan and honey alone 
(Goy et al., 2009; Islam et al., 2011I; Liu et al., 2006; Mandal & Mandal, 2011).Such results could 
be due to the massive increase in the surface to volume ratio of the nanofibers. 
Thus, due to the enhanced antibacterial activity of the HPCS nanofibers loaded with 30% honey 
they will be selected to be further loaded with other antimicrobials. Despite the increased swelling 
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 ability of the 10% honey HPCS nanofibers, the main aim of the present study is to develop an 
efficient antimicrobial wound dressing. Consequently, the HPCS formula that was selected to be 
further loaded with natural materials and optimized as a nanofibrous antimicrobial wound dressing 
is 7% PVA, 3.5% Chitosan & 30% Honey. 
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 4.3 Evaluation of HPCS Nanofibers Loaded with Natural Extracts as 
Antimicrobial Wound Dressings (Sarhan et al., 2016b). 
 
To enhance the antibacterial activity of the HPCS (30%:7%:3.5%) nanofibers, they were loaded 
with two natural extracts that have demonstrated antibacterial and potential wound healing 
capability through previous literature. Thus, the HPCS (30%:7%:3.5%) nanofibers were loaded 
with aqueous extracts of Allium sativum (AE) and Cleome droserifolia (CE) and the resulting 
nanofibrous mats were examined for their swelling, weight loss, antibacterial, cytotoxicity, wound 
healing abilities as well as their abilities to enhance cell proliferation. 
4.3.1 Fabrication of the electrospun HPCS, HPCS-AE, HPCS-CE, and HPCS-AE/CE 
nanofibers. 
As previously demonstrated, electrospinning HPCS nanofibers containing high concentrations of 
H and CS was only possible by aging the solution of  PCS with 30% H for a week. Allium sativum 
aqueous extract was included in the HPCS combination via substituting 50% of the solvent in 
which the HPCS were prepared resulting in the formation of HPCS-AE solution that was 
subsequently electrospun into HPCS-AE nanofibers. Upon preparation of the HPCS-AE it was 
observed that the solution exhibited high viscosity that was inappropriate for electrospinning, thus 
the solution was aged for a week at room temperature while observing the viscosity of the solution 
at different time intervals.  
It was observed that the substitution of 50% of the solvent of the HPCS with aqueous extract of 
AE resulted in a massive reduction in its viscosity as compared to the HPCS solution which was 
utilized as the control (table 2). The observed reduction in viscosity could be due to degradation 
of the CS polysaccharide into its lower molecular weight oligomers due to the addition of the AE 
aqueous extracts. 
As demonstrated in table 2, the reduction in viscosity imparted by the addition of the aqueous AE 
extract was very sharp and was observed from the first two hours (1410 mPas) and reached 
maximum decrease in viscosity after 48 h reaching to 420 mPas as compared to 3660mPas in the 
case of the HPCS solution without the aqueous AE extract. This indicates the vital role played via 
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 the AE aqueous extract in the CS degradation with the subsequent reduction in the solution 
viscosity.  
 Before electrospinning and after both the HPCS and HPCS-AE solutions have reached to the 
optimum viscosity required for electrospinning, the dry powder of CE (10%) was added as stirred 
for 1h. It should be noted that addition of the CE extract to both the HPCS and HPCS-AE solutions 
was not possible before aging because of the increased viscosities of the solutions that were 
difficult to be stirred. It was realized that the addition of the CE dry powder extract did not affect 
the required viscosity for electrospinning even after aging.  
 
The as-prepared solutions of HPCS and HPCS-AE were electrospun (NANON-O1A, MECC, 
Japan) and collected as nanofibrous mats for further examinations. It was observed that the 
addition of AE aqueous extracts to the HPCS solution has facilitated the electrospinning process, 
which was attributed to the reduction in viscosity imparted by the AE on the solution. However, 
due to the massive decrease in viscosity undesirable dripping has occurred. The parameters used 
during the electrospining of the HPCS-AE nanofibers and that allowed for a continuous and steady 
jet were a voltage of 27 kV, a flow rate of 0.5 ml/h, and 13 cm as the distance between the needle 
and the collector. Collection of the nanofibrous mats continued for 4.5h and their surface 
morphology was observed using SEM (Figure 17). Both the HPCS and HPCS-AE demonstrated a 
compact, uniform, smooth, and bead-free morphology. Additionally, it was realized that the 
HPCS-AE exhibited the least nanofiber diameter and the most focused diameter distribution 
among the tested nanofibrous mats (145 ± 58nm). 
 
Upon the addition of the dry powder of CE to both the HPCS-AE and the HPCS solutions, the 
process of electrospinning became more difficult until optimizing the parameters of 
electrospinning to be 28kv, 0.7 ml/h flow rate and 14 cm as the distance between the needle and 
the collector. The nanofibers were collected for 3.5 hours, however it was still critical to achieve 
a uniform nanofiber deposition. This may be due to the sticky nature of Cleome droserifolia (CE) 
as it exhibits glandular sticky leaves (Płachno et al., 2009). 
Figure 17 demonstrates a bimodal diameter distribution of both the HPCS-AE/CE and HPCS-CE 
nanofibers, because of the addition of high CE concentration in addition to its sticky nature. 
Moreover, noticeable branching was observed with a noticeable formation of clusters at the 
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 branching points within the collected nanofibers (Xu et al., 2011). This branching could be 
attributed to spinning highly concentrated solution (Reneker & Yarin., 2005) using a high voltage 
combined with the sticky nature of electrospun solution. Electrospinning high concentrated 
solutions results in a jet with large diameter, which could result in the formation of branches (Yarin 
et al., 2005). This in turn leads to large inter-fiber spaces, which proofed to be more beneficial in 
cell related applications such as tissue engineering and wound healing (Gu et al., 2013; Shokrgozar 
et al., 2011) taking into consideration the density of the electrospun nanofibrous mat.  
 
4.3.2 Evaluation of the swelling and weight loss abilities of the fabricated nanofibers. 
 
The fabricated nanofibers of HPCS-CE, HPCS-AE and HPCS-AE/CE were crosslinked and 
examined for their swelling capabilities after immersion in PBS (pH 7.4) for 1, 4, and 24 h. 
Crosslinking of the fabricated electrospun nanofibers was done by exposing the nanofibers to GA 
vapors for 1 hour and 3 hours with subsequent heating at 40°C in order to remove any residues of 
GA and enhance the crosslinking of the nanofibers.  
As observed in figure 18, the HPCS-CE and the HPCS-AE at one hour crosslinking, demonstrated 
similar swelling capabilities with a slight decrease in the swelling (%) of both the HPCS-CE and 
HPCS-AE as compared to the previously examined HPCS (30%H) (Figure 15), especially after 24 
hours of immersion in the PBS (Figure 18a). At three hours crosslinking noticeable decrease in the 
swelling ability of the HPCS-CE was observed.  On the other hand, the low swelling (%) of the 
HPCS-AE/CE nanofibrous mats was observed at one and three hours crosslinking times, 
demonstrating values of less than 15% swelling as compared to ~90% swelling in the case of the 
HPCS-AE and previously examined HPCS (30%H) (Figure 15) after immersion in PBS buffer for 
24 h (Figure 18b). Such results illustrate that the swelling abilities of both the HPCS and the HPCS-
AE nanofibers greatly decreased upon addition of the CE. This could be attributed to the CE sticky 
nature which hinders the chain disentanglements and intermolecular motion of the fabricated 
nanofibers and thus hinders their swelling abilities (Plachno et al., 2009). 
Increasing the time of crosslinking permits maintaining a more compact nanofibrous structure that 
allows the water uptake ability of the porous structure of the nanofibers to be realized. At the same 
time, the extent of crosslinking should not be increased to the point that hinders the chain 
entanglements and intermolecular motion within the nanofibers (Li et al., 2013; Kim et al., 1992). 
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 Upon increasing the time  of crosslinking to 3 h, the swelling ability of both the HPCS-AE and 
HPCS-AE/CE increased, whereas, nearly no effect was realized on the HPCS-CE  nanofibers, 
which demonstrated similar swelling (%) at both the crosslinking times (1 h and 3 h) examined. 
Such results illustrate that the increase in the time of crosslinking affected only the nanofibrous 
mats containing the aqueous AE. This could be due to the fact that the AE containing nanofibers 
demonstrated increased weight loss as compared to the HPCS-CE nanofibers (Figure 18c). Thus, 
upon crosslinking the AE containing nanofibers a more compact structure could be maintained for 
longer periods of time resulting in the enhancement observed in their swelling capabilities after 
three hours crosslinking. 
According to the swelling results of the examined nanofibers (Figure 15 & 18), it is expected that 
the HPCS-AE/CE nanofibers would demonstrate nearly no capability for management of exudates. 
Whereas, the HPCS-CE, HPCS (30%H) and HPCS-AE nanofibrous wound dressings would 
demonstrate moderate capability for exudate management. The HPCS, HPCS-AE and HPCS-CE 
samples demonstrated moderate swelling capabilities as compared to nanofibers previously 
electrospun lacking honey (Jannesari et al., 2011). This could be due to honeys’ high water 
solubility which results in increasing the weight loss of the electrospun nanofibers.  Moreover, 
despite that chitosan enhances the water uptake capability of the electrospun nanofibers, increasing 
the chitosan concentration results in an opposite effect. This was previously illustrated by Son et 
al., who observed that in nanofibrous mats of chitosan/ poly(vinyl alcohol) having low chitosan 
concentration, polymeric hydrogels are easily formed via the hydrophilic poly(vinyl alcohol) in 
solutions thus leading to enhanced swelling. However, upon increasing the concentration of 
chitosan, the intermolecular forces between the amine groups and the side chains of chitosan 
increase and decrease the swelling capability (Son et al., 2009). 
 
4.3.3 Evaluation of the antibacterial abilities of the fabricated nanofibers. 
 
Research into development of effective antimicrobial wound dressings represents an increasing 
trend within the wound dressing market. This is because of the major complications associated 
with infected wounds that are resistant to current treatment protocols. Chronic non-healing wounds 
are usually treated with antimicrobial therapeutics either systemic or topical (Lipsky & Hoey., 
2009).  It was observed that ˃ 60% of these patients received antibiotic treatments for a prolonged 
period of time (Howell-Jones et al., 2005; Tammelin et al., 1998). With the alarming rise in 
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 antibiotic resistance alternative antibacterials are of great necessity. Silver-based dressings 
represent one of the most common alternative antibacterials now effectively used in wound 
treatment. Unfortunately, resistance against silver as well as undesirable side effects have been 
reported (Lansdown, 2002).  
The developed HPCS nanofibrous mats exhibited mild antibacterial activity against S. aureus and 
weak antibacterial activity against E. coli. To enhance the antibacterial activity of the developed 
HPCS nanofibers, CE, AE and their combination were loaded within the HPCS nanofibers and 
examined for their antibacterial abilities against S. aureus, E. coli and two resistant strains; MDR 
P. aeruginosa and MRSA. The selected bacterial strains for the study are considered among the 
most common bacterial pathogens encountered at the wound site (Bessa et al., 2015). Aquacel Ag 
was examined for its antibacterial effect and compared to the antibacterial activities of the 
fabricated nanofibrous wound dressings. Recently, it was reported that the Aquacel Ag 
demonstrated the strongest antibacterial activity among other silver-based wound dressings in the 
market (Yunoki et al., 2015). 
 
The antibacterial effect of Allium sativum has been attributed to its content of thiosulfinates 
including diallyl sulphide, allyl methyl sulphide, and diallyl disulphide, where they disrupt cell 
components and block the pathways of various bacterial enzymes (Elsom, 2000; Chen et al., 
1999).Whereas Cleome’s antibacterial activity has been attributed to its content of various terpenes 
including the β-eudesmol, sesquiterpenes carotol, and δ-cadinene (Muhaidat et al., 2015). 
Figure 19 represents the antibacterial activities of the developed HPCS, HPCS-CE, HPCS-AE and 
HPCS-AE/CE nanofibrous wound dressings in comparison with the commercial Aquacel Ag 
wound dressing. It was observed that complete inhibition of S.aureus was achieved via both the 
HPCS-AE and HPCS-AE/CE nanofibrous mats compared to noticeable reduction in bacterial 
count with the Aquacel Ag wound dressing (Figure 19a). Such effect is mainly attributed to the 
inclusion of the AE aqueous extracts within the HPCS nanofibrous mats. Additionally, it was 
realized that among the fabricated nanofibrous mats, only the HPCS-AE/CE demonstrated mild 
antibacterial activity against MRSA, thus illustrating that the combined effects of both the CE and 
AE was needed to achieve antibacterial effect against MRSA (Figure 19b). It is of note that the 
achieved antibacterial effect against MRSA was not significant as compared to the negative control 
(p < 0.05) and less than that observed with the Aquacel Ag.  On the other hand, no antibacterial 
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 activity was demonstrated against both the E. coli and the MDR P. aeruginosa, whereas, the 
Aquacel Ag exhibited bactericidal activity against E. coli and enhanced bacterial inhibition against 
MDR P. aeruginosa (Figure 19 c & 19 d). 
The antibacterial activities of the chitosan, honey, Cleome droseifolia and Allium sativum were 
reported against both Gram negative and Gram positive bacteria (Muhaidat et al., 2015; Muzzarelli 
et al., 1990; Gaherwal et al., 2004). Additionally, increased antibacterial effect against S. aureus 
compared to E. coli was observed for chitosan (No et al., 2002) and Cleome droseifolia oil 
(Muhaidat et al., 2015) as well as the honey and Allium sativum mixture (Andualem, 2013). This 
agrees with the results reported here regarding the enhanced antibacterial activity against the 
examined S.aureus and MRSA strains.  
 
4.3.4 Evaluation of the wound healing abilities of the fabricated nanofibers. 
 
The fabricated nanofibrous wound dressings and the commercial dressing Aquacel Ag were 
applied on a 9 mm excisional wound on the dorsal back of mice. For determination of the change 
in wound size over time, photographs of the wound area were taken on days 3, 5, 7, 10 and 12 
(Figure 20). The wound healing ability of the examined nanofibrous wound dressings was 
determined via measurement of the percentage of the wound size remaining exposed at each time 
point as compared to the wound size on day 0 (Figure 20).   
Honey and chitosan have well proven ability to enhance the wound healing process (Mandel & 
Mandel, 2011; Dai et al., 2011; Seckam & Cooper, 2013).  Chitosan has been observed to 
beneficially influence every stage in the wound healing process (Dai et al., 2011). Chitosan 
indirectly enhances cell proliferation (Azuma et al., 2015) and stimulates migration of both the 
polymorphonuclear cells (PMN) and mononuclear cells (MN). Both of which showed the ability 
to degrade chitosan into its low molecular weight oligomers that exhibit profound capability to 
promote cell migration (Minami et al., 1997). Moreover, chitosan was observed for its stimulatory 
effects on macrophage nitric oxide production (Peluso et al., 1994). Honeys’ wound healing ability 
has been historically recognized since ancient times. Such wound healing ability is related to 
honeys’ ability to provide a moist wound healing environment, fast autolytic debridement and pro- 
as well as anti-inflammatory effects, in addition to honeys’ antibacterial and antioxidant activities 
(Tonks et al., 2003, Majtan et al., 2006, Molan & Rhodes., 2015).  Allium sativum have been 
recently studied for its effect on enhancing the wound healing process where it was reported that 
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 it increases the re-epithelialization and neovascularization (Sidik et al., 2006). On the other hand, 
Cleome droserifolia, has not yet been evaluated for its effect on the wound healing process, 
however, Cleomes’ antioxidant activity have been well observed (El-Khawaga et al., 2010; El-
Shenawy & Abdel-Nabi, 2004) and antioxidants have been known for their ability to enhance the 
wound healing process via prevention of the overexposure of the wound site to oxidative stress 
which leads to delay in the wound healing process (Fitzmaurice et al., 2011). 
As demonstrated in figure 20, the wound size decreased noticeably on day 3 as observed with the 
HPCS, HPCS-AE and HPCS-AE/CE nanofibrous dressings as compared to the wounds of the 
negative control.  Additionally, all the examined wound dressings as well as the Aquacel Ag 
exhibited significant decrease in the wound size as well as the Aquacel Ag as compared to the 
negative control on days 5 and 7. At the same time there was nearly no reduction in the wound 
size of the negative control at day 5 (Figure 20).  
It was observed that the rate of wound closure enhanced greatly with the HPCS nanofibrous mats 
and upon addition of aqueous extracts of AE in the HPCS-AE nanofibrous mats, the rate of wound 
closure increased. On the other hand, the rate of wound closure decreased upon addition of the dry 
extract of CE to the HPCS-CE nanofibrous mats.  Whereas, the inclusion of the combination of 
both extracts within the nanofibrous mats of HPCS-AE/CE resulted in similar rates of wound 
closure to the HPCS nanofibrous dressings (Figure 20). Interestingly, it was observed that the 
HPCS-AE demonstrated enhanced wound closure rate as compared to the Aquacel Ag, whereas, 
both the HPCS and the HPCS-AE/CE demonstrated similar rates of wound closure to the 
commercial Aquacel Ag wound dressing.  
 
The histopathology of the wound tissue was subsequently examined to observe the effect of the 
fabricated nanofibrous dressings on the different stages involved in the wound healing process. 
The wound tissues were H&E stained and their histopathology studied and scored at days 3, 5, 7, 
10 and 12. Moreover, the collagen deposition in the wounded tissues was examined and scored at 
day 10 after staining the wound tissue with the MT stain (Figures 21 & 22, and Table 3). Necrotic 
tissue is usually accumulated in chronic wounds. Necrotic tissue is defined as dead tissue which 
most frequently results from inadequate blood supply. As observed in figure 21 and table 3, the 
application of all of the developed nanofibrous wound dressings as well as the positive control 
Aquacel Ag to the wound site reduced the necrosis as compared to the negative control, with the 
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 most enhanced reduction in necrosis observed with the HPCS-CE since day 5. Additionally, the 
number of inflammatory cells reduced as compared to the negative control upon application of the 
developed nanofibrous wound dressings, where they completely disappeared at day 10 with the 
HPCS-AE/CE nanofibrous dressing. This indicates that the fabricated nanofibrous wound 
dressings prevented the prolongation of the inflammatory phase, which could be attributed to the 
anti-inflmmatory effects of the materials of the wound dressings as honey and Allium sativum. 
Moreover, it was realized that the number of macrophage cells was greater than the number of 
neutrophils in the treated wounds.   
 
Early epithelization was observed in all the treated wounds as compared to the negative control 
with the AquacelAg, HPCS-AE/CE and HPCS-AE nanofibrous wound dressings demonstrating 
the earliest epithelization as well as formation of thicker epidermis (Figure 21 and Table 3). 
Additionally, both the HPCS-AE/CE and the Aquacel Ag allowed for earlier formation of 
granulation tissue. Moreover, the examined nanofibrous wound dressings as well as the Aquacel 
Ag allowed mature formation of granulation tissue together with dense collagen deposition (Figure 
21 and Table 3). This was confirmed by the MT staining of the wound tissues at day 10 which 
showed that the regenerated collagen in the treated wounds was denser as compared to the negative 
control, and that both the nanofibrous mats of HPCS and the Aquacel Ag demonstrated the most 
dense deposition of collagen. It was also observed that the HPCS-AE, HPCS-AE/CE, HPCS, and 
the Aquacel Ag exhibited the most uniform distribution of collagen (Figure 22 and Table 3).  
Overall, the scoring of the data of the histologic examination revealed that among the examined 
nanofibrous wound dressings, the HPCS-AE/CE exhibited the most enhanced effect on the wound 
healing process followed by the HPCS nanofibrous wound dressing having scores very similar to 
the Aquacel Ag. Both nanofibrous dressings allowed decrease in the inflammatory phase, and 
earlier formation of granulation tissue as well as earlier epithelization and deposition of thicker 
epidermis. Additionally, both nanofibrous wound dressing’s induced uniform and dense deposition 
of collagen.
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 4.3.5 Evaluation of the fibroblast cytotoxicity of the fabricated nanofibers and their effect on 
fibroblast cell proliferation. 
 
The fabricated HPCS, HPCS-CE, HPCS-AE and HPCS-AE/CE nanofibrous mats as well as the 
commercial wound dressing Aquacel Ag were tested for their cytotoxicity using the MTT assay. 
Additionally, the effect of the fabricated nanofibrous dressings and the commercial wound 
dressing Aquacel Ag on fibroblast cell proliferation was evaluated via the MTT assay. 
Oxidoreductase cellular enzymes reflect the number of viable cells via reduction of the soluble 
tetrazolium dye (MTT; 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) to the 
insoluble purple formazan salt. The developed nanofibers were extracted and diluted to yield 
different extract concentrations; 100%, 75%, 50% and 25%, that were tested for their cytotoxicity. 
The fibroblast cells were cultured in the different dilutions of the extract and the cytotoxicity was 
determined via estimation of the viable cells after 48h (Figure 23a). 
It was realized that both the HPCS-CE and the HPCS nanofibrous mats demonstrated the highest 
fibroblast cell viability of 90% and 87%, respectively in the 100% extract solution. Whereas, 
significant reduction in cell viability of 68% (p < 0.05) was observed with the HPCS-AE that 
increased to 75% upon adding CE to the HPCS-AE/CE nanofibers in the 100% extract solution 
(Figure 23a).On the other hand, it was observed that the commercial dressing Aquacel Ag at all 
tested dilutions exhibited increased cytotoxicity to the cultured fibroblasts (p < 0.05) and showed 
viable fibroblast cell counts of  approximately 9% similar to the results observed with the cytotoxic 
control (Figure 23a). 
Figure 23b demonstrates fibroblast cell proliferation results at 1 and 3 days as determined via the 
MTT assay. The OD values of the HPCS-AE/CE, HPCS-CE and HPCS nanofiber mats increased 
with the increase in culture time. Both the HPCS and the HPCS-CE nanofibrous mats exhibited 
the most significant enhancement (p < 0.05) in proliferation after 3 days of incubation (Figure 
23b). Whereas the HPCS-AE nanofibrous mats exhibited nearly the same OD values at 1 & 3 days. 
On the other hand, the Aquacel Ag exhibited significant cytotoxic effect on the proliferation of the 
fibroblast cells as observed from the low OD values (Figure 23b). Such results confirm the 
previously reported cytotoxicity for the Aquacel Ag wound dressing in the previous evaluation of 
the cytotoxicity (Figure 23a). The observed cytotoxicity of the commercial wound dressing 
Aquacel Ag was previously reported in different studies (Yunoki et al., 2015; Burd et al., 2007). 
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 Generally, the HPCS-CE and HPCS nanofibrous dressings exhibited the highest levels of cell 
proliferation and viability within the examined nanofibrous dressings. The addition of CE dry 
extract to the nanofibers of the HPCS-AE has increased their proliferation and cell viability results. 
Interestingly, all the fabricated nanofibrous mats exhibited major increase in cell proliferation and 
viability as compared to the Aquacel Ag commercial wound dressing (Figures 23a and 23b). 
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 4.4 Evaluation of HPCS Nanofibers Loaded with Apitherapeutics and 
Bacteriophages as Antimicrobial Wound Dressings. 
 
Apitherapeutics were loaded within the HPCS (30%:7%:3.5%) nanofibers as an alternative 
approach to enhance the antibacterial abilities of the developed nanofibers. Two apitherapeutics, 
namely: bee venom and propolis were loaded within the HPCS (30%:7%:3.5%) nanofibers and 
tested for their antibacterial abilities. Additionally, the nanofibrous mat that demonstrated the most 
enhanced antibacterial activity among the developed HPCS nanofibers loaded with natural extracts 
and apitherapeutics was selected and further loaded with bacteriophage. The bacteriophage was 
isolated against a bacteria resistant to the selected nanofibrous mat and electrospun with the 
selected combination of the nanofibrous mat, thus extending the spectrum of antibacterial activity 
of the selected nanofibrous mat. The developed apitherapeutic and bacteriophage loaded 
nanofibrous mats were examined for their swelling, weight loss, antibacterial, cytotoxicity, wound 
healing abilities as well as their abilities to enhance cell proliferation. 
4.4.1Fabrication of the electrospun HPCS-Pr and HPCS-BV nanofibers. 
Recently, propolis (Pr) has been co-spun into polymeric nanofibers and examined for its effect on 
the mechanical and antibacterial properties of the electrospun nanofibers. Ethanolic and aqueous 
propolis extracts have been loaded within the nanofibers in different concentrations ranging from  
2 to 10% (Sutjarittangtham et al., 2012; Sutjarittangtham et al., 2014), however it was observed 
that at concentrations above 8% of ethanolic or aqueous propolis extract the solution could not be 
electrospun (Sutjarittangtham et al., 2014). Thus, in the current study the ability to fabricate 
uniform nanofibers loaded with 10% propolis was examined within the HPCS nanofibers.  
Bee venom on the other hand has not yet been formulated in the nanofibrous form, however its 
diverse biomedical properties have been documented via different studies (Ali, 2012; Kwon et al., 
2002; Kim et al., 2013). It was observed that bee venoms’ antibacterial property was achieved via 
concentrations ranging from 12.5 to 25 ug/ml for Gram-positive bacteria and 1 to 10 mg/ml for 
Gram-negative bacteria (Lowenstein et al., 1997). Thus, bee venom was loaded within the HPCS 
nanofibers in the concentration of 1 mg/ml to be able to target both Gram positive and Gram 
negative bacteria. 
52 
 
  
The aqueous extracts of Pr and the dry powder of BV were added to the prepared solutions of 
HPCS prior to electrospinning. The electrospun mats were characterized via SEM (Figure 24) then 
subjected to analysis of the diameter of the nanofibers via image J. The HPCS solutions were 
previously spun into uniform bead free nanofibers of 464 ± 185 nm in diameter. As observed in 
figure 24, electrospinning of 10% Pr within the HPCS solution allowed for the collection of dense 
nanofibrous mats. However, due to the high concentration of Pr included within the nanofibers, 
noticeable branching was observed together with cluster formation within the nanofibers. 
Additionally, an increase in the diameter of the nanofibers over that of the previously spun HPCS 
was observed, where the average nanofiber diameter reached to 737 ± 260 nm with broad diameter 
distribution. 
On the other hand, the inclusion of the BV within the HPCS nanofibers allowed for uniform 
deposition of the nanofibers with average diameter of 459 ± 140 nm and a focused diameter 
distribution (Figure 24). The inclusion of BV did not result in variation in the morphology of the 
nanofibers over the previously collected HPCS nanofibers. This could be attributed to the minute 
concentration of the included BV. 
The parameters that were utilized in electrospinning both the HPCS-BV and HPCS-Pr solutions 
were a high electric potential of 27 kV (E-spin, NanoTech, Kalyan-pur, India) and a constant flow 
rate of 0.5 ml/h was maintained, whereas, the distance between the nozzle and the collector was 
maintained at 15 cm. 
4.4.2 Evaluation of the swelling and weight loss abilities of the fabricated nanofibers. 
 
The developed nanofibers of HPCS-Pr and HPCS-BV were examined for their swelling abilities 
after immersion in PBS (pH 7.4) for 1, 4, and 24 h. Crosslinking was performed by exposing the 
nanofibers to GA vapors for 1 & 3 hours with subsequent heating at 40°C. 
 
As observed in figure 25, the HPCS-BV demonstrated enhanced swelling values as compared to 
the HPCS-Pr nanofibers at 1, 4 and 24h. The HPCS-BV exhibited swelling values similar to those 
previously reported for the HPCS nanofibers. This is because of the small concentration of BV 
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 added to the HPCS nanofibers, thus, such low concentration did not result in variation of the 
swelling properties of the HPCS nanofibers. 
The HPCS-Pr nanofibers exhibited very small swelling values, especially at 4h and 24h. This may 
be attributed to the high concentration of the included propolis (10%), which decreased the 
available void left for water uptake and swelling. Moreover, the observed increase in weight loss 
(Figure 25c) of the HPCS-Pr nanofibers is another reason for the decreased swelling values 
recorded for the HPCS-Pr due to the loss of the compact structure that allows the water uptake 
(Figure 25). 
The increase in the crosslinking time resulted in slight effect on the swelling abilities of the HPCS-
BV nanofibers, where a slight decrease in the swelling ability was observed at 24h. This could be 
attributed to the effect of crosslinking on hindering of the chain entanglements and intermolecular 
motion within the nanofibers (Kim et al., 1992).The effect of crosslinking was more pronounced 
on the HPCS-Pr nanofibers, where the swelling abilities of the HPCS-Pr nanofibers decreased 
noticeably. On the other hand, weight loss was slightly decreased upon increasing the crosslinking 
time to 3h.  
  
4.4.3 Evaluation of the antibacterial abilities of the fabricated nanofibers. 
Propolis and bee venom are two natural apitherapeutics that have demonstrated effective 
antibacterial activity against different kinds of bacteria (Hegazi et al., 2015; Popova et al., 2005; 
Kujumgiev et al., 1999). Bee venom’s antibacterial activity is related to a number of peptides like 
melittin, adolapin, apamin and mast cell degranulating peptides as well as biologically active 
amines and non-peptide components (Kwon et al., 2002; Fennel., 1968). Whereas propolis 
antibacterial activity is mainly attributed to its content of flavonoids and cinnamic acid (Sharaf et 
al., 2013; Popova et al., 2005). It was observed that propolis prevents cell wall division, and causes 
disorganization of the cytoplasm, cell wall and the cytoplasmic membrane leading to inhibition of 
protein synthesis and bacteriolysis (Lotfy, 2006).  
In this research propolis and bee venom have been loaded within the previously spun HPCS 
nanofibers and examined for their antibacterial activities against S. aureus, E. coli and two resistant 
strains; MDR P. aeruginosa and MRSA. The commercial wound dressing Aquacel Ag was used 
as a positive control, whereas untreated bacterial broth was utilized as a negative control.  
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 As observed in figure 26, the inclusion of bee venom within the HPCS nanofibers in the HPCS-
BV nanofibers allowed for noticeable enhancement in the antibacterial activity even against 
resistant bacterial strains. The HPCS-BV nanofibers allowed for complete bacterial inhibition of 
E.coli similar to the effect of the commercial Aquacel Ag. Such results agree with the previously 
reported enhanced antibacterial activity of bee venom against E.coli (Hegazi et al., 2014). 
Additionally the HPCS-BV nanofibers exhibited enhanced antibacterial activity over the 
commercial Aquacel Ag against the tested Gram positive strains where it demonstrated ~ 6 log 
and 5 log reduction in the bacterial count of S.aureus and MRSA respectively as compared to ~ 4 
log and 2 log reduction in case of the Aquacel Ag. However, the HPCS-BV nanofibers exhibited 
no antibacterial activity against P. aeruginosa, whereas, the Aquacel Ag demonstrated enhanced 
antibacterial activity against it (Figure 26). 
The HPCS-Pr nanofibers on the other hand exhibited weaker antibacterial activity than the HPCS-
BV nanofibers. As compared to the Aquacel Ag, the HPCS-Pr demonstrated enhanced 
antibacterial activity against both S.aureus and MRSA, whereas against E.coli and MDR P. 
aeruginosa it exhibited nearly no antibacterial activity compared to enhanced antibacterial activity 
with the Aquacel Ag (Figure 26). 
According to the antibacterial results of the HPCS nanofibers loaded with the natural extracts 
(Figure 19) and apitherapeutics (Figure 26), it was observed that the HPCS-BV nanofibers 
exhibited the most enhanced antibacterial activity among the developed nanofibers. The HPCS-
BV nanofibers demonstrated enhanced antibacterial activity against E.coli, S.aureus, and MRSA, 
stronger than that observed with the commercial wound dressing Aquacel Ag.  However, it 
exhibited nearly no antibacterial activity against P. aeruginosa, unlike the Aquacel Ag that 
demonstrated enhanced antibacterial activity against it. P. aeruginosa is considered the most 
commonly encountered Gram negative bacteria in wounds (Gjødsbøl et al., 2006; Burmølle, 2010). 
Thus, HPCS-BV was selected to be further loaded with a bacteriophage against P. aeruginosa in 
order to develop a nanofibrous wound dressing with broad spectrum antibacterial activity against 
the most common bacterial pathogens encountered at the wound site. 
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 4.4.4 Isolation, electrospinning and antibacterial evaluation of the bacteriophage loaded 
nanofibers 
The alarming rise in bacterial resistance has revived the interest in bacteriophage therapy. 
Bacteriophages are viruses that specifically infect and rapidly destroy bacteria. Although 
bacteriophages are now witnessing increased research and are applied in food preservation, 
integration of phage therapy in human therapeutics is still facing many challenges among them is 
their narrow host range (Sarhan & Azazzy., 2015b). Utilization of bacteriophage in wound care 
has been examined in a number of studies (Rhoads et al., 2009; Seth et al., 2013), however, its 
integration into nanofibrous wound dressing with broad spectrum antibacterial activity has not yet 
been realized. 
The phage plaque assay was utilized for the isolation of a bacteriophage against the MDR P. 
aeruginosa from the different sewage samples collected and then subsequently purified and 
amplified into a P. aeruginosa phage (PS1) suspension. The PS1 phage was then subjected to 
morphological characterization via TEM. The results of the TEM imaging revealed that the PS1 
phage exhibits an icosahedral head of 71 nm in diameter and a contractile tail of 110–115 nm in 
length (Figure 27a). Thus, the bacterial virus was classified as a representative of the Myoviridae 
family (Soothill, 1992; Ackermann et al., 1994).  
The PS1 phage stock solution (109-1010 PFU mL -1 ) was loaded within the HPCS-BV solution and 
subjected to electrospinning at 27 kV, 0.5 ml/h as flow rate, whereas the distance between the 
needle and the collector was maintained at 13 cm. The fibers collected were characterized via SEM 
which revealed a dense and uniform bead free deposition of the HPCS-BV/PS1 nanofibers (Figure 
27b). The analysis of the fiber diameter distribution illustrated that the diameter distribution of the 
collected nanofibers did not show a noticeable difference from that of the HPCS-BV nanofibers 
(Figure 26) with an average diameter of 498 ±145 nm (Figure 27c) and a focused fiber diameter 
distribution. 
The HPCS-BV/PS1 nanofibers were examined for their antibacterial activity against MDR P. 
aeruginosa. Bacteriophages are characterized by their instant antibacterial activity, where 
lysogenic phages are adsorbed on the surface of the bacterial cell followed by injection of the 
phages’ genetic material into the bacterial cell cytoplasm. The host cell machineries are then 
utilized for making new phages and then the host cell is killed at the end of the growth cycle 
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 (Sulakvelidze, 2011). To observe the antibacterial activity of the phage loaded nanofibers, the 
examined nanofibers as well as the controls were tested for the antibacterial activity after 24h. The 
results revealed strong antibacterial activity against MDR P. aeruginosa for the HPCS-BV/PS1 
nanofibers which exceeded that of the Aquacel Ag (Figure 27d). Complete bacterial inhibition of 
the MDR P. aeruginosa was achieved via the HPCS-BV/PS1 nanofibers whereas the Aquacel Ag 
still showed week bacterial growth (Figure 27d).  
Loading of the HPCS-BV nanofibers with the PS1 bacteriophage allowed for extension of the 
antibacterial activity of HPCS-BV against MDR P. aeruginosa. At the same time, the developed 
HPCS-BV/PS1 represents a broad spectrum bacteriophage formulation, where the combination of 
the natural materials of the nanofiber and the bacteriophage allowed the nanofibrous formulation 
to exhibit broad spectrum antibacterial activity. The observed results (figures 26 & 27d) illustrate 
that the HPCS-BV/PS1 nanofibers exhibit enhanced antibacterial activity over the commercial 
Aquacel Ag even against resistant bacterial strains. Aquacel Ag was recently reported to exhibit 
the strongest antibacterial activity among other silver based wound dressings in the market 
(Yunoki et al., 2015). Thus, this indicates the enhanced efficacy of the developed HPCS-BV/PS1 
as an antibacterial formulation.  
 
4.4.5 Evaluation of the wound healing abilities of the fabricated nanofibers. 
The developed nanofibrous mats were evaluated for their effect in enhancing the wound healing 
process. Propolis has well proven ability to enhance the wound healing process (Mandel & 
Mandel, 2011; Seckam & Cooper, 2013; Dai et al., 2011; McLennan et al., 2008), whereas the 
wound healing ability of bee venom is recently recognized (Amin & Abdel-Raheem, 2014).  
Propolis, an important component of the bee hive was observed to exhibit wound healing ability 
due to its antimicrobial, antioxidant, immunomodulatory, anti-inflammatory and analgesic effects 
(Sforcin, 2007; Cardoso et al., 2010; Ramos et al., 2012).  It was demonstrated that both caffeic 
and phenethyl ester present in propolis exhibit immunosuppressive activities on T-cells which play 
a significant role in several inflammatory diseases (Lotfy, 2006). Bee venom exhibits anti-
inflammatory and antimicrobial activities that were proven beneficial in enhancing the wound 
healing process (Hider, 1988; Seo et al., 2008). It was recently observed that bee venom limits the 
prolongation of inflammation via regulating the levels of inflammatory cytokines (Kwon et al., 
2002; Abu-Seida, 2015). 
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 A 9 mm excisional wound was performed on the dorsal back of mice upon which the developed 
nanofibrous mats were applied. The wound region was photographed on days 3, 5, 7, 10 and 12 to 
illustrate the variation in the wound over time (Figure 28). Additionally, to determine the ability 
of the nanofibrous mats to enhance the wound closure rate, the wound size remaining exposed (%) 
was determined by comparing the wound size at each time point with the wound size at day 0 
(Figure 28). Aquacel Ag was utilized as the positive control in the wound healing study of the 
developed nanofibrous mats and the subsequent histopathological examination. 
As observed in figure 28, the HPCS-Pr, HPCS-BV and HPCS-BV/PS1 nanofibers as well as the 
Aquacel Ag exhibited enhanced wound closure rate as compared to the negative control covered 
with a cotton gauze. 
 Interestingly, it was observed that the HPCS-Pr demonstrated enhanced wound closure rate as 
compared to the commercial Aquacel Ag wound dressing. The enhanced effect of HPCS-Pr on 
wound healing was realized from day 3, with significant reduction in the wound size as compared 
to both the negative control and the Aquacel Ag. The HPCS-BV nanofibers, on the other hand 
exhibited similar wound closure rate to the positive control Aquacel Ag, whereas upon addition of 
PS1 to the HPCS-BV nanofibers a slight enhancement in the wound closure rate was observed 
(Figure 28). This could be attributed to the change in the weight loss rate of the HPCS-BV/PS1 
nanofibers as compared to the HPCS-BV nanofibers because of the dilution of the HPCS-BV 
polymeric solution with 10% of the phage stock solution while electrospinning the HPCS-BV/PS1 
nanofibers. This allows for the presence of increased concentration of the materials of the 
nanofibers at the wound site which leads to enhancement of the wound healing process due to the 
beneficial effects of the materials of the nanofibers on the wound healing process. 
The reduction in the healing time could be attributed to the presence of the apitherapeutics, honey, 
propolis and bee venom as well as chitosan in the developed nanofibers. This is due to the anti-
inflammatory effect of these materials that prevent prolongation of the inflammatory response that 
delays the wound healing process (Alvarez-Suarez et al., 2014). Moreover, the antibacterial 
properties of the utilized materials; honey, bee venom, propolis and chitosan prevent the presence 
of persistent inflammatory stimuli due to the presence of bacteria at the wound site and thus prevent 
the prolongation of the inflammatory phase (Bjarnsholt et al., 2008).  
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 It is worth mentioning that the fabricated nanofibrous wound dressings easily attached to the 
wound site, eliminating the need for biological adhesives. This could be attributed to the 
hydrophilic nature of the CS, P and H in addition to the increased water solubility of the high 
honey concentration included within the nanofibers. Thus, the fabricated nanofibrous wound 
dressings allow to keep the wound desirably hydrated. 
Samples of the wound tissue were H&E stained and their histopathology evaluated and scored at 
days 3, 5, 7, 10 and 12 days. Moreover, samples at day 10 were MT stained and examined for 
collagen deposition (Figures 29 & 30 and Table 4). 
It was observed from the histological data (Figure 29 and Table 4) that the HPCS-Pr allowed for 
the most enhanced reduction in necrosis since day 5. At the same time, all the examined 
nanofibrous dressing and the Aquacel Ag decreased the necrosis as compared to the negative 
control. Such effect could be attributed to the anti-inflammatory effect of honey, chitosan, bee 
venom, and propolis which reduces the damage caused by the free radicals resulting from 
inflammation thus preventing further necrosis (Alvarez-Suarez et al., 2014).  
Additionally, the application of the developed nanofibrous dressings to the wound site prevented 
prolongation of the inflammatory phase, especially with the HPCS-Pr and the HPCS-BV/PS1 
nanofibrous wound dressings, where the inflammatory cells were last observed at day 7, whereas 
in the case of the negative control they persisted till day 12. Consequently, this allowed for early 
epithelization as well as formation of thick epidermis in the wounds treated with the nanofibrous 
dressings as well as the Aquacel Ag (Figure 29 and Table 4). Such results agree with previously 
reported results for bee venom, honey and propolis regarding their anti-inflammatory effect and 
thus their ability to decrease inflammation (Kwon et al., 2002; Molan, 2006; Han et al., 2012; 
Castaldo, 2002; Peng et al., 2008). 
Earlier formation of granulation tissue was observed in the wounds treated with the Aquacel Ag, 
HPCS-Pr, and HPCS-BV/PS1, thus, indicating accelerated wound healing rate. Dense collagen 
deposition was observed with all the tested nanofibrous dressings and was confirmed via staining 
of the wounds with MT stain at day 10 and comparing them to the commercial Aquacel Ag due it 
its documented effect on enhancing the wound healing process (Barnea et al., 2010)  (Figure 30 
and Table 4). 
As seen in figure 30 all the examined nanofibrous dressings allowed for dense collagen deposition 
as well as uniform collagen distribution similar to that observed with the Aquacel Ag. Previously, 
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 it was reported that the presence of large amounts of collagen is correlated to adequate wound 
healing (Drucker et al., 1998). 
Overall, it was observed that the developed nanofibrous dressings demonstrated enhanced wound 
healing rates as compared to the Aquacel Ag. In Fact, the HPCS-Pr demonstrated enhanced effect 
on wound healing more than that observed via the Aquacel Ag according to the histopathological 
examination and the scoring of the histologic data (Table 4), whereas, the HPCS-BV and HPCS-
BV/PS1 nanofibrous dressings demonstrated similar results to the Aquacel Ag. Such results are of 
significant importance due to the current focus on honey and natural products with antimicrobial 
activity to be used as advanced antimicrobial wound care products in clinical practice (Alvarez-
Suarez et al., 2014; Frost & Sullivan, 2014). Especially, that the current therapeutic protocols rely 
on silver, and despite their efficacy as antimicrobial wound dressings the undesirable side effects 
associated with silver are generating increasing concern (Demling & DeSanti, 2001; Alvarez-
Suarez et al., 2014). 
4.4.6 Evaluation of the fibroblast cytotoxicity of the fabricated nanofibers and their effect on 
fibroblast cell proliferation. 
 
The developed HPCS-Pr, HPCS-BV and HPCS-BV/PS1 nanofibers were evaluated for their 
cytotoxicity on human dermal fibroblasts as well as for their effect on the cell proliferation via the 
MTT assay. Additionally, the effect of the commercial wound dressing Aquacel Ag on cell 
cytotoxicity and proliferation was evaluated and used as a positive control in both tests. 
The developed nanofibers were extracted and diluted to yield different extract concentrations; 
100%, 75%, 50% and 25%), that were tested for their cytotoxicity. The fibroblast cells were 
cultured in the different dilutions of the extract and the cytotoxicity was determined via estimation 
of the no of viable cells after 48h (Figure 31a). 
                                       
As observed in figure 31a, the HPCS-BV nanofibers exhibited the highest cell viability even at 
100% extract concentration thus indicating that loading of HPCS nanofibers with BV did not affect 
the biocompatibility of the nanofibers. Whereas, the HPCS-BV/PS1 nanofibers demonstrated a 
minor decrease in the viability of the fibroblast cells compared to the HPCS-BV nanofibers. This 
may be attributed to the increase in weight loss of the HPCS-BV/PS1 compared to the HPCS/BV 
nanofibers due to the loading of the nanofibers with 10% phage stock solution, where the loaded 
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 solution affected the degradation rate of the polymeric based nanofibers, resulting in an increase 
in weight loss of the nanofibers. Thus, the amount of the released components including BV from 
the HPCS-BV/PS1 nanofibers increased which resulted in a minor change in cell viability. 
However, despite the reduction in cell viability due to the HPCS-BV/PS1 nanofibers it still 
exhibited significant (p < 0.05) enhancement in cell viability compared to the commercial Aquacel 
Ag dressing that demonstrated noticeable cytotoxic effects. 
On the other hand, the HPCS-Pr nanofibers demonstrated a noticeable reduction in cell viability 
in the 100% and 75% extract solutions (Figure 31a). This may be due to the increased 
concentration of propolis loaded within the nanofibers. Propolis has been proven to exert cytotoxic 
effects on different tumor cell lines, however, it also demonstrated some cytotoxicity for non-
tumor cell lines (da Silva et al., 2013; Calhelha et al., 2014). Moreover, Kim et al studied the 
cytotoxic effects of polyurethane nanofibers loaded with 5, 10 and 30% of propolis solution and 
demonstrated that the 5% propolis solution loaded nanofibers allowed for the most enhanced cell 
proliferation even after 7 days, whereas increasing the concentration of the loaded propolis 
solution to 30% resulted in decreased proliferation rates, taking into consideration that loading 
with 10% propolis solution extract contains less amount of propolis than loading with the same 
percent of dry powder propolis extract as was performed in the current study (Kim et al., 2014). 
Despite the reduction in cell viability observed with the HPCS-Pr nanofibers it still demonstrated 
significant (p < 0.05) enhancement in cell viability compared to the Aquacel Ag commercial 
dressing (Figure 31a). 
The effect of the developed nanofibers as well as the Aquacel Ag on fibroblast cell proliferation 
was studied at 1 and 3 days. Figure 26b demonstrates the proliferation results as determined via 
the MTT assay. It was observed that HPCS-Pr demonstrated the lowest OD values among the 
developed nanofibers, whereas the HPCS-BV nanofibers exhibited the highest OD values followed 
by the HPCS-BV/PS1 nanofibers at 24h. However, none of the developed nanofibers allowed an 
enhancement in the proliferation of the fibroblast cells after 3 days of incubation. This may be 
related to the increased concentration of the released BV and Pr in the medium following 
prolonged incubation, especially that recent evaluation of the HPCS nanofibers on the fibroblast 
cell proliferation revealed significant enhancement in proliferation at 3 days of incubation. 
Compared to the commercial Aquacel Ag dressing, both the HPCS-BV and HPCS-BV/PS1 
demonstrated significant increase in cell viability at both 24 and 72h as observed via the OD 
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 values. The observed cytotoxicity of the Aquacel Ag was previously reported in different studies 
(Yunoki et al., 2015; Burd et al., 2007). 
 
It is of note that the swelling capabilities of the nanofibrous mats and their capabilities to enhance 
cell proliferation and viability could be increased by increasing the pore diameter. This could be 
achieved by changing of the parameters utilized during the electrospinning process (Kazemi 
Pilehrood et al., 2014) or by inclusion of some treatments as carbon nanotubes before 
electrospinning (Shokrgozar et al., 2011). Additionally, the nanofibrous mats density must be 
taken into consideration as an increase in the density will result in reduction in the breathability of 
the fabricated nanofibrous mats and thus, lead to restriction in nutrient and metabolic waste 
transportation and reduction in cell viability as well as decrease in the swelling capability of the 
fabricated nanofibrous mats. Within this context it was observed that ultrasonication of the 
fabricated nanofibrous mats could help overcome such limitation (Lee et al., 2011). Moreover, 
collection of nanofibrous mats of low density on a substrate could be another approach to be 
undertaken to overcome such limitation. Thus, future work on the fabricated nanofibrous mats will 
consider optimization of the breathability of the nanofibrous mats by different approaches with 
subsequent testing of the effect of each approach on the cell proliferation and viability as well as 
the swelling capability of the fabricated nanofibers. 
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 5. CONCLUSION  
 
Non-healing wounds represent a pressing health care problem with major socioeconomic impacts. 
The success in managing bacteria in wounds is of outmost importance, this is because bacterial 
infection stimulates the immune system which in turn prolongs tissue inflammation thus further 
delaying the healing process. Moreover, wound associated bacterial infection usually develops 
resistance to commonly used antibacterials, thus leading to increased risk of systemic infections. 
Antimicrobial advanced wound dressings stand as an important sector in the treatment of wound 
infections. Silver-based dressings stand as one of the most common and effective antimicrobial 
dressings used. However, despite their enhanced broad spectrum antibacterial activity, 
development of resistance has been reported together with some undesirable side effects of silver. 
Thus, through the current research different approaches have been undertaken to develop a series 
of effective antimicrobial wound dressings based on effective antimicrobials that are more 
biocompatible and able to achieve enhanced antibacterial and wound healing activity. 
The first objective in this study was to develop nanofibrous wound dressing based on high honey 
concentration. Different concentrations of honey (H) and chitosan (CS) were electrospun with 
poly(vinyl alcohol) (P) resulting in HPCS nanofibers having H concentrations up to 40% and CS 
concentration up to 5.5%. The combination of H and CS had a synergistic effect on the solution 
viscosity causing it to reach to the viscosity optimum for electrospinning. Such effect allowed for 
the first time for the development of nanofibers comprising 40% honey of their actual weight as 
compared to only 9% in previous attempts without the use of toxic solvents. Chemical and physical 
crosslinking of the fabricated HPCS nanofibers allowed different degrees of crosslinking, thus 
extending their areas of application.   
Subsequently, different honey concentrations (10%, 20% and 30%) were electrospun within the 
chitosan (3.5%) /poly (vinyl alcohol) (7%) nanofibers to study the effect of changing the honey 
concentration on the different properties of the electrospun nanofibers. It was observed that 
increasing the honey concentration resulted in an increase in the fibre diameter from 284 ± 97 nm 
with 10% honey to 464 ± 185 nm with 30% honey. The swelling of the nanofibers was greatly 
influenced by the concentration of incorporated honey and the degree of crosslinking. Highest 
swelling extent was observed with HPCS nanofibers having 10% honey, and the least swelling 
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 was noted in the HPCS nanofibers having 30% honey. The crystallization and thermal stability of 
the nanofibers on the other hand were not affected by changing the honey concentration within the 
developed HPCS nanofibers. The antibacterial activities of the HPCS nanofibers with different 
honey concentrations was evaluated against S.aureus and E.coli at two different bacterial counts. 
It was observed that increasing the honey concentration within the HPCS nanofibers enhanced 
their antibacterial activity against both S. aureus and E.coli at 7 × 107 CFU/ml. Whereas, at 7 × 
108 CFU/ml nearly no antibacterial effect was realized against E.coli at all honey concentrations 
included within the HPCS nanofibers.  Due to the enhanced antibacterial activity of the HPCS 
nanofibers loaded with 30% honey they were selected to be further loaded with other 
antimicrobials.  
 
The second objective was to load the developed HPCS nanofibers with natural extracts to enhance 
their antibacterial and wound healing abilities. Allium sativum (AE) and Cleome droserifolia (CE) 
were loaded within the selected HPCS nanofibers. Allium sativum aqueous extract substituted 
50% of the solvent of the HPCS in the HPCS-AE nanofibers and 10% of dried aqueous extract of 
Cleome droserifolia were loaded within the HPCS in the HPCS-CE nanofibers whereas, the 
HPCS-AE/CE were loaded with both the AE and CE extracts. The HPCS, HPCS-CE, HPCS-AE 
and HPCS-AE/CE nanofibrous mats were characterized and examined for their weight loss, 
swelling, cytotoxicity and wound healing capabilities. Moreover, the antibacterial activities of the 
developed nanofibers were evaluated against S. aureus, E.coli, MRSA and MDR P. aeruginosa. 
The antibacterial, wound healing abilities and cytotoxicity results were compared to those of the 
commercial wound dressing Aquacel Ag.  It was observed that substitution of 50% of the solvent 
with AE resulted in massive reduction in the HPCS solution viscosity. The HPCS-AE/CE 
nanofibrous mats demonstrated the lowest swelling capabilities and the highest weight loss among 
the fabricated nanofibers at two tested crosslinking degrees (1h and 3h exposure to GA vapours 
followed by heating at 40 ºC for 24h) showing values of less than 90% weight loss and 15% 
swelling as compared to 60-70% weight loss and ~ 90% swelling in the case of HPCS and HPCS-
AE after immersion in PBS buffer for 24h. The antibacterial evaluation demonstrated that the 
fabricated nanofibers exhibited no antibacterial activities against E.coli and MDR P. aeruginosa. 
However, complete bacterial inhibition of S. aureus better than that produced with the commercial 
dressing Aquacel Ag was achieved with both the HPCS-AE and the HPCS-AE/CE nanofibrous 
dressings. Moreover, the bacterial count of MRSA decreased by 1.5 log with the HPCS-AE/CE as 
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 compared to 3.5 log decrease in bacterial count with the Aquacel Ag. On evaluation of the wound 
healing capabilities of the fabricated nanofibrous dressings as compared to the Aquacel Ag, it was 
observed that the HPCS-AE/CE and the HPCS exhibited similar wound closure rates whereas the 
HPCS-AE allowed enhancement in the wound closure over that exhibited via the Aquacel Ag. The 
scoring of the histopathological data showed that both the HPCS and the HPCS-AE/CE 
nanofibrous wound dressings demonstrated the most enhanced effects on the different stages in 
the wound healing process with scores very close to the Aquacel Ag. Most importantly, it was 
observed that the HPCS-CE, HPCS-AE/CE and HPCS exhibited the highest levels of proliferation 
and cell viability as compared to the commercial Aquacel Ag that demonstrated noticeable 
cytotoxicity.  
 
The third objective achieved in this study was to load the fabricated HPCS nanofibers with 
apitherapeutics as another approach to develop effective biocompatible antimicrobial wound 
dressings.  The HPCS nanofibers were loaded with apitherapeutics; bee venom (0.01%) in the 
HPCS-BV nanofibers and propolis (10%) in the HPCS-Pr nanofibers. The developed nanofibers 
were characterized and examined for their swelling and weigh loss abilities as well as their 
antibacterial activities against S. aureus, E. coli, MRSA and MDR P.aeruginosa. It was observed 
that the diameter of the HPCS-Pr nanofibers was 737 ± 260 nm, whereas, the HPCS-BV exhibited 
nanofiber diameter of 459 ± 140 nm. Moreover, the lowest swelling values were observed with the 
HPCS-Pr nanofibers, showing values of 20% and 29% as compared to 76% and 90% with the 
HPCS-BV nanofibers at 1 and 3 h of crosslinking, respectively. Whereas, the lowest weight loss 
values 65-55% were exhibited by the HPCS-BV nanofibers after 24h in PBS at the two tested 
crosslinking degrees (1h and 3h exposure to GA vapours followed by heating at 40 ºC for 24h). 
The results of the antibacterial study demonstrated strong antibacterial activity of the HPCS-Pr 
nanofibers against the tested Gram positive strains S.aureus and MRSA as compared to the 
commercial Aquacel Ag wound dressing. However, the HPCS-BV demonstrated enhanced 
antimicrobial activity over the HPCS-Pr nanofibers where it exhibited enhanced antibacterial 
activity against S.aureus, MRSA and E.coli more than that observed with the Aquacel Ag. 
Nevertheless, no antibacterial activity was achieved against MDR P. aeruginosa whereas the 
Aquacel Ag exhibited strong antibacterial activity against it. Thus, the HPCS-BV was selected to 
be further loaded with a bacteriophage against P. aeruginosa and achieve the forth objective of the 
current study.  The bacteriophage PS1 was isolated against the examined MDR P. aeruginosa and 
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 loaded within the HPCS-BV nanofibers extending the spectrum of antibacterial activity of the 
HPCS-BV/PS1 to include P.aeruginosa causing nearly complete inhibition of it. The developed 
HPCS-Pr, HPCS-BV and HPCS-PV/PS1 were further tested for their cytotoxicity and wound 
healing abilities. The wound healing study results demonstrated that the HPCS-Pr exhibited wound 
closure rates and histopathological scores better than those demonstrated with the Aquacel Ag, 
whereas the HPCS-BV and HPCS-BV/PS1 exhibited similar wound healing results to the Aquacel 
Ag. Most importantly, it was observed that the developed HPCS-BV and HPCS-BV/PS1 
nanofibers demonstrated enhanced biocompatibility as compared to the Aquacel Ag that exhibited 
strong cytotoxicity. Whereas, the HPCS-Pr demonstrated some cytotoxicity at 100% and 75% 
extract solutions however, they were significantly lower than those observed with the Aquacel Ag. 
 
Through the current study, a series of nanofibrous wound dressings based on natural materials 
were fabricated. The fabricated nanofibrous dressings, HPCS, HPCS-AE, HPCS-CE, HPCS-
AE/CE, HPCS-BV, HPCS-Pr and HPCS-BV/PS1demostrated enhanced wound healing abilities 
and variable antibacterial effects against the examined bacterial strains as compared to the 
commercial Aquacel Ag. Most importantly the Aquacel Ag was proved to exhibit noticeable 
cytotoxicity on fibroblasts, whereas the fabricated nanofibrous dressings demonstrated enhanced 
biocompatibility, with the HPCS demonstrating the most enhanced cell viability and proliferation 
results. The HPCS nanofibrous dressing comprising 10% H demonstrated the highest swelling 
capability and thus the highest ability to absorb exudates. Among the developed nanofibrous 
dressings the HPCS-Pr demonstrated the most enhanced effect on wound healing, more 
pronounced than Aquacel Ag. Whereas, the HPCS-BV/PS1 demonstrated the most enhanced 
antibacterial activities exceeding the commercial Aquacel Ag and at the same time demonstrating 
similar wound healing effects and enhanced biocompatibility. Overall, the fabricated series of 
nanofibrous dressings exhibited antibacterial and wound healing abilities as well as enhanced 
biocompatibility, thus they represent competitive candidates to be used as effective wound 
dressings. 
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 6. RECOMMENDATIONS AND FUTURE DIRECTIONS  
Recommendations for future work on the developed series of honey based nanofibrous dressings 
include examination of the mechanical properties of the developed nanofibrous dressing and 
optimization of the mechanical properties of the developed nanofibrous dressings to be suitable 
for wound healing applications via the use of different fillers or different levels of crosslinking as 
well as utilization of polymers with enhanced mechanical properties. Furthermore, evaluation and 
optimization of the breathability of the developed series of honey based dressings will be 
undertaken. Additionally, the effect of loading the nanofibrous dressings with different natural 
materials as well as growth factors on the wound healing and antibacterial abilities of the 
developed nanofibrous dressings will be further explored. That’s in addition to evaluating the 
effect of co-spinning different kinds of polymers with honey and evaluating the effect of such 
combinations on the swelling, degradation, and mechanical properties of the developed nanofibers. 
 
The possible effect of honey and Allium sativum aquous extracts on the degredation of chitosan 
will be investigated via determination of the molecular weight of the chitosan after treatment with 
honey and Allium sativum aquous extracts. Additionally, the kinetics of release of the natural 
componenets included within the nanofibers will be studied as well as the degredation rate of the 
developed nanofibrous mats. Moreover, more biocompatible methods of crosslinking will be 
investigated. Additionally, the wound healing abilities of the developed nanofibrous mats will be 
tested on chronic non-healing wounds as well as infected wounds. 
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 7. TABLES  
Table 1. Change in the viscosity (mPas) of the P, PCS and HPCS solutions upon aging (Sarhan 
& Azazzy, 2015). 
 
 
Sample 2h 24h 48h 168h 
P (7%) 300 328 385 404 
HP (30%:7%) 175 214 245 319 
PCS (7%:3.5%) 86120 162830 152020 122180 
HPCS(10%:7%:3.5%) 41120 9770 6100 2787 
HPCS(30%:7%:3.5%) 27500 6520 3830 1851 
 
 
Table 2: Change in the viscosity (mPas) of the HPCS and HPCS-AE solutions upon aging 
(Sarhan et al., 2016). 
Sample 2h 24h 48h 168h 
HPCS 27610 6990 3660 1980 
HPCS-AE 1410 640 420 420 
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Table 3. Histological scoring system for MT and H&E stained wound tissues for both the control and experimental groups (Sarhan et al., 2016).  
Histopatholog-
ical lesions 
Control group Aquacel Ag HPCS-AE HPCS               HPCS-AE/CE             HPCS-CE 
3 5 7 10 12 3 5 7 10 12 3 5 7 10 12 3 5 7 10 12 3 5 7 10 12 3 5 7 10 12 
Necrosis +++ +++ ++ + - ++ ++ + - - ++ ++ + - - ++ ++ + - - ++ ++ + - - ++ ++ - - - 
Inflammatory 
cells 
+++ +++ ++ ++ ++ +++ +++ +++ + + ++ ++ ++ + + +++ +++ ++ - - +++ ++ ++ - - ++ ++ ++ + + 
Hemorrhage ++ ++ ++ + - - - - - - - - - - - - - - - - - - - + - - - - - - 
Granulation 
tissue 
maturation 
- - ++ ++ ++ - ++ ++ +++ +++ - - ++ ++ +++ - - ++ +++ +++ - + +++ +++ +++ - + + +++ +++ 
Epithelization  - - - - +++ - - + +++ +++ - - - ++ +++ - - - +++ +++ - - - +++ +++ - - - + +++ 
Epidermis 
Thickness 
- - - - ++ - - - ++ + - - - - ++ - - - ++ + - - - + ++ - - - - + 
Collagen 
deposition 
       + +        +++ +++        ++ +++        +++  +++        ++  +++        ++  ++ 
Collagen 
distribution 
       + +        +++ +++        +++ +++        +++  +++        +++  +++        ++  ++ 
The number of the histopathological scores: 0:_; 1:+; 2:++; 3:+++.
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          Table 4. Histological scoring system for Masson’s trichome and H&E stained wound tissues for both the control and experimental groups. 
Histopatholog-
ical lesions 
Control group Aquacel Ag HPCS-Pr HPCS-BV           HPCS-BV/PS1 
3 5 7 10 12 3 5 7 10 12 3 5 7 10 12 3 5 7 10 12 3 5 7 10 12 
Necrosis +++ +++ ++ + -- ++ ++ + -- -- ++ ++ + -- -- ++ ++ + -- -- ++ ++ + -- -- 
Inflammatory 
cells 
+++ +++ ++ ++ + +++ +++ +++ + + ++ ++ ++ -- -- +++ +++ ++ + -- +++ ++ ++ -- -- 
Hemorrhage ++ ++ ++ + -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- + -- 
Granulation 
tissue 
maturation 
-- -- ++ ++ ++ -- ++ ++ +++ +++ -- +++ +++ +++ +++ -- -- ++ +++ +++ -- + +++ +++ +++ 
Epithelization  -- -- -- -- +++ -- -- + +++ +++ -- -- -- +++ +++ -- -- -- +++ +++ -- -- -- +++ +++ 
Epidermis 
Thickness 
-- -- -- -- ++ -- -- -- ++ + -- -- -- ++ +++ -- -- -- ++ ++ -- -- -- ++ ++ 
Collagen 
deposition 
        +       +++  +++        +++ +++        +++ +++        ++ ++ 
Collagen 
distribution 
        +        +++ +++        +++ +++        +++ +++        +++ +++ 
¶  
          The number of the histopathological scores: 0:--; 1:+; 2:++; 3:+++
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 8. FIGURES 
 
 
 
Fig 1: Schematic illustration of the different phases involved in the wound healing process. 
 
 
                 Fig 2. Schematic illustration of the wound bacterial microbiology. 
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                              Fig 3. Schematic presentation of the electrospinnig process. 
         
Fig 4. Schematic illustration of the resemblance of the nanofibrous structure to the extracellular 
matrix (ECM) of the skin 
72 
 
                                
                                         Fig 5. Schematic illustration of bacteriophage. 
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 Fig 6. SEM images of the electrospun nanofibrous mats with the highest honey concentration 
within the HP and the HPCS nanofibers :( a) HP (20%:10%), (b) HPCS (20%:7%:3.5%) (c) HP 
(30%:10%), (d) HPCS (30%:7%:3.5%) (Sarhan & Azazzy, 2015a). 
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Fig 7. SEM images of the electrospun nanofibers containing maximum concentration (%) of honey 
and chitosan within the HPCS nanofibers: (a) HPCS (35%:7%:3.5%), (b) HPCS (40%:7%:3.5%), 
(c) HPCS (30%:5%:4.5%), (d) HPCS (30%:5%:5.5%) (Sarhan & Azzazy., 2015a). 
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Fig 8. FTIR spectra for (a) chitosan (CS) (b) poly vinyl alcohol (P) and (C) HPCS nanofibers 
(30%:7%:3.5%). 
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Fig 9. SEM images of the chemically (a, b, c, d) and physically (e, f) cross-linked HPCS 
(30%:7%:3.5%) nanofibrous mats. Cross-linking was performed by exposure to GA vapors with 
subsequent heating under vacuum at 40◦C for 24 h. Different mats were exposed to GA for 
different time intervals (a) 3 days, (b) 2 days, (c) 3 h, and (d) 1 h. Images (e) and (f) demonstrate 
the successful physical cross-linking attempts: (e) heating for 15 min at 110◦C under vacuum and 
(f) heating for 24h at 70◦C under vacuum (Sarhan & Azzazy., 2015a) 
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Fig 10. SEM images of the crosslinked and non-crosslinked electrospun HPCS nanofibers 
(30%:7%:3.5%), after 1 year of storage on shelf. (a, b) non-crosslinked  HPCS  (c) crosslinked 
HPCS via 1hr exposure to GA (d) crosslinked HPCS via 3hr exposure to GA. 
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Fig 11. SEM images of the electrospun honey/polyvinyl alcohol/chitosan (HPCS) 
nanofibrousmats with increasing concentrations of honey (a, c, e) and their diameter distribution 
(b, d, f):  (a, b) HPCS (10%:7%:3.5%), (c, d) HPCS (20%:7%:3.5%), and (e, f) HPCS 
(30%:7%:3.5%) (Sarhan et al., 2016a). 
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Fig 12. TEM (a) & SEM (b) images of honey/polyvinyl alcohol/chitosan (HPCS) nanofibers 
(30:7:3.5 w %) illustrating the inclusion of honey within the nanofibers (Sarhan et al., 2016a). 
 
 
Fig 13. XRD diffraction patterns of the honey/polyvinyl alcohol/chitosan (HPCS) nanofibers with 
increasing honey concentrations. The weight blending ratios of the electrospun mats were 7% 
polyvinyl alcohol (P), 3.5% chitosan (CS), and increasing concentrations of honey (H): 10%, 20%, 
and 30% (Sarhan et al., 2016a). 
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Fig 14. TGA of the honey/polyvinyl alcohol/chitosan (HPCS) nanofibers with increasing honey 
concentrations. The weight blending ratios of the electrospun mats were 7% polyvinyl alcohol (P), 
3.5% chitosan (CS), and increasing concentrations of honey (H): 10%, 20%, and 30% (Sarhan et 
al., 2016a) 
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Fig 15. Swelling % (a & b), and weight loss % (c) of the honey/polyvinyl alcohol/chitosan (HPCS) 
nanofibers mats with increasing honey concentrations. The weight blending ratios of the 
electrospun mats were 7% polyvinyl alcohol (P), 3.5% chitosan (CS), and increasing 
concentrations of honey (H) 10%, 20%, and 30%. The swelling abilities of the nanofibers (a) 1 h 
crosslinked (1 h CL) (b) 3 h crosslinked (3 h CL) were tested after immersion in PBS (pH 7.4) for 
1, 4, and 24 h. The weight loss of the 1 h and 3 h crosslinked nanofibers (c) were tested after 
immersion in PBS (pH 7.4) for 24 h (Sarhan et al., 2016a). 
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Fig 16. The antibacterial activity of the electrospun honey/polyvinyl alcohol/chitosan (HPCS) 
nanofibrous mats against 1 × 108 CFU/ml and 1 × 107 CFU/ml  of E. coli (a) and  S. aureus (b) 
represented by reduction in the log (CFU) after 24 h. The weight blending ratios of the electrospun 
mats were 7% polyvinyl alcohol (P), 3.5% chitosan (CS), and increasing concentrations of honey 
(H); 10%, 20%, and 30% (n = 3, Student’s t-test, *p < 0.05 versus the  negative control) (Sarhan 
et al., 2016a). 
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Fig 17. SEM images of the electrospun nanofibrous mats and their diameter distribution of  HPCS, HPCS-
AE, HPCS-CE, and HPCS-AE /CE (Sarhan et al., 2016b). 
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Fig 18. % Swelling (a & b) and % weight loss (c) of the HPCS-AE, HPCS-CE and HPCS-AE /CE. 
The swelling capabilities of the nanofibers (a) 1 h crosslinked (1h CL) (b) 3h crosslinked (3h CL) 
were examined after immersion in PBS (pH 7.4) for 1, 4, and 24 h. The weight loss of the 1h and 
3h crosslinked nanofibers (c) were examined after immersion in PBS (pH 7.4) for 24h (Sarhan et 
al., 2016b).  
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Fig 19. The antibacterial activity of the electrospun mats of HPCS, HPCS-AE, HPCS-CE, (HPCS-
AE /CE and Aquacel Ag wound dressing against S. aureus (a)  MRSA (b) E. coli ( c) and MDR 
P. aeruginosa (d) at 24 h on 7 × 108 CFU/ml bacteria. Aquacel Ag was utilized as the positive 
control and the negative control was kept untreated. Data represents mean ± SD (n = 3, Student’s 
t-test, *p < 0.05) (Sarhan et al., 2016b). 
 
86 
 
                                
 Fig 20. Photographic images of the extent of the  wound closure (a) graphical demonstration of 
the changes in the size of wound (b) on days 3, 5, 7, 10 and 12 for the HPCS, HPCS-AE, HPCS-
CE, HPCS-AE/CE nanofibrous mats and the Aquacel Ag wound dressing. The Aquacel Ag was 
utilized as the positive control and the negative control was kept untreated and covered with a 
cotton gauze (Sarhan et al., 2016b). 
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Fig 21. Histopathological evaluation of sections of the H&E stained wound tissue treated with the 
HPCS, HPCS-AE, HPCS-AE/CE, HPCS-CE nanofibrous mats and the Aquacel Ag wound 
dressing at days 3, 5, 7, 10 & 12 days (Original magnification 100). The Aquacel Ag was utilized 
as the positive control, and the negative control was untreated and covered with a cotton gauze. 
HPCS: Micrographs of the central area of the wound treated with the HPCS nanofibrous dressing. 
Note the increased infiltration of the inflammatory cells at 3 & 5 days and the formation of matured 
granulation tissue with well oriented deposition of collagen as well as thick  layer of epidermis at 
days 10 & 12 and the near disappearance of the inflammatory cells. HPCS-AE: Micrographs of 
the central area of the wound treated with the HPCS-AE nanofiber dressing. Note the massive 
inflammatory cell infiltration at days 3, 5 & 7 and the exudate observed at 5 &7 days. Mature 
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 granulation tissue that is well vascularized and with good oriented collagen deposition at day 10 
was observed. HPCS-CE: Micrographs of the central area of the wound treated with the HPCS-
CE nanofiber dressing. Note the massive infiltration of inflammatory cell at 3, 5, & 7 days and the 
enhanced vascularization (note the newly formed blood capillaries) within the matured formed 
granulation tissue. Well oriented deposition of collagen was observed since day 10. HPCS-AE/CE: 
Micrographs of the central area of wounds treated with the HPCS-AE/CE nanofibrous dressing. 
Note the massive inflammatory cell infiltration at 3, 5 & 7 days and the well vascularized 
granulation tissue formed with well oriented deposition of collagen since day 10. Notice the 
deposition of thick layer of epidermis since day 10 and that the inflammatory cells is nearly 
diminished. Aquacel Ag: Micrographs of the central area of wounds treated with the positive 
control Aquacel Ag dressing. Note the massive inflammatory cell infiltration at days 3 & 5 and 
the formation of mature granulation tissue that is highly vascularized and note the deposition of 
collagen since day 7. Notice the thick epidermal layer deposition since day 10 and that the 
inflammatory cells are greatly diminished. -ve control: Micrographs of central wound area of 
untreated controls: Note the massive inflammatory cell infiltration and the observed hemorrhage 
at days 7 & 12 as well as the disorganized granulation tissue. Notice the epithelial layer absence 
at day 10 and the deposition of thin epidermal layer at day 12 (Sarhan et al., 2016b). 
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 Fig 22. Histopathological evaluation of sections of the MT stained wound tissues treated with the 
HPCS, HPCS-AE, HPCS-AE/CE, HPCS-CE nanofibrous mats and the Aquacel Ag wound 
dressing at day 10 (Original magnification 100). The Aquacel Ag was utilized as the positive 
control and the negative control was kept untreated and covered with a cotton gauze. Notice 
deposition of dense collagen in the HPCS, HPCS-AE, HPCS-AE/CE, HPCS-CE nanofiber 
dressings and the Aquacel Ag as compared to the negative control (-ve control) (Sarhan et al., 
2016b).
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Fig 23. Fibroblast cell viability (a) and fibroblast cell proliferation (b) as determined via the MTT 
assay for the HPCS, HPCS-AE, HPCS-CE, HPCS-AE/CE and Aquacel Ag.  Aquacel Ag was used 
as the positive control in the two assays. Data represents mean ± SD (n = 3, Student’s t-test, *p < 
0.05 versus the HPCS mats, ***p< 0.05 versus culture times 24h) (Sarhan et al., 2016b). 
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Fig 24.  SEM images of the HPCS-Pr and HPCS-BV nanofibers and their corresponding diameter 
distribution. 
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Fig 25. % Swelling (a & b) and % weight loss (c) of the HPCS-Pr and HPCS-BV nanofibrous 
mats. The swelling capabilities of the nanofibers (a) 1 h crosslinked (1h CL) (b) 3h crosslinked 
(3h CL) were examined after immersion in PBS (pH 7.4) for 1, 4, and 24 h. The weight loss of the 
1h and 3h crosslinked nanofibers (c) were examined after immersion in PBS (pH 7.4) for 24h.  
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Fig 26. Illustration of the antibacterial activity of the HPCS-Pr, HPCS-BV nanofibrous mats and 
Aquacel Ag wound dressing. The antibacterial activity was tested against E.coli (a) S. aureus (b) 
MRSA (c) and MDR P. aeruginosa (d) at 24 h on 7 × 108 CFU/ml bacteria. Aquacel Ag was 
utilized as the positive control, whereas the negative control was kept untreated. Data represent 
mean ± SD (n = 3, Student’s t-test, *p < 0.05). 
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Fig 27. Illustration of the morphology of the isolated PS1 phage (a) and the electrospun HPCS-
BV/PS1 nanofibers (b) and their diameter distribution (c). Illustration of the antibacterial activity 
of the HPCS-BV, HPCS-BV/PS1 nanofibers against MDR P. aeruginosa at 24 h on 7 × 108 
CFU/ml bacteria (d). Aquacel Ag was utilized as the positive control, whereas the negative control 
was kept untreated. Data represent mean ± SD (n = 3, Student’s t-test, *p < 0.05). 
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Fig 28. Photographic images of the wound healing process (a) graphical illustration of the variation 
in the size of the wound (b) on days 3, 5, 7, 10 and 12 for the nanofibrous dressings HPCS-Pr, 
HPCS-BV, HPCS-BV/PS1 and the untreated negative control (-ve control) as well as the positive 
control treated with the commercial wound dressing Aquacel Ag . 
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Fig 29. Histopathological evaluation of sections of the H&E stained wound tissue treated with the 
HPCS-Pr, HPCS-BV, HPCS-BV/PS1 nanofibrous mats and the Aquacel Ag wound dressing at 
different time intervals (3, 5, 7, 10 & 12 days) (Original magnification 100). The Aquacel Ag was 
utilized as the positive control and the negative control was kept untreated and covered with a 
cotton gauze. HPCS-Pr: Micrographs of the central area of the wound treated with the HPCS-Pr 
nanofibrous dressing. Note the necrosis at day 3, and the massive infiltration of inflammatory cells 
at days 3, 5, & 7. Highly vascularized granulation tissue was noticed since day 5. Notice the 
epithelization and thick epidermal layer at days 10 & 12.HPCS-BV and HPCS-BV/PS1: 
Micrographs of the central area of the wound treated with the HPCS-BV and HPCS-BV/PS1 
nanofiber dressing, respectively. Note the massive inflammatory cell infiltration at days 3, 5, & 7, 
necrosis was observed at days 3 and 5. Note the well vascularized granulation tissue since day 7. 
Notice the epithelization since day 10 and formation of thick epidermal layer at 10 & 12 days. 
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 Aquacel Ag:  Micrographs of the central area of wounds treated with the positive control Aquacel 
Ag dressing. Note the necrosis at days 3 & 5 and the massive inflammatory cell infiltration. Notice 
the highly vascularized well oriented granulation tissue since day 7 and the epithelization and 
formation of thick epidermis at days 10 & 12. –ve cont.: Micrographs of central wound area of 
untreated controls covered with a cotton gauze. Note the massive inflammatory cell infiltration 
and necrosis till day 7 and deposition of thin epidermal layer at day 12. 
 
                                  
Fig 30. Histopathological evaluation of sections of the MT stained wounds treated with the HPCS-
BV, HPCS-Pr, HPCS/BV/PS1 nanofibrous mats and Aquacel Ag wound dressing at day 10 
(Original magnification 100). The Aquacel Ag was used as the positive control. Notice deposition 
of dense collagen in the wounds treated with the developed HPCS-Pr, HPCS-BV, HPCS-BV/PS1 
nanofiber dressings similar to that observed with the positive control Aquacel Ag dressing. Note 
that the most uniform and dense collagen deposition was observed with the wound treated with 
the HPCS-Pr nanofibrous dressing.  
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Fig 31. Illustration of results of the MTT assay for determination of the fibroblast cell (ATCC; crl-
2522) viability (a) and proliferation (b) for the HPCS-Pr, HPCS-BV, HPCS-BV/PS1 nanofibrous 
mats and the Aquacel Ag wound dressing.  Aquacel Ag was used as the positive control in both 
assays. Data represent mean ± SD (n = 3, Student’s t-test, *p < 0.05 versus the Aquacel Ag 
dressings). 
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a  b  s t r a  c t
Honey  nanofibers  represent  an attractive formulation  with  unique medicinal  and wound healing advan-
tages. Nanofibers  with  honey  concentrations of <10% were prepared,  however,  there  is a need to  prepare
nanofibers  with  higher  honey concentrations to  increase the  antibacterial and wound  healing  effects.
In  this work, chitosan  and  honey  (H) were  cospun with  polyvinyl alcohol (P)  allowing the  fabrication
of nanofibers  with  high  honey  concentrations  up  to 40% and  high  chitosan concentrations up  to  5.5%  of
the total weight  of the  fibers using biocompatible  solvents (1%  acetic  acid).  The fabricated  nanofibers
were  further  chemically  crosslinked,  by  exposure  to  glutaraldehyde  vapor,  and  physically  crosslinked by
heating  and freezing/thawing.  The  new HP–chitosan  nanofibers  showed  pronounced  antibacterial  activ-
ity against  Staphylococcus  aureus  but  weak  antibacterial activity against  Escherichia  coli.  The developed
HP–chitosan nanofibers  revealed  no cytotoxicity  effects  on cultured  fibroblasts.  In  conclusion, biocom-
patible,  antimicrobial  crosslinked  honey/polyvinyl  alcohol/chitosan  nanofibers  were  developed which
hold potential as  effective  wound dressing.
© 2014  Elsevier  Ltd. All  rights  reserved.
1. Introduction
Electrospinning is  recognized as an efficient method for pro-
ducing nanofibers (Li & Xia, 2004). The electrospun fibers show
the advantages of high porosity and large surface to volume
ratio (Altstädt, Lovera, Schmidt, Schmidt, & Fery, 2008). More-
over, nanofibers resemble the natural extracellular matrix and were
reported to  promote proliferation and migration of cells (Bhardwaj
& Kundu, 2010). Electrospun nanofibers represent an efficient for-
mulation for drugs and natural remedies as they allow loading high
concentration of combinations of natural and synthetic materials
and controlled/sustained release (Meinel, Germershaus, Luhmann,
Merkle, & Meinel, 2012).
Honey has profound medicinal and nutritional properties (Khan,
Abadin, & Rauf, 2007). It exhibits antimicrobial activity, debriding
∗ Corresponding author at: Department of Chemistry, School of Sciences & Engi-
neering, SSE #  1184, The American University in Cairo, AUC Avenue, PO  Box 74, New
Cairo 11835, Egypt. Tel.: 202 2615 2559; fax: +202 2795 7565.
E-mail address: hazzazy@aucegypt.edu (H.M.E. Azzazy).
and deodorising action as well as anti-inflammatory, antioxidant
and wound healing activities (Lusby, Coombes, & Wilkinson, 2002).
In 2013, Maleki et al. were able to  fabricate honey/polyvinyl
alcohol nanofibers. Unfortunately, the maximum concentration
that could be incorporated within the electrospun nanofibers was
2.25% honey of the total weight of the nanofibrous mat  (Maleki,
Gharehaghaji, & Dijkstra, 2013). Recently, Wang and He (2013),
worked on fabrication of high honey concentration nanofibers,
however, the maximum concentration of included honey was 9%
with 10% polyvinyl alcohol of the total weight of the nanofibrous
mat  (Wang & He, 2013). Thus, there is  a  need to  fabricate nanofibers
composed primarily of high honey concentrations. Such concen-
trations will maximize the therapeutic and nutritional benefits of
honey nanofibrous formulations in smaller dosage forms.
Chitosan is a  biodegradable, biocompatible polymer with
antibacterial, aqueous adsorption and wound healing ability
(Schiffman & Schauer, 2007). Also, it can promote tissue
regeneration and achieve hemostasis (Busilacchi, Gigante, Mattioli-
Belmonte, Manzotti, & Muzzarelli, 2013; Muzzarelli, Greco,
Busilacchi, Sollazzo, & Gigante, 2012). Chitosan meets also
the demands of several industrial and biomedical activities
http://dx.doi.org/10.1016/j.carbpol.2014.12.051
0144-8617/© 2014 Elsevier Ltd. All  rights reserved.
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(Muzzarelli, 2010; Muzzarelli, Greco, Busilacchi, Sollazzo, &
Gigante, 2012b; Muzzarelli, El Mehtedi, & Mattioli-Belmonte,
2014).
Because of the high viscosity of chitosan in  solutions,
electrospinning of chitosan was only possible by using toxic
or highly concentrated acidic solvents (Geng, Kwon, & Jang,
2005; Homayoni, Ravandi, & Valizadeh, 2009; Su et al., 2011).
Residues of such solvents are unfavorable especially in appli-
cations requiring biocompatible materials. Aqueous salts of
chitosan were prepared, but the concentration of the incorpo-
rated chitosan did not exceed 1% (Charernsriwilaiwat, Opanasopit,
Rojanarata, Ngawhirunpat, & Supaphol, 2010; Charernsriwilaiwat,
Opanasopit, Rojanarata, & Ngawhirunpat, 2011). Another approach
for electrospinning chitosan in more biocompatible solvents
was via co-spinning with other readily spun polymers. Among
them, co-spinning chitosan with polyvinyl alcohol is one of
the most common composites (Liao et al., 2011; Yan et al.,
2012; Zhou et al., 2007). Still, nanofibers prepared by this
method could only incorporate limited chitosan concentra-
tions.
It is the aim of the present work to co-spin high concentrations
of chitosan and honey with polyvinyl alcohol using biocompatible
solvents. This would maximize the benefit of these two important
materials in the smallest dosage form.
2. Experimental
2.1. Materials
Chitosan (Mwt: 240 kDa, DDA: 84%; Chitoclear, cg110, TM 3728;
Primex; Siglufjordur, Iceland). Polyvinyl alcohol (Mwt: 85,000;
Sigma Aldrich, St. Louis, USA), acetic acid (glacial, 99–100%;
Merck, Wadeville, South Africa), glutaraldehyde (25% in  H2O;
Sigma Aldrich, St. Louis, USA). Nutrient broth & nutrient agar
(Becton Dickinson and Company, USA). Trypsin (85450C-25G;
Sigma Aldrich), RPMI 1640 with l-Glutamine (R8758; Life Science),
fetal bovine serum (10270-106; Gibco), thiazolyl blue tetrazolium
bromide–MTT (M2128-1G; Sigma Aldrich), PBS, trypan blue and
triton X (Sigma Aldrich, St. Louis, USA). Clover honey was  obtained
from the faculty of Agriculture, Cairo University. The viscosity of
the honey was 15,300 mpas and its total soluble solid content was
81%.
2.2. Preparation of the polyvinyl alcohol/chitosan (P-chitosan),
honey/polyvinyl alcohol (HP) and honey/polyvinyl
alcohol/chitosan (HP–chitosan) solutions
Different solutions composed of different weight ratios of
P-chitosan and HP as well as HP–chitosan were prepared as fol-
lows: P-chitosan (7%:1.5%, 7%:2.5% and 7%:3.5%); HP (20%:10%
and 30%:10%), and HP–chitosan (30%:7%:1.5%, 30%:7%:3.5%,
30%:5%:5.5%, 30%:5%:4.5%, 20%:7%:3.5% and 40%:7%:3.5%). Solu-
tions were prepared in 1% acetic acid. Each of the as prepared
solutions of HP–chitosan was aged at room temperature for dif-
ferent time intervals.
2.3. Viscosity measurements
The viscosity of the polyvinyl alcohol (7%), P-chitosan (7%:3.5%),
HP (30%:7%), and HP–chitosan (30%:7%:3.5% and 10%:7%:3.5%) sam-
ples were determined using a  viscometer (Myr; VR-3000, Viscotech
Hispania, Tarragona, Spain). The solutions were aged at room tem-
perature for a  week. The viscosity of all samples was tested at
different time intervals (0, 24, 48 h and 1 week). The average value
of three measurements was reported as mean ± SD.
2.4. Electrospinning of polyvinyl alcohol/chitosan (P-chitosan),
honey/polyvinyl alcohol (HP) and honey/polyvinyl
alcohol/chitosan (HP–chitosan) nanofibers
Each of the as-prepared solutions of P-chitosan, HP  and
HP–chitosan with different weight blending ratios was electrospun
into nanofibers via the electrospinner (E-spin, NanoTech, Kalyan-
pur, India). The solutions were loaded in a  5 ml plastic syringe that
was attached to  a  stainless steel needle (22 gauge) as a nozzle. The
electrospun polymer solutions were subjected to  different voltages
(Gamma  High Voltage Power Supply, USA) for adjustment of the
optimum voltage for each of the spun solutions. The flow rate of the
solution was maintained at 10 l/min and the distance between
the nozzle and the collector was maintained at 15 cm. Collection
of the samples was done on a ground collector wrapped with an
aluminum sheet.
2.5. Cross-linking of fiber mats
Physical and chemical methods were used to crosslink the fiber
mats of HP–chitosan. Glutaraldehyde (GA) was used for chemical
crosslinking. The fiber mats were placed in  a closed desiccator that
was saturated with GA vapors (40 ml). Exposure of the nanofiber
mats to  the GA vapors was  done for different time intervals (30, 60,
120 and 180 min  as well as 48 h and 72 h). Subsequently, enhance-
ment of the crosslinking reaction and removal of unreacted (GA)
were done via heating the nanofiber mats in  an oven under vacuum
at 70 ◦C for 24 h as well as at 40 ◦C for 24 h. Physical crosslinking was
performed by freezing/thawing and heating techniques. Freezing
and thawing was performed via freezing the fiber mats for 15 min
in liquid nitrogen followed by thawing at room temperature for
15 min  for three successive cycles. Heating was carried out under
vacuum in an oven (Jeiotech, OV-11, South Korea) at both 110 ◦C,
100 ◦C for 15 min  and 80 ◦C for 25 min as well as at 70 ◦C for 24  h.
2.6. Characterization and measurements of the electrospun
nanofibers
The morphologies of the electrospun nanofibers were observed
using scanning electron microscopy (FESEM, Leo Supra 55, Zeiss
Inc., Oberkochen, Germany). Fourier transform infrared spec-
troscopy (FTIR) was  performed for the raw polyvinyl alcohol and
chitosan and the HP–chitosan nanofibrous mats using FTIR (Thermo
scientific, Nicolet 380, USA). The transmission mode with KBr pel-
lets was used for bulk chitosan and polyvinyl alcohol as well as and
HP–chitosan nanofibrous mats.
2.7. Degree of swelling and weight loss
The HP–chitosan nanofibrous mats were tested for the degree
of swelling and weight loss that were calculated according to  Eqs.
(1) and (2),  respectively. Both tests were carried out in phosphate
buffered saline [PBS], pH (7.4) at 37 ◦C for 1, 4 and 24 h.
Degree of swelling (%) =
[
M −  Mi
Mi
]
× 100 (1)
Sharma, Dinda, & Mishra (2013)
Weight loss (%) =
[
Mi − Md
Mi
]
× 100 (2)
where M is the swollen weight of the nanofibrous sample which
was dried using a filter paper, Md is the dried mass of the nanofi-
brous sample after being immersed in buffer medium, measured by
drying the swollen mats at 40 ◦C until constant weight was reached,
and Mi  is  the initial dry mass of sample.
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2.8. Assessment of antibacterial activity
Viable cell count technique was used to determine the antibac-
terial activity of the electrospun HP–chitosan nanofibrous mats
with 30% honey/7% polyvinyl alcohol and increasing chitosan con-
centrations (1.5%, 3.5%, and 5.5%). The antibacterial activity was
assessed against both Staphylococcus aureus and Escherichia coli.
Each of the S.  aureus and E. coli were added into 10 ml  nutrient
broth medium that was adjusted to an OD of 0.1 at 625 nm.  Sub-
sequently (0.1 g) of the HP–chitosan nanofibrous mats were added
to each of the S.  aureus and E. coli test tubes. All the nanofibrous
mats were UV sterilized for 20 min  prior to antibacterial testing.
The S. aureus and E. coli tubes containing the nanofibrous mats and
a control were then incubated at 37 ◦C with shaking at 100 rpm.
Samples from the treated bacterial broth and the control were taken
and serially diluted in nutrient broth at 24 and 48 h. Subsequently,
100 L  from each dilution were spread on nutrient agar plates that
were then incubated at 37 ◦C for 24 h,  after which the numbers of
surviving colonies were counted.
The antibacterial activity was estimated according to  Eq. (3):
Antibacterial activity = (log CFU ∗ t −  log CFU ∗ 0)
− (log CFUt  − log CFU0) (3)
where CFU0 and CFUt  are the number of colony forming units at
time zero and time t for the nanofibrous samples; CFU*0 and CFU*t
are the number of colony forming units at time zero and time t for
the control (Amrit, Hendrix, Dutschik, & Warmoeskerken, 2012).
2.9. Cytotoxicity evaluation (MTT assay)
Primary skin fibroblast cells of neonatal mice origin were used
to evaluate the toxicity of the HP–chitosan nanofibrous mats with
increasing chitosan concentrations (1.5%, 3.5%, and 5.5%) and 30%
honey/7% polyvinyl alcohol. Preparation of the primary cell cul-
ture was done according to the method of Seluanov, Vaidya, and
Gorbunova (2010). Non crosslinked and crosslinked nanofibrous
mats were tested for each concentration. Crosslinking was  achieved
via exposure to  GA vapors for 180 min, followed by heating at 70 ◦C
under vacuum. Cytotoxicity was evaluated via the addition of the
extracts of the nanofiber scaffolds to cells cultured in a  24-well plate
and the cytotoxicity was determined via MTT  assay. The nanofi-
brous mats were extracted via soaking the scaffolds in  culture
media for 24 h at 37 ◦C. Subsequently the extracts were harvested
for cytotoxicity testing. Normal cells without any treatment were
used as the negative control whereas (1% Triton X) was  used as
the positive control. The cells were seeded in  a  24 well plate at a
density of 104 cells/well and incubated in a  humidified incubator
with 5% CO2 for 24 h at 37 ◦C before treatment with the extracts
to allow cell attachment. Subsequently, the extract for each scaf-
fold was added to the cell monolayer and incubated for 48 h into
CO2 incubator at 37 ◦C and 5% CO2. Triplicate wells were prepared
for each sample. After 48 h, the difference in morphology between
cell controls and scaffold extracts was observed by  observing the
cells under inverted microscope. Cell viability was assessed after 3
days via MTT  assay. The absorbance was determined at 570 nm.  And
percent of cell survival was  calculated according to the following
equation:
Survival% =
[
Asample − Ab
Ac − Ab
]
×  100 (4)
where Ac is  the negative control; Ab is  the blank.
The average value of three measurements was reported as
mean ±  SD. Analysis of the data was  done via  analyses of  variance
(ANOVA) test. And results were considered statistically significant
with a  probability less than 0.05.
3. Results and discussion
3.1. Preparation of polyvinyl alcohol/chitosan (P-chitosan),
honey/polyvinyl alcohol (HP)and honey/polyvinyl
alcohol/chitosan (HP–chitosan) nanofibers
The solutions of P-chitosan, HP, and HP–chitosan were tested
for viscosity at different time intervals as shown in Table 1.  At  zero
time, the viscosity of (HP; 30%:7%) was  very low (175 mpas) and the
viscosity of the (P-chitosan; 7%:3.5%) was  very  high (85,440 mpas)
making both solutions impossible to  spin. Whereas, the combina-
tion of (HP–chitosan; 30%:7%:3.5%) exhibited 34,000 mpas at day
zero. Such viscosity value, however, was  still above the optimum
viscosity required for spinning. Thus, the HP–chitosan solutions
were allowed to age at room temperature for a week. Interest-
ingly, the viscosity of the HP–chitosan solutions dropped noticeably
upon aging. This was  unlike the P-chitosan and the HP solu-
tions that exhibited increased viscosities after aging for one week
(Table 1).
The decrease in  viscosity of the HP–chitosan solutions with time
could be due to enzymatic degradation of chitosan via  the enzymes
present in  the honey. Small amounts of enzymes occur naturally
in honey, including enzymes that transform polysaccharides into
smaller products as amylase. Chitosan is most likely to be affected
by such enzymes (Xie, Jia, Huang, & Zhang, 2011). Moreover, hydro-
gen peroxide, which is  an important component of honey, may  have
contributed to  the enzymatic degradation of chitosan (Brudzynski,
2006). Interestingly, it was observed that the increase in  the honey
concentration within the HP–chitosan mixtures has resulted in fur-
ther reduction in the viscosity of the solutions (Table 1).
3.2. Morphology of the polyvinyl alcohol/chitosan (P-chitosan),
honey/polyvinyl alcohol (HP) and honey/polyvinyl
alcohol/chitosan (HP–chitosan) nanofibers
Different concentrations of the P-chitosan, HP and HP–chitosan
were electrospun. For P-chitosan combinations, the highest con-
centration of chitosan that could be electrospun with polyvinyl
alcohol using 1% acetic acid, was 1.5%. For HP combinations the
highest concentration of honey that could be electrospun with
polyvinyl alcohol was  20% honey (Fig. 1a). However the electrospun
fibers showed clusters, which are most probably clusters of honey
that were not  included within the polyvinyl alcohol nanofibers.
Remarkably, upon addition of 3.5% chitosan to the same HP com-
bination, uniform nanofibers were produced (Fig. 1b). This is  due
Table 1
Change in the viscosity (mpas) of the polyvinyl alcohol (P), honey/P (HP), P-chitosan, and HP–chitosan solutions upon aging.
time P  (7%) (mpas) HP (30%:7%) (mpas) P-chitosan (7%:3.5%) (mpas) HP–chitosan (10%:7%:3.5%) (mpas) HP–chitosan (30%:7%:3.5%) (mpas)
0 h 300 175 85,440 48,010 34,000
24  h  328 214 162,830 9770 6520
48  h  385 245 152,020 6100 3830
168 h  404 319 122,180 2787 1851
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Fig. 1. SEM images of the electrospun nanofiber mats with the highest concentration (%) of honey within the honey/polyvinyl alcohol (HP) and the HP–chitosan nanofibers:
(a)  HP (20%:10%), (b) HP–chitosan (20%:7%:3.5%) (c) HP (30%:10%), (d) HP–chitosan (30%:7%:3.5%).
to the favorable effect of chitosan on the viscosity of the solution
allowing it to reach to the optimum degree of chain entanglements
required to  form uniform nanofibers.
Upon increasing the honey concentration to  30% in the HP
combination the honey clusters increased extensively (Fig. 1c)  indi-
cating the inability of the polyvinyl alcohol polymer to incorporate
higher concentrations of honey even at higher concentrations of
polyvinyl alcohol, where the decrease in viscosity imparted by
honey on the HP combination could not be overcome by increasing
the concentration of polyvinyl alcohol. On the other hand, increas-
ing the chitosan concentration to 3.5% in the P-chitosan resulted in
highly viscous solution that was impossible to  spin (Table 1). Inter-
estingly, the combination HP–chitosan (30%:7%:3.5%), upon aging
for more than 2 days acquired the optimum viscosity required for
easy spinning and formation of uniform nanofibers (Fig. 1d). Such
combination of HP–chitosan allowed for the first time the pro-
duction of biocompatible fibers via biocompatible solvents of high
concentrations of both honey and chitosan.
Realizing the synergistic effect of both honey and chitosan on the
viscosity of the HP–chitosan combinations, attempts were made to
increase the concentration of the incorporated honey and chitosan.
Spinning 35% and 40% honey within the combination of chitosan
(3.5%)/polyvinyl alcohol (7%) was successful (Fig. 2a  and b). Also,
spinning 4.5% and 5.5% chitosan in the presence of 30% honey was
achieved (Fig. 2c and d). However, due to the high viscosity of
the increased concentration of chitosan, the concentration of PVA
incorporated was decreased to 5%.
In previous attempts to prepare nanofibers containing high
honey concentration, the maximum incorporated concentration
that was electrospun with polyvinyl alcohol was 9% (Wang & He,
2013). This is  because increasing the honey concentration results
in remarkable decrease in viscosity of the solution, thus mak-
ing it impossible to electropsin. This is the first report to  prepare
nanofibers with honey concentrations reaching to 40% of the actual
weight of the nanofiberous mat. Furthermore, the favorable effect
of honey on the viscosity of the chitosan solution upon aging
allowed for the first time the incorporation of higher chitosan con-
centrations reaching to 5.5% while using biocompatible solvents.
The FTIR spectra of the polyvinyl alcohol CH and HP–chitosan
nanofibers were analyzed. Chitosan exhibited characteristic bands
at 3429 cm−1and 1655 cm−1 corresponding to the OH and the
amide O  C NH2 groups. The bands of the CH3 and CH3 O groups
could be observed between 1000 and 2000 cm−1 (Paipitak, Pornpra,
Mongkontalang, Techitdheer, & Pecharapa, 2011). The FT-IR spec-
tra of polyvinyl alcohol showed bands at 3429 cm−1,  2923 cm−1,
and 1444 cm−1 the characteristic bands for OH, CH2,  and CH OH
groups (Yan et al., 2012). The previous characteristic bands of both
polyvinyl alcohol and chitosan were all preserved in  the result-
ing  hybrid fibers. However, it was observed that the absorption
peak at about 3429 cm−1 and 1655 cm−1 concerned with OH and
amide O C NH2 groups shifted to a  lower wave number in the
composite HP–chitosan. At the same time, the characteristic peak
in the hybrid HP–chitosan at 1058 cm−1 could be attributed to  the
C O C symmetric stretching and C O H bending vibrations of
protein in  honey. Whereas, the amide band of protein in honey
could be observed at 1641 cm−1 (Philip, 2009). Moreover, the peaks
between 900 cm−1 and 750 cm−1 were attributed to the anomeric
region, which is  a characteristic of saccharide configuration of
honey (Jaganathan & Mandal, 2009; Philip, 2010).
3.3. Morphology before and after cross-linking treatment
It  was  observed that the nanofibrous scaffolds of HP–chitosan
combinations lose their nanofibrous structure in  aqueous media.
Thus, efficient crosslinking was  necessary to  broaden the possible
applications of the developed nanofibers.
Through the present work different crosslinking strategies were
undertaken, to allow efficient crosslinking without jeopardizing the
biocompatibility of the fibers. In chemical crosslinking the temper-
ature of heating did not exceed 110 ◦C. This is  because excessive
heating above 140 ◦C can result in  reduction of the honey qual-
ity and increase in the hydroxymethylfurfural content (Tosi, Ré,
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Fig. 2. SEM images of the electrospun nanofiber mats with the maximum concentration (%) of both honey and chitosan within the honey/polyvinyl alcohol/chitosan
(HP–chitosan) nanofibers: (a) HP–chitosan (35%:7%:3.5%), (b)  HP–chitosan (40%:7%:3.5%), (c) HP–chitosan (30%:5%:4.5%), (d) HP–chitosan (30%:5%:5.5%).
Lucero, & Bulacio, 2004). Fig. 3 shows the images of the chemically
cross-linked nanofibers after immersion in  PBS for 15 min.
The fibers that were subjected to GA vapors for three days
showed superior crosslinking (Fig. 3a) and maintained their orig-
inal shapes and no swelling was observed. Fibers subjected to  GA
vapors for 2 days showed similar results however slight swelling
was observed (Fig. 3b). Interestingly, decreasing the exposure
time to GA vapors to 3 h maintained their nanofibrous structure
with some swelling (Fig. 3c). Meanwhile, decreasing the exposure
time to 1 h (Fig. 3d) showed lower crosslinking efficiency, where
partial degradation of the outer layers of the fibers began with
noticeable swelling. However, crosslinking efficiency decreased
noticeably upon decreasing the GA exposure time to  30 min, where
the percentage of the degraded fibers increased and the nanofi-
brous structure in the outer layer was  nearly lost. Subjecting the
nanofibers to GA vapors for 1 h and 3 h,  with subsequent heating for
24 h to promote crosslinking at 40 ◦C, showed the same crosslinking
efficiency as nanofibers heated at 70 ◦C. It  was reported that expos-
ing honey to  40 ◦C for 96 h did not affect any of its biomolecules
(Molan, 1992).
Fig. 3. SEM images of the chemically cross-linked Honey/polyvinyl alcohol/chitosan (HP–chitosan) (30%:7%:3.5%) nanofibrous mats. Cross-linking was performed by  exposure
to  GA vapors and then heating at 70 ◦C under vacuum for 24 h. Different mats were exposed to GA for different time intervals (a) 3 days, (b)  2  days, (c) 3 h, and (d) 1 h.
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Fig. 4. SEM images of the honey/polyvinyl alcohol/chitosan (HP–chitosan) (30%:7%:3.5%) nanofiber mats that exhibited physical cross-linking by: (a)  heating at 110 ◦C for
15  min  under vacuum and (b) heating at 70 ◦C for 24 h  under vacuum.
Among the different physical crosslinking procedures applied,
cross-linked fibers could only be achieved by  heating at 110 ◦C for
15 min  (Fig. 4a), it could be observed also that such fibers exhibited
noticeable swelling. Meanwhile, heating at 70 ◦C for 24 h showed
partially degraded swollen fibers (Fig. 4b). Heating induces the
crystallization of the incorporated polymers (Kang et al., 2010).
Freezing and thawing in  liquid nitrogen as well as heating at ele-
vated temperatures made the nanofibrous scaffold brittle and liable
to cracking.
It is worth noting, that upon physical cross-linking by heat-
ing, a change in  the color of the nanofibers was observed from
white to light brown. The same effect was observed upon aging
of the nanofibers for several months. Such color change may  indi-
cate possible interactions between the sugar aldehyde groups and
the chitosan amino groups.
3.4. Weight loss and water retention behavior
The water uptake capability and degree of weight loss of the
electrospun fibers were investigated. As shown in Fig. 5,  the non-
crosslinked fibers exhibited swelling capabilities between 46% and
197%, with the highest swelling observed for the sample containing
3.5% chitosan and 20% honey (HP–chitosan: 20%:7%:3.5%) tested
at 4 h. Although, polyvinyl alcohol, chitosan and honey enhance
water uptake, the samples showed moderate swelling capabili-
ties when compared to previously spun chitosan and polyvinyl
alcohol fibers lacking honey. Jannesari, Varshosaz, Morshed, and
Zamani (2011),  reported that the swelling value of polyvinyl alco-
hol/chitosan nanofibers was 390% after 24 h compared to  135% for
the HP–chitosan: 3.5%:20%:7% in  the present work.
Such results may  be attributed to the high water solubil-
ity of honey, where although honey increases the water uptake
(MohdZohdi, Abu BakarZakaria, Yusof, Mohamed Mustapha, &
Abdullah, 2011), its high water solubility leads to an increase
in the degradation rate of the fibers. Similarly, Wang et al.
observed the same effect upon inclusion of 20% honey in a gela-
tine/chitosan/honey hydrogel. Honey first promotes swelling due
to  its high osmolarity, however, upon water uptake the high water
solubility of honey accelerates the degradation rate and thus results
in low swelling due to the absence of a compact structure to retain
the water (Wang, Zhu, Xue, & Wu,  2012). Thus, the highest swelling
percent in  all tested samples were observed at 4 h that decreased
at 24 h. Moreover, upon comparing the HP–chitosan samples of
30%:7%:3.5% and 20%:7%:3.5% (Fig. 5a), it was observed that an
increase in  the water uptake capability is achieved upon decreasing
the honey concentration.
On the other hand, chitosan with its decreased water solubil-
ity decreases the weight loss within the HP–chitosan nanofibrous
mats, which is observed upon comparing the decrease in swelling
and the increase of the weight loss of the (HP–chitosan;
30%:7%:1.5%) compared to  (HP–chitosan; 30%:7%:3.5%) (Fig. 5a
and b). However, upon increasing the chitosan concentration to
5.5% in the HP–chitosan nanofibers, a  marked increase in  the
swelling percent was only observed at 24 h.  This is  because,
Fig. 5. % Swelling (a)  and %  weight loss (b) of the honey/polyvinyl alcohol/chitosan (HP–chitosan) nanofiber mats with different weight ratios of HP–chitosan after immersion
in  PBS (pH 7.4) for 1, 4, and 24 h. Different weight ratios of the tested HP–chitosan included: (A) 30%:7%:1.5%, (B) 30%:7%:3.5%, (C) 30%:7%:5.5%, and (D) 20%: 7%:3.5%.
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Fig. 6. The antibacterial activity of the electrospun honey/polyvinyl alcohol/chitosan (HP–chitosan) of mats against S. aureus (a) and E. coli (b) at 24 and 48  h on 7 × 108 CFU/ml
bacteria. The weight blending ratios of the electrospun mats were 7% polyvinyl alcohol, 30% honey and increasing concentrations of chitosan; (A) 1.5%, (B) 3.5%, and (C) 5.5%.
although chitosan enhances water uptake, increasing the chitosan
concentration above a  certain level does produce the opposite
effect. This was explained by Son et al., who observed that in the
chitosan/polyvinyl alcohol nanofibrous scaffolds of low chitosan
concentrations, the hydrophilic polyvinyl alcohol could easily form
polymeric hydrogels in solutions thus allowing enhanced swelling.
Whereas, above certain concentration of chitosan, the intermolec-
ular forces between the chitosan side chains and the amine groups
increase, thus leading to decreased swelling (Son, Yeom, Song, Lee,
& Hwang, 2009).
3.5. Antibacterial evaluation
The antimicrobial activity of honey is due to its ability to produce
hydrogen peroxide, its high sugar content, its acidity and its con-
tent of flavonoids (Vandamme, Heyneman, Hoeksema, Verbelen,
& Monstrey, 2013). On  the other hand, the antibacterial activity
of chitosan is mainly due to  the interaction between the chitosan
polycations and the negatively charged surfaces of bacteria, which
leads to loss of bacterial membrane permeability leading to cell
leakage and death (Muzzarelli, Tarsi, Filippini, Giovanetti, Biagini,
& Varaldo, 1990).
Considering its biodegradable nature, the antibacterial activity
of the HP–chitosan nanofibrous mats is dependent on the con-
centration of its components in  the media which increases with
time. As shown in Fig. 6a,  the antibacterial activity against S. aureus
increased with increasing the chitosan concentration within the
HP–chitosan nanofibers. Moreover, increasing the incubation time
resulted in  marked increase in antibacterial activity especially with
the 3.5% and 5.5% incorporated chitosan concentrations. Complete
bacterial inhibition was achieved at 48 h with the 5.5% chitosan.
This may  be attributed to  the decreased solubility of chitosan, thus
at longer incubation periods larger percentage of the nanofibers
are degraded leading to increase in the concentration of available
chitosan thus leading to increased antibacterial activity.
Testing the HP–chitosan nanofibrous mats on E. coli revealed
weak antibacterial activity (Fig. 6b). Such results agree with the
results of No, Young Park, Ho Lee, and Meyers (2002) who  observed
the weak antibacterial activity of chitosan against gram negative
bacteria (No, Young Park, Ho Lee, & Meyers, 2002).
It is worth mentioning that the nanofibrous structure enhanced
the antibacterial activity of the included components. The tested
sample (0.1 g)  contains less than 20 ppm chitosan and approx-
imately 0.175% honey and produced pronounced antibacterial
effects against S.  aureus and weak antibacterial effects against E. coli
compared to no antibacterial effect at such concentrations for both
honey and chitosan alone (Goy, Britto, & Assis, 2009; Islam, Masum,
Mahbub, & Haque, 2011I; Liu et al., 2006; Mandal & Mandal, 2011).
Such results could be attributed to the dramatic increase in  the
surface to volume ratio of the nanofibers.
3.6. Cytotoxicity evaluation
Cells grown with the extracts of the HP–chitosan nanofibers
showed similar morphologies to  that of the negative control
(data not shown). Primary skin fibroblast cells were cultured with
the extract of the crosslinked and noncrosslinked HP–chitosan
nanofibrous scaffolds having the concentrations of 30%:7%:1.5%,
30%:7%:3.5% and 30%:7%:5.5% for 3 days and their toxicities were
evaluated using MTT  assay as shown in  Fig. 7.
Fig. 7.  Effect of electrospun honey/polyvinyl alcohol/chitosan (HP–chitosan)
nanofibers on cultured fibroblasts investigated using MTT  assay. Different
HP–chitosan nanofibrous scaffolds with 30% honey, 7% polyvinyl alcohol, and dif-
ferent concentrations of chitosan: (A) 5.5%, (B) 3.5%, and (C) 1.5%, were tested. Both
non-crosslinked and crosslinked HP–chitosan nanofibrous scaffolds were tested. The
data  represents the mean ± SD (N =  3).
142 W.A. Sarhan, H.M.E. Azzazy /  Carbohydrate Polymers 122 (2015) 135–143
Cells cultured with the HP–chitosan nanofibrous scaffolds
exhibited no significant differences in  cell viability to those of the
negative control (cultured with no nanofibrous scaffolds) (p <  0.05)
and significantly different and improved viability than the cells
cultured with the positive control. Such results indicate the bio-
compatibility of the developed HP–chitosan nanofibrous scaffolds.
It was realized, however, that the crosslinked nanofibers in all
tested nanofibrous samples showed slight decrease in the viability
of the cells compared to  the noncrosslinked nanofibers. This may
be due to  the traces of GA remaining on the nanofibers. Still, the
viability of the cells cultured with the crosslinked nanofibers after
3 days were similar to those of the negative control indicating good
biocompatibility.
4. Conclusions
In this study, polyvinyl alcohol was co-spun with honey and
chitosan resulting in  HP–chitosan nanofibers with honey concen-
trations ranging from 20% to 40% and chitosan concentrations
ranging from 1.5% to 5.5%. The combination of chitosan and honey
had a synergistic effect on the viscosity of the solution allowing it
to reach the optimum viscosity required for electrospinning. Such
effect allowed for the first time for fabrication of nanofibers com-
prising 40% of their actual weight honey compared to 9% in previous
attempts and up to  5.5% chitosan without the use of high concen-
trated acids or toxic solvents. Physical and chemical crosslinking of
the developed HP–chitosan nanofibers resulted in different degrees
of crosslinking which may  extend their applications. The devel-
oped nanofibers (HP–chitosan; 30%:7%:3.5%) exhibited enhanced
antibacterial activity against S. aureus but poor antibacterial activity
against E. coli.  The antibacterial activity increased by increasing the
concentration of the incorporated chitosan within the nanofibers
from 1.5% to  5.5%. Additionally, changing the concentrations of
chitosan and honey resulted in different degrees of water uptake
ranging from 46% to  197%. The degradation rate of the devel-
oped nanofibers was inversely related to  the concentration of the
chitosan within the nanofibers. Glutaraldehyde crosslinked and
noncrosslinked nanofibers had no toxicity on cultured primary
fibroblasts. The developed HP–chitosan nanofibers with high con-
centrations of honey and chitosan hold the potential as effective
biocompatible wound dressings.
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ABSTRACT: Two natural extracts were loaded within
fabricated honey, poly(vinyl alcohol), chitosan nanofibers
(HPCS) to develop biocompatible antimicrobial nanofibrous
wound dressing. The dried aqueous extract of Cleome
droserifolia (CE) and Allium sativum aqueous extract (AE)
and their combination were loaded within the HPCS
nanofibers in the HPCS-CE, HPCS-AE, and HPCS-AE/CE
nanofiber mats, respectively. It was observed that the addition
of AE resulted in the least fiber diameter (145 nm), whereas
the addition of the AE and CE combination resulted in the
least swelling ability and the highest weight loss. In vitro
antibacterial testing against Staphylococcus aureus, Escherichia
coli, Methicillin-resistant S. aureus (MRSA), and multidrug-
resistant Pseudomonas aeruginosa was performed in comparison with the commercial dressing AquacelAg and revealed that the
HPCS-AE and HPCS-AE/CE nanofiber mats allowed complete inhibition of S. aureus and the HPCS-AE/CE exhibited mild
antibacterial activity against MRSA. A preliminary in vivo study revealed that the developed nanofiber mats enhanced the wound
healing process as compared to the untreated control as proved by the enhanced wound closure rates in mice and by the
histological examination of the wounds. Moreover, comparison with the commercial dressing Aquacel Ag, the HPCS, and HPCS-
AE/CE demonstrated similar effects on the wound healing process, whereas the HPCS/AE allowed an enhanced wound closure
rate. Cell culture studies proved the biocompatibility of the developed nanofiber mats in comparison with the commercial
Aquacel Ag, which exhibited noticeable cytotoxicity. The developed natural nanofiber mats hold potential as promising
biocompatible antibacterial wound dressing.
KEYWORDS: honey chitosan nanofibers, natural extracts, antibacterial, wound healing, cell culture
■ INTRODUCTION
Chronic nonhealing wounds have a major socioeconomic
impact with more than 25 billion dollars as the cost of
nonhealing wounds.1 One of the main reasons that complicates
and delays the wound healing process is bacterial infection.
Thus, advanced antimicrobial wound dressings are witnessing
increased demand within the wound care market. Such
dressings allow the sustained release of the loaded antimicro-
bials, thus permitting the realization of their antibacterial
activity while maintaining a healthy concentration to the
healing tissues. Antimicrobials as silver, iodine, and chlorhex-
idine have a broad spectrum of antibacterial activity and are
extensively used in wound treatment; however, they may
damage healthy tissues.2,3 Thus, investigation of additional
antimicrobials is warranted.
Allium sativum (garlic) has been known historically for its use
to treat infectious diseases.4 Allium sativum exhibits well proven
antibacterial activity against both Gram-positive and Gram-
negative bacteria as well as resistant bacterial strains.5−8 Such a
therapeutic effect of Allium sativum is mainly attributed to its
water-soluble and oil-soluble organosulfur compounds.
Cleome droserifolia (Forssk.), Del., a member of the
Cleomaceae family, is another plant of striking medical
importance.9 Cleome droserifolia is still traditionally used by
the Egyptian Bedouins in the treatment of diabetes and
wounds. Cleome droserifolia is also used for treating rheumatism,
scabies, and inflammation10 that is in addition to its proven
antioxidant activity.11,12 The phytochemical studies revealed the
enrichment of Cleome with different beneficial compounds
including phenolics, flavonoids, terpenoids, and alkaloids.13−15
Recently, the antibacterial effects of Cleome droserifolia have
been observed and were linked to its content of different
terpenes.9 However, studies regarding the Cleome’s biological
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activity as well as its phytochemistry are still far from being
complete.9
It has been argued that the antimicrobial efficacy alone of an
advanced dressing is insufficient and other properties that
enhance the wound healing process are also required.16 Thus,
through the current research, a new series of electrospun
nanofibrous wound dressings based on high concentrations of
honey and chitosan, and enriched with Allium sativum and
Cleome droserifolia, has been developed for enhanced
antimicrobial and wound healing activity. Honey and chitosan
are well-known for their wound healing and antibacterial
properties.17−20Moreover, the nanofibrous structure resembles
the extracellular matrix of the skin and thus enhances the
healing process. In our previous research, the developed honey/
chitosan-based nanofibrous mats were proved to have mild
antibacterial activity.21 Consequently, this study aims to
enhance the antibacterial activity of honey chitosan nanofiber
mats by adding natural extracts and test the combination of the
natural extracts with honey and chitosan within the nanofibrous
structure for their antibacterial and wound healing abilities.
■ EXPERIMENTAL SECTION
Materials. Fresh bulbs of Allium sativum (AE) were purchased
from a local vendor, and honey (clover) was obtained from the faculty
of Agriculture, Cairo University. Cleome droserifolia (CE) was collected
from the mountains of Sinai, Egypt. Chitosan (Mw of 240 kDa and
DDA of 84%, Chitoclear, cg110, TM 3728) was supplied from Primex
(Siglufjordur, Iceland). Poly(vinyl alcohol) (Mw of 85 kDa),
glutaraldehyde (25% in H2O), and absolute ethanol (≥99.8%) were
supplied from Sigma-Aldrich (St. Louis, MO). Glacial acetic acid (99−
100% purity) was provided from Merck (Wadeville, South Africa).
Muller Hinton broth, agar−agar, nutrient broth, and nutrient agar
were purchased from Oxoid (Basingstocke, UK). AquacelAg
(ConvaTec Inc.) was purchased from a local pharmacy in Egypt.
Fetal bovine serum (FBS), thiazolyl blue tetrazolium bromide-MTT
(M2128-1G), phosphate buffered saline (PBS), Dulbecco’s modified
eagle medium (DMEM), and triton X were supplied from Sigma-
Aldrich (St. Louis, MO).
Preparation of Aqueous Extracts of Allium sativum (AE) and
Cleome droserifolia (CE). Bulbs of fresh AE were extracted according
to the method of ref 22. Fresh bulbs of AE (10 g) were peeled, washed
with distilled water several times, and then the AE was homogenized
aseptically using a sterile mortar and a pestle. Subsequently, Whatman
No. 1 paper was used to filter the homogenized mixture. The obtained
filtrate was then directly used in the preparation of the electrospinning
solutions. On the other hand, dried leaves of CE were extracted
according to established protocols.23 The air-dried aerial parts of CE
were powdered and extracted via boiling in distilled water for 2 min
and then allowed to stand for 10 min before filtration. Whatman No. 1
paper was used to filter the boiled mixture. Subsequently, a rotary
evaporator was used to remove the water, and the remaining extract
was dried in a vacuum oven at 40 °C (Jeiotech, OV-11, South Korea)
until a dry powder of CE extract was obtained. The powder was
weighed and stored until further use.
Preparation of the Electrospun Solutions. Various blend
solutions of honey/poly(vinyl alcohol)/chitosan (HPCS), honey/
poly(vinyl alcohol)/chitosan/Allium sativum extract (HPCS-AE),
honey/poly(vinyl alcohol)/chitosan/Cleome droserifolia extract
(HPCS-CE), and honey/poly(vinyl alcohol)/chitosan/Allium sativum
extract/Cleome droserifolia extract (HPCS-AE/CE) were prepared. In
the preparation of the blend solution of (HPCS-AE), AE was used as
50% of the solvent in which honey (30 w/v), chitosan (3.5 w/v), and
poly(vinyl alcohol) (7 w/v) were dissolved. Both of the blend
solutions of HPCS and HPCS-AE were prepared in 1% of aqueous
acetic acid. Both solutions were allowed to age at room temperature
for 1 week. Cleome droserifolia dry powder extract (CE) (10 w/v) was
added to both as-prepared HPCS and HPCS-AE blend solutions
before electrospinning and stirred for 1 h to form the blend solutions
of HPCS-CE (30:7:3.5:10 wt %) and HPCS-AE/CE (30:7:3.5:10 wt
%) in 50% AE as the solvent, respectively. During preparation of all
blend solutions, poly(vinyl alcohol) was dissolved separately in one-
half the volume of the solvent at 100 °C with stirring followed by
addition of the remaining volume of the solvent with the other
constituents to the cooled solutions to avoid any degradation of the
active constituents due to exposure to elevated temperatures.
Viscosity Measurements. The aqueous AE extract replaced 50%
of the solvent of the HPCS blend solution; thus, its effect on the
viscosity of the blend solution had to be examined. The viscosity of the
HPCS-AE (30%:7%:3.5%:50%) blend solution was determined and
compared to that of the HPCS (30%:7%:3.5%). The viscosity of the
aged solutions was determined using a viscometer (Myr; VR-3000,
Viscotech Hispania, Tarragona, Spain) at different time intervals (0,
24, 48 h, and 1 week). The average value of three measurements was
reported as mean ± SD.
Electrospinning of the As-Prepared Blend Solution. The
electrospinning of the HPCS, HPCS-AE, HPCS-CE, and HPCS-AE/
CE solutions was performed using NANON-O1A electrospinner
(MECC, Japan). The as-prepared solutions were loaded in a 5 mL
plastic syringe attached to an 18 gauge stainless steel needle as the
nozzle. Different voltages and flow rates were applied to each of the
blend solutions, and the optimum values that allowed the most
uniform nanofibers were selected for collection of the nanofibrous
mats. The distance between the needle and the collector was kept at
13 cm. Samples were collected on ground collector that was wrapped
in aluminum sheets and cotton gauze. During collection, a stationary
collecting surface was used, but the spinneret moved transversely at a
speed of 100 mm/s and a width of 100 mm.
Characterization and Measurements. The morphologies of the
developed nanofibers were observed using scanning electron
microscopy (FESEM, Leo Supra 55, Zeiss Inc., Oberkochen,
Germany). Diameters of the fabricated nanofibers were measured
using Image-J software. For each of the developed nanofibrous mats,
100 fibers were measured from three different images, and the average
diameter was calculated.
Assessment of the Swelling and Weight Loss of the Cross-
Linked Nanofibrous Mats. The developed HPCS, HPCS-AE,
HPCS-CE, and HPCS-AE/CE nanofibrous mats were cross-linked
via exposure to vapors of glutaraldehyde (GA) (40 mL) for 1 and 3 h.
The cross-linked nanofibrous mats were subsequently heated at 40 °C
in a vacuum oven to remove any traces of unreacted GA and to
enhance the cross-linking. The swelling ability and weight loss of the
cross-linked nanofibrous mats were evaluated via placing the mats in
phosphate buffered saline, PBS (pH 7.4) at 37 °C. The following
relationships were used for determination of the swelling ability of the
nanofibrous mats at 1, 4, and 24 h, and their weight loss at 24 h:
= − ×M M Mdegree of swelling (%) [ / ] 100i i (1)
= − ×M M Mweight loss (%) [ / ] 100i d i (2)
where M is the weight of the swollen nanofibrous mats after plotting
their surface with filter paper, and Md is the weight of the dried
nanofibrous mats after being removed from the phosphate buffer
saline. The swollen nanofibrous mats were dried in an oven at 40 °C
until constant weight was achieved. Mi is the initial dry weight of the
electrospun nanofibrous mats.24
Antibacterial Evaluation. The developed HPCS, HPCS-AE,
HPCS-CE, and HPCS-AE/CE were evaluated for their antibacterial
activities using the viable cell count technique as compared to
AquacelAg (ConvaTec Inc.) as the positive control. The antibacterial
activities of the developed nanofibrous mats and the AquacelAg were
tested against Staphylococcus aureus, Escherichia coli, multidrug-resistant
(MDR) Pseudomonas aeruginosa, and methicillin-resistant Staph-
ylococcus aureus (MRSA). The electrospun nanofibrous mats were
UV sterilized for 20 min, then 0.05 g of each of the developed
nanofibrous mats as well as AquacelAg were added to sterile tubes
containing 3 mL of sterile Muller Hinton broth. Each of the tested
bacterial strains was incubated overnight at 37 °C, and fresh colonies
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were used to prepare bacterial suspensions for each of them. The
turbidity of the bacterial suspensions was adjusted to 0.5 McFarland
standard (1 × 108 cfu/mL). Aliquots (30 uL) of each bacteria were
added to the sterile tubes with the nanofibrous mats and the
AquacelAg. The tubes as well as negative controls were subsequently
incubated at 37 °C with shaking at 100 rpm. Following 24 h of
incubation, 10 uL from each of the treated bacterial broth as well as
the controls were taken, and serial dilution was performed. From each
dilution, 50 uL was spread on nutrient agar plates that were incubated
at 37 °C. After 24 h of incubation, the surviving colonies were counted.
The plates that allowed counting from 10 to 150 CFU were used for
counting. The experiment was repeated three times, and the mean
value of CFU was recorded.
In Vivo Wound Healing Studies. In vivo wound healing studies
were performed on male mice weighing 25 g. All animals were
anaesthetized with a mixture of ketamin HCl (50 mg/kg) and xylene
HCl (20 mg/kg), and then their backs were shaved. A 9 mm wound
was created on the back of each mice with a biopsy puncher. The
HPCS, HPCS-AE, HPCS-CE, and HPCS-AE/CE were UV sterilized
for 20 min, and each of the nanofibrous mats was placed on the wound
site. AquacelAg (ConvaTec Inc.) was used as the positive control,
whereas the negative control remained untreated and was covered with
a cotton gauze. The change in the wound area was measured at 3, 5, 7,
10, and 12 days. The extent of wound healing is expressed as the
percentage of wound area that remained exposed. Each sample as well
as the controls were tested on three mice, and the mean value of three
measurements was recorded.
= ×W Wwound size (%) [ / ] 100(3,5,7,10,12) (0)
where W(0) and W(3,5,7,10,12) represent the exposed areas of the wounds
on days 0 and 3, 5, 7, 10, and 12, respectively.25
Histological Examination and the Scoring System Used for
the Histologic Outcomes. The wound site with the surrounding
muscle and skin was cut and then fixed with 10% buffered formalin.
The collected samples were then put in paraffin and sectioned. Each of
the tissue samples was then subjected to Hematoxylin and Eosin
(H&E) staining as well as Masson’s trichrome (MT) staining. The
H&E stained sections were evaluated and scored at days 3, 5, 7, 10,
and 12, and the MT stained sections were evaluated and scored at day
10. The stained sections were evaluated for the following histologic
outcomes: necrosis, amount and kind of inflammatory infiltrates,
hemorrhage, granulation tissue, epithelization, thickness of the
epidermis, and collagen deposition. A histologic scoring system was
used to assess each parameter, and a score of 0−3 was assigned for
each sample. Necrosis, hemorrhage, inflammatory infiltrates, collagen
deposition, epithelization, and thickness of the epidermis were graded
as 0 (none), 1 (scant), 2 (moderate), and 3 (abundant). Severity of
inflammation was scored as follows: 0 (no inflammatory cells) no
inflammation; 1 (presence of abundant macrophages and scarce
neutrophils); 2 (presence of equal macrophages and neutrophils); and
3 (presence of abundant neutrophils and scarce macrophages). The
maturation (thickness) of the granulation tissue was graded as 0
(immature), 1 (mild maturation), 2 (matured), and 3 (fully matured
with collagen deposition). Collagen distribution (based on the
collagen fibers distribution in the microscopic fields) was graded as
0 (no collagen distributed), 1 (nonuniform distribution), 2 (mild
uniformity in distribution), and 3 (uniform distribution).
Cell Viability Assay. The HPCS, HPCS-AE, HPCS-CE, and
HPCS-AE/CE as well as AquacelAg as a positive control were tested
for their cytotoxicity. The nanofibrous samples were UV sterilized for
30 min, and then the extract solutions of each of the nanofibrous mats
and the AquacelAg were prepared via immersion of the sterilized mats
in DMEM with 1% PS and 10% heat-inactivated FBS and incubating
them at 37 °C. The extract solutions of the tested samples were then
filtered via sterile disposable filters (0.20 mm, Merck, Darmstadt,
Germany). DMEM medium was then used to make several dilutions of
the extract (0%, 25%, 50%, and 100%). Human fibroblast cells (HFD4,
ATCC; crl-2522) (1 × 104 cells per well) were incubated for 24 h in a
96 well plate. The extract solutions were then added to the plate and
incubated in a CO2 incubator at 37 °C. After 24 h, the human
fibroblast cells were incubated with the extract solution for 48 h.
Subsequently, MTT solution (20 ul) was added to each well and then
incubated for 4 h. The formed dark blue formazan crystals were
dissolved in DMSO (200 uL), and their optical density was recorded
at a wavelength of 595 nm to determine the viability of each sample.
The obtained results were compared to the results obtained from an
untreated control.26
Cell Proliferation. The cell proliferation ability of the developed
HPCS, HPCS-AE, HPCS-CE, and HPCS-AE/CE as well as AquacelAg
as a positive control was evaluated. The human fibroblast cells were
seeded (1 × 104 cells/well) on the tested samples and incubated for 1
and 3 days. At each time point, the tested samples were removed from
the original plate to a new 24 culture plate that contains fresh media (1
mL) and MTT solution (100 uL) per well, and then incubated for 4 h.
The formed formazan crystals were dissolved in DMSO, and the
optical density was measured at 595 nm.26
■ RESULTS AND DISCUSSION
Viscosity Measurements of the HPCS and HPCS-AE
Blend Solutions. It was recently proven that electrospinning
HPCS nanofibers with high honey and CS concentrations was
made possible only via aging the solution of PVA/CS with the
30% honey for a week.21,27 In the present work, AE substituted
50% of the solvent in which the HPCS solution was prepared.
It was observed that the HPCS-AE solution exhibited very high
viscosity at the time of preparation; thus the solution was
allowed to age at room temperature for a week while
monitoring its viscosity at different time intervals. As shown
in Table 1, the addition of the aqueous AE to the HPCS
solution resulted in a massive decrease in its viscosity as
compared to the control HPCS solution. Such a decrease in
viscosity could be attributed to the degradation of the CS
backbone due to the addition of the aqueous extracts of AE.
As can be noted from Table 1, the decrease in viscosity
imparted via the addition of the aqueous AE was very sharp,
and it was realized from the first 2 h (1410 mPa·s) and reached
its maximum reduction in viscosity after 48 h, reaching to 420
mPa·s as compared to 3660 mPa·s for the HPCS solution
lacking the aqueous AE. This illustrates that AE played an
important role in the degradation of the CS chains with the
subsequent decrease in viscosity of the solution.
Prior to electrospining and after both solutions of HPCS and
HPCS-AE have reached the viscosity optimum for electro-
spinning, the CE (10%) dry powder extract was added and
stirred for an hour. It is worth mentioning that the CE extract
could not be added to both the HPCS and the HPCS-AE
solutions before aging due to the very high viscosities of the
solutions, which were difficult to stir. It was observed that the
addition of CE dry powder extract did not affect the viscosity
required for electrospinning even after aging.
Electrospinning of the (HPCS), (HPCS-AE), (HPCS-CE),
and (HPCS-AE/CE) Solutions. Recently, we have managed to
electrospin HPCS nanofibers, which contained up to 40%
honey and 5.5% CS. The developed HPCS nanofibers
represented the first successful report of preparing nanofibers
Table 1. Change in the Viscosity (mPa·s) of the HPCS and
HPCS-AE upon Aging
sample 2 h 24 h 48 h 168 h
HPCS 27 610 6990 3660 1980
HPCS-AE 1410 640 420 420
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including high concentrations of honey and chitosan using
biocompatible solvents.21
Aqueous AE extract substituted 50% of the HPCS solvent,
whereas the dry powder of CE (10% w/v) was added to both of
the prepared solutions of the HPCS and HPCS-AE prior to
electrospinning. The prepared solutions were then electrospun
and collected as nanofibrous mats for subsequent examination.
The addition of the aqueous AE with its imparted effect on
the viscosity of the solution has facilitated the electrospinning
process. However, due to the massive reduction in viscosity,
undesirable dripping has occurred during the electrospinning.
The parameters that allowed a steady and continuous jet for the
HPCS-AE solutions included a voltage of 27 kV, a flow rate of
0.5 mL/h, and the distance between the needle and the
collector was kept at 13 cm. The nanofibers were collected for
4.5 h, and the surface morphology of the resulting nanofibrous
mats was examined using SEM (Figure 1). The SEM
micrographs of both of the nanofibers (HPCS and HPCS-
AE) showed a dense, compact, smooth, and uniform bead-free
morphology. Moreover, it was observed that the inclusion of
the AE allowed for the least fiber diameter among the examined
nanofibrous mats (145 ± 58 nm) as well as the most focused
fiber diameter distribution. Upon the addition of the CE to
both the HPCS and the HPCS-AE solutions, it became more
difficult to electrospin the solutions until optimizing the
electrospinning parameters to be 28 kV, 0.7 mL/h flow rate,
while the distance between the needle and the collector was
maintained at 14 cm. The nanofibers were collected for 3.5 h;
however, achieving a uniform fiber deposition was still critical.
This may be attributed to the sticky nature of the Cleome
droserifolia (CE) where they exhibit glandular sticky leaves.28
Figure 1 shows a bimodal diameter distribution of the HPCS-
CE and HPCS-AE/CE nanofibers, due to the addition of a high
concentration of the CE combined with its sticky nature.
Figure 1. SEM images of the electrospun nanofibers and their diameter distribution illustrating variation in morphology and fiber diameter of the
honey/poly(vinyl alcohol)/chitosan (HPCS) nanofibers due to the incorporation of the natural extracts: Allium sativum (AE), Cleome droserifolia
(CE), and their combination (AE/CE).
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Additionally, noticeable branching of the fibers was observed
with a noted formation of clusters at the branching point.29 The
observed branching is most probably due to spinning of a
highly concentrated solution30 using a high voltage in addition
to the sticky nature of such a solution. Spinning of high
concentrated solutions leads to a jet with relatively large
diameter, which could lead to the formation of branches.31 This
in turn resulted in larger interfiber spaces, which was proved to
be more useful in cell related applications such as wound
healing and tissue engineering,32,33 taking into consideration
the density of the collected nanofibrous mat.
Assessment of the Swelling and Weight Loss Abilities.
Determination of the swelling capability of the nanofibers
allows prediction of their exudate management ability.34 The
developed nanofibers of HPCS, HPCS-AE, HPCS-CE, and
HPCS-AE/CE were cross-linked and tested for their swelling
abilities after immersion in PBS (pH 7.4) for 1, 4, and 24 h.
Cross-linking of the developed nanofibers was performed via
exposing the nanofibrous mats to the GA vapors for 1 and 3 h21
followed by heating at 40 °C to enhance the cross-linking of
nanofibers and remove any GA residues.
It was realized that at 1 h cross-linking, the HPCS, HPCS-
AE, and HPCS-CE exhibited almost similar swelling abilities
with a slight reduction in the swelling percent of both HPCS-
AE and HPCS-CE especially after 24 h of immersion in the
PBS (Figure 2a). At 3 h cross-linking the HPCS-CE exhibited
noticeable reduction in its swelling ability, whereas the swelling
percent of the HPCS-AE/CE nanofibrous mats was observed to
be the lowest at both the 1 and the 3 h cross-linking times,
showing values of less than 15% swelling as compared to
approximately 90% of swelling in the case of both the HPCS
and the HPCS-AE after 24 h of immersion in the PBS buffer
(Figure 2b). Such results indicate that the addition of the CE to
both the HPCS and the HPCS-AE nanofibers greatly decreased
their swelling abilities. This may be due to the sticky nature of
the CE, which hinders the intermolecular motion, and chain
disentanglements of the developed nanofibers, and thus hinders
their swelling capabilities.28 As the swelling of the nanofibers
can give some indication about their breathability, it seems that
the breathability of both HPCS-CE and HPCS-AE/CE
decreased, especially that of the HPCS-AE/CE.
Increasing the cross-linking time allows also maintaining a
compact nanofibrous structure that permits the water uptake
capability of the porous nanofibrous structure to be realized. At
the same time, the cross-linking degree should not be increased
to the point hindering the intermolecular motion and chain
entanglements within the nanofibers.35,36Increasing the cross-
linking time enhanced the swelling ability of HPCS-AE and
HPCS-AE/CE at 3 h cross-linking but had nearly no effect on
the HPCS and HPCS-CE nanofibers, which exhibited similar
swelling values at both of the tested cross-linking times (1 and
3 h). Such results indicate that the slight increase in the cross-
linking time affected only the nanofibers containing the
aqueous AE. This may be attributed to the fact that the AE
containing nanofibers exhibited increased weight loss as
compared to the HPCS and HPCS-CE nanofibers (Figure
2c). Upon cross-linking of the AE containing nanofibers, a
more compact nanofibrous structure could be maintained for a
longer period of time, which resulted in the enhancement
realized in their swelling abilities after 3 h cross-linking.
According to the results of the swelling study, it is expected
that the HPCS-AE/CE nanofibers would exhibit nearly no
ability for exudate management, whereas the HPCS, HPCS-AE,
and HPCS-CE nanofiber wound dressings would exhibit
moderate ability for exudate management. The HPCS,
HPCS-AE, and HPCS-CE samples exhibited moderate swelling
abilities as compared to previously spun CS/PVA nanofibers
lacking honey.24This may be attributed to the high water
solubility of honey, which leads to an increase in the weight loss
of the nanofibers.21 Moreover, despite that CS enhances the
water uptake ability of the nanofibers, increasing the
concentration of CS leads to an opposite effect. This was
observed by Son et al., who demonstrated that in nanofibrous
mats of CS/PVA of low CS concentration, polymeric hydrogels
are readily formed by the hydrophilic PVA in solutions, thus
resulting in enhanced swelling. However, upon increasing the
CS concentration, the intermolecular forces between the amine
groups and the CS side chains increase and reduced the
swelling ability.37
Assessment of the Antibacterial Activity. Chronic,
nonhealing wounds that suffer from resistant bacterial strains
experience major complications as well as delayed healing.
Thus, research into the development of effective antimicrobial
wound dressings represents an increasing trend within the
wound dressing market. Silver-based dressings stand as one of
the most common and effective antimicrobial dressings used.
However, development of resistance has unfortunately been
reported together with some undesirable side effects of silver.38
Recently, we have proven that the HPCS nanofiber mats exhibit
mild antibacterial activity against S. aureus and weak
antibacterial activity against E. coli.21 To enhance the
antibacterial activity of the HPCS nanofibers, AE and CE and
Figure 2. Swelling % (a and b) and weight loss % (c) of the (HPCS),
(HPCS-AE), (HPCS-CE), and (HPCS-AE/CE). The swelling abilities
of the fibers (a) 1 h cross-linked (1 h CL) and (b) 3 h cross-linked (3
h CL) were tested after immersion in PBS (pH 7.4) for 1, 4, and 24 h.
The weight loss of the 1 and 3 h cross-linked nanofibers (c) was tested
after immersion in PBS (pH 7.4) for 24 h.
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their combination were loaded within the HPCS nanofibers and
tested for their antibacterial activity against S. aureus and E. coli
as well as two resistant strains, MRSA and MDR P. aeruginosa.
The antibacterial effect of the commercial wound dressing,
AquacelAg, was tested and compared to the antibacterial effects
of the developed nanofibrous wound dressings. Recently,
Yunoki et al. reported that the AquacelAg showed the highest
antibacterial activity among other silver-based dressings in the
market.39
The antibacterial activity of honey has been attributed to its
capability for hydrogen peroxide production, its increased sugar
content, as well as its acidity in addition to its flavonoid
content.40 On the other hand, CS’s antibacterial activity is
mainly due to its polycationic nature, which leads to cell leakage
and death upon its interaction with the negatively charged
surfaces of the bacteria.41 The thiosulfinates mainly including
diallyl sulfide, diallyl disulfide, and allyl methyl sulfide have
been linked to the antibacterial activity of the aqueous extracts
of Allium sativum through their ability to disrupt cell
components as well as blocking pathways of different bacterial
enzymes.42,43Cleome’s antibacterial activity has been linked to
its content of different terpenes including the sesquiterpenes
carotol, β-eudesmol, and δ-cadinene.9
The antibacterial activities of Allium sativum aqueous extract
and Cleome droserifolia dry extract have been screened via
measuring the inhibition zone. The results demonstrated
enhanced antibacterial activity of AE against S. aureus, and
week antibacterial activity against E. coli and MRSA, whereas no
antibacterial activity was noted against P. aeruginosa. Cleome
droserifolia, on the other hand, demonstrated only weak
antibacterial activity against MRSA and S. aureus (results not
shown).
Figure 3 represents the antibacterial effects of the developed
HPCS, HPCS-AE, HPCS-CE, and HPCS-AE/CE nanofibrous
mats in comparison with the commercial wound dressing
AquacelAg. It was observed that both the HPCS-AE and the
HPCS-AE/CE nanofibrous mats exhibited complete bacterial
inhibition against S. aureus as compared to noticeable bacterial
reduction with the AquacelAg dressing (Figure 3a). Such effect
is mainly due to the inclusion of the aqueous AE within the
HPCS nanofibers. Moreover, it was observed that among the
developed nanofibrous mats, only the HPCS-AE/CE exhibited
some antibacterial activity against MRSA, thus indicating that
the combined antibacterial effects of both the AE and the CE
were required to achieve antibacterial activity against the
MRSA-resistant strain (Figure 3b). Still, the achieved
antibacterial activity against MRSA was not significant as
compared to the negative control (p < 0.05) and less than that
realized with the AquacelAg.
On the other hand, none of the developed nanofibers
exhibited antibacterial activity against both the E. coli and the
MDR P. aeruginosa, whereas the AquacelAg exhibited complete
inhibition of E. coli and enhanced inhibition against MDR P.
aeruginosa (Figure 3c and d).
The antibacterial activities of the honey, CS, Allium sativum,
and Cleome droseifolia were reported against both Gram-
positive and Gram-negative bacteria.9,41,44 Moreover, enhanced
antibacterial activity against S. aureus as compared to E. coli was
reported for CS45 and Cleome droseifolia oil9 as well as the
mixture of honey and Allium sativum.46 This coincides with the
results obtained here regarding the increased antibacterial
activity observed against the tested S. aureus and MRSA strains.
Assessment of the Wound Healing Ability. The
developed nanofiber dressings and the AquacelAg commercial
dressing were applied on an excisional 9 mm wound on the
dorsal back of mice. Photographs of the wound region were
taken on days 3, 5, 7, 10, and 12 to determine the change in the
wound size over time (Figure 4). To determine the wound
healing ability of the tested dressings, the percentage of the
wound size remaining exposed was determined via comparing
Figure 3. Antibacterial activity of the electrospun mats of (HPCS), (HPCS-AE), (HPCS-CE), and (HPCS-AE/CE) against S. aureus (a), MRSA (b),
E. coli (c), and MDR P. aeruginosa (d) at 24 h on 7 × 108 CFU/mL bacteria. Data represent mean ± SD (n = 3, Student’s t test, *p < 0.05).
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the size of the wound at each time point with the size of the
wound on day 0 (Figure 4).
Honey and CS have been reported to enhance wound
healing.47,48 Honey enhances the tissue repair process via
stimulating the leukocytes to release cytokines and triggering an
immune response against infection.49 Moreover, honey allows
fast autolytic debridement and suppression of inflammation.50
CS has been reported to indirectly enhance cell proliferation in
vivo.51 Additionally, immediate migration of polymorphonu-
clear cells (PMN) and mononuclear cells (MN) was observed
after application of CS. The PMN and MN degrade CS into its
low molecular weight oligomers and monomers, which exhibit
strong ability for promoting cell migration.52 Allium sativum
enhances the wound healing process via increasing the re-
epithelialization as well as the profuse dose-dependent
neovascularization.53,54 Cleome droserifolia, on the other hand,
has not yet been studied for its effect on wound healing;
however, Cleome is known for its antioxidant activity,11,55 and
antioxidants have been correlated to the enhancement of the
wound healing process via preventing the overexposure of the
wound to oxidative stress, which delays the wound healing
process.56
As observed in Figure 4, the wound size was noticeably
reduced on day 3 with the HPCS, HPCS-AE, and HPCS-AE/
CE nanofiber dressings as compared to the negative control
wounds. Significant reduction in the wound size was observed
with all of the tested dressings as well as the AquacelAg as
compared to the negative control on days 5 and 7. At the same
time, the negative control nearly exhibited no reduction in
wound size in day 5 (Figure 4). It was observed that the wound
closure was greatly enhanced with the HPCS nanofiber mats,
and upon addition of AE in the HPCS-AE mats, the wound
closure rate increased. On the other hand, the wound closure
rate was reduced upon addition of the CE to the HPCS-CE
nanofibrous mats, whereas the combination of both extracts
within the HPCS-AE/CE nanofiber dressings showed wound
closure rates similar to those of the HPCS dressing (Figure 4).
Upon comparing the wound closure rate of the developed
nanofibrous dressings to the commercial AquacelAg, it was
observed that the HPCS and the HPCS-AE/CE showed similar
effects, whereas the HPCS-AE showed enhanced wound
closure rates.
It is also of note that all of the developed nanofibrous
dressings attached easily to the wounds with no need for
biological adhesives. This is due to the hydrophilic nature of the
PVA, CS, and honey in addition to the high water solubility of
the high concentration of honey incorporated. Thus, the
developed dressings allow the wound to stay desirably
hydrated.
Assessment of the Histological Outcomes. The wound
tissues were H&E stained, and their histopathology was
examined and scored at days 3, 5, 7, 10, and 12 and were
also MT stained and evaluated for collagen deposition at day 10
(Figures 5 and 6, and Table 2). The histological data
demonstrated that all of the developed nanofibrous dressings
together with the AquacelAg reduced the necrosis as compared
to the negative control with the HPCS-CE showing the most
enhanced reduction since day 5 (Figure 5 and Table 2).
Moreover, the application of the developed dressings to the
wound site has reduced the number of inflammatory cells as
compared to the control where they were completely
diminished at day 10 in the case of HPCS-AE/CE nanofibrous
dressing. Additionally, it was observed that the number of
macrophage cells was greater than the neutrophils in all of the
treated wounds. As compared to the negative control, it was
observed that the developed dressings as well as the AquacelAg
allowed early epithelization with the AquacelAg, HPCS, and
HPCS-AE/CE showing the earliest epithelization as well as
thicker observed epidermis (Figure 5 and Table 2). Moreover,
it was observed that the HPCS-AE/CE and the AquacelAg
allowed earlier granulation tissue formation. Additionally, the
tested nanofibrous dressings and the AquacelAg have allowed
mature granulation tissue formation with dense collagen
deposition (Figure 5 and Table 2). This was confirmed via
Masson’s trichome staining of the wounds on day 10, which
demonstrated that the collagen regenerated in the treated
wounds was denser than the negative control, and that both
AquacelAg and the HPCS showed the most dense collagen
deposition. Moreover, the AquacelAg, HPCS, HPCS-AE/CE,
and HPCS-AE demonstrated the most uniform collagen
distribution (Figure 6 and Table 2).
Overall, the scoring of the histologic data indicated that
among the tested nanofiber dressings, the HPCS-AE/CE has
demonstrated the most enhanced effect on wound healing
followed by the HPCS dressing with scores very similar to
those of AquacelAg. Both nanofiber dressings allowed
reduction in the inflammatory phase, and earlier granulation
tissue formation as well as earlier epithelization and formation
Figure 4. Photographic images of the extent of wound healing: (a)
graphical illustration of the changes in wound size (b) on days 3, 5, 7,
10, and 12 for the developed nanofibrous dressings HPCS, HPCS-AE,
HPCS-CE, and HPCS-AE/CE as well as the untreated negative
control (-ve control) and the treated positive control with the
commercial dressing AquacelAg.
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of thicker epidermis. Additionally, both dressings induced
dense and uniform collagen deposition.
Assessment of the Cell Viability and Proliferation. The
cytotoxicity of the developed HPCS, HPCS-AE, HPCS-CE, and
HPCS-AE/CE nanofiber mats as well as the commercial wound
dressing, AquacelAg, were investigated using MTT assay.
Soluble MTT is metabolized into the insoluble purple formazan
salt via the enzymes found inside the mitochondria of the viable
cells. The fibroblast cells were cultured in different concen-
trations of the extract solutions of the tested nanofiber mats
(100%, 75%, 50%, and 25%), and the cytotoxicity was
estimated via determining the viable cell densities after 48 h
(Figure 7a). It was observed that the HPCS and the HPCS-CE
mats exhibited the highest cell viability of 90% and 87%,
respectively, in the 100% extract solution, whereas the HPCS-
AE exhibited significant decreased cell viability of 68% (p <
0.05) that increased to 75% upon addition of the CE in the
HPCS-AE/CE nanofibers in the 100% extract solution (Figure
7a). On the other hand, it was realized that the AquacelAg
exhibited significant cytotoxicity to the cultured fibroblasts at all
tested dilutions (p < 0.05) and demonstrated viable cell counts
of ∼9% similar to the results of the positive cytotoxic control
(Figure 7a).
Figure 5. Histopathological evaluation of skin sections. Micrographs of H&E stained tissues of wounds treated with the developed nanofiber
dressings and the AquacelAg as well as untreated negative control at different time intervals (3, 5, 7, 10, and 12 days) (original magnification 100).
HPCS: Micrographs of the central wound area in mice treated with the HPCS nanofiber wound dressing. Note the massive infiltration of
inflammatory cells at days 3 and 5 and the matured granulation tissue with well oriented collagen deposition as well as thick epidermal layer in days
10 and 12 and that the number of inflammatory cells is greatly diminished. HPCS-AE: Micrographs of the central wound area in mice treated with
the HPCS-AE nanofibrous wound dressing. Note the massive infiltration of inflammatory cells at days 3, 5, and 7 with observed exudation on days 5
and 7. Mature well vascularized granulation tissue with well oriented collagen deposition was observed on day 12. HPCS-CE: Micrographs of the
central wound area in mice treated with the HPCS-CE nanofibrous wound dressing. Note the massive inflammatory cell infiltration in days 3, 5, and
7 and the well vascularized (note the newly formed blood capillaries) mature granulation tissue formation with well oriented collagen deposition
since day 10. HPCS-AE/CE: Micrographs of the central wound area in mice treated with the HPCS-AE/CE nanofiber wound dressing. Note the
massive infiltration of inflammatory cells in days 3, 5, and 7 and the formation of mature well vascularized granulation tissue with well oriented
collagen deposition since day 10. Notice the formation of thick epidermal layer since day 10 and that the number of inflammatory cells is greatly
diminished. AquacelAg: Micrographs of the central wound area in mice treated with the AquacelAg wound dressing. Note the massive infiltration of
inflammatory cells in days 3 and 5 and the formation of highly vascularized mature granulation tissue with collagen deposition since day 7. Notice the
formation of thick epidermal layer since day 10 and that the number of inflammatory cells is greatly diminished. -ve control: Micrographs of central
area of wound in untreated controls. Note the massive infiltration of inflammatory cells and the hemorrhage in days 7 and 12 and the disorganized
granulation tissue. Notice the absence of epithelial layer in day 10 and the thin epidermis on day 12.
Figure 6. Histopathological evaluation of skin sections. Micrographs of
Masson’s trichome stained tissues of wounds treated with the
developed nanofibrous dressings and the AquacelAg as well as
untreated negative control at day 10 (original magnification 100).
Notice the dense collagen deposition in the AquacelAg, HPCS, HPCS-
AE/CE, HPCS-AE, and HPCS-CE nanofibrous dressings as compared
to the negative control (-ve control).
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Fibroblast cell proliferation was evaluated via incubation of
the fibroblast cells on the HPCS, HPCS-AE, HPCS-CE, HPCS-
AE/CE, and AquacelAg dressings for 1 and 3 days. Figure 7b
illustrates the analysis results of the fibroblast cell proliferation
as determined by the MTT assay. The OD values of the HPCS,
HPCS-CE, and HPCS-AE/CE nanofibrous mats increased with
culture time. The HPCS and the HPCS-CE illustrated the most
significant enhancement (p < 0.05) in proliferation at 3 days of
incubation (Figure 7b), whereas the HPCS-AE mats demon-
strated nearly the same OD values at both 1 and 3 days. The
AquacelAg, on the other hand, demonstrated a significant
cytotoxic effect on the fibroblast cell proliferation as observed
from its low OD values (Figure 7b). Such results confirm the
cytotoxicity previously realized for the AquacelAg dressing in
the cytotoxicity evaluation (Figure 7a). The realized cytotox-
icity of the AquacelAg was previously observed via different
studies.39,57
Generally, the HPCS and the HPCS-CE demonstrated the
highest levels of cell viability and proliferation within the tested
nanofibrous mats. The addition of the CE extract to the HPCS-
AE nanofibers has enhanced their viability and cell proliferation
results. Interestingly, all of the developed nanofibrous dressings
demonstrated major enhancement in cell viability and
proliferation as compared to the commercial AquacelAg
(Figure 7a and b).
It is worth mentioning that swelling abilities of the
nanofibrous mats as well as their abilities to enhance cell
viability and proliferation could be enhanced via increasing the
pore diameter. This could be achieved via manipulation of the
processing parameters during electrospinning58 or via inclusion
of certain treatments as carbon nanotubes prior to electro-T
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Figure 7. Cell viability (a) and cell proliferation (b) determined by the
MTT assay for the developed nanofibrous mats: HPCS, HPCS-AE,
HPCS-CE, and HPCS-AE/CE. AquacelAg served as a positive control
in both assays. Data represent mean ± SD (n = 3, Student’s t test, *p <
0.05 versus the HPCS mats, ***p < 0.05 versus culture times 24 h).
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spinning.59 Moreover, the density of the nanofibrous mats must
be taken into consideration as increased density will lead to
reduction in the breathability of the developed mats, which will
consequently lead to restriction of cell viability and trans-
portation of nutrients and metabolic wastes as well as reduction
in the swelling ability of the developed nanofibrous mats.
Within this context, it was reported that ultrasonication of the
developed nanofibrous mats could overcome such limita-
tion.32,60 Moreover, collecting low density nanofibrous mats on
a substrate could be another approach to overcome such
limitation. Consequently, future work on the HPCS, HPCS-AE,
HPCS-CE, and HPCS-AE/CE developed nanofibrous mats will
consider optimizing the nanofibrous mats’ breathability via
different approaches followed by testing the effect of each
approach on the cell viability and proliferation as well as the
swelling ability of the developed nanofibers.
■ CONCLUSIONS
Honey, chitosan, and poly(vinyl alcohol) nanofibers (HPCS)
and HPCS nanofibers with 50% of the solvent substituted with
Allium sativum extract (HPCS-AE) as well as HPCS and HPCS-
AE nanofibers loaded with 10% of Cleome droserifolia extract in
the (HPCS-CE) and (HPCS-AE/CE) were fabricated via
electrospinning, characterized, and tested for their swelling,
weight loss, antibacterial, cytotoxicity, and wound healing
abilities, as well as their effect on fibroblast cell proliferation. It
was observed that substituting 50% of the solvent with Allium
sativum extract resulted in a massive decrease in the viscosity of
the HPCS solution. The HPCS-AE/CE nanofibrous scaffolds
exhibited the lowest swelling abilities and the highest weight
loss among the developed nanofibers at the two tested cross-
linking degrees, showing values of less than 15% swelling and
90% weight loss as compared to approximately 90% swelling
and 60−70% weight loss in the case of both HPCS and HPCS-
AE after 24 h of immersion in PBS buffer. While none of the
developed nanofibers produced noticeable antibacterial effects
against E. coli and MDR Pseudomonas aeruginosa, the HPCS-
AE/CE and the HPCS-AE nanofibrous scaffolds exhibited
complete bacterial inhibition of S. aureus better than that
produced with the commercial dressing AquacelAg. Moreover,
the bacterial count of MRSA resistant strain was reduced by 1.5
log with the HPCS-AE/CE as compared to a 3.5 log reduction
with the AquacelAg. On testing the wound healing abilities of
the developed nanofiber dressings as compared to the
AquacelAg, it was observed that the HPCS and the HPCS-
AE/CE produced similar wound closure rates, whereas the
HPCS-AE has allowed enhanced wound closure. The scoring of
the histologic data demonstrated that the HPCS-AE/CE and
the HPCS nanofibrous dressings exhibited the most enhanced
effects on the wound healing process with scores very similar to
those of AquacelAg. Additionally, it was observed that HPCS,
HPCS-CE, and HPCS-AE/CE demonstrated the highest levels
of cell viability and proliferation, while the commercial
AquacelAg has exhibited noticeable cytotoxicity. Therefore,
the antibacterial and wound healing properties of the developed
nanofiber mats, as well as their minimal side effects, make them
competitive candidates for use as effective wound dressings.
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The effect of increasing honey concentrations from 10% to 30% within the Honey (H)/polyvinyl alcohol (P)/chi-
tosan (CS) nanofibers was investigated. Changes in the electrospun nanofiber diameters, crystallinity, thermal
behavior, porosity and antibacterial activity have been assessed using SEM, XRD, DSC, TGA,mercury porosimeter
and viable cell count technique. The HPCS nanofiberswere cross-linked and tested for their swelling abilities and
degradation behavior. The mean diameter of HPCS nanofibers increased from 284 ± 97 nm to 464 ± 185 nm
upon increasing the honey concentration from 10% to 30%. Irrespective the honey concentrations, the nanofibers
havedemonstrated enhanced porosity. Increasing the honey concentration resulted in a reduction in the swelling
of the 1 h cross-linked HPCS nanofibers containing 10% and 30% H from 520% to 100%; respectively. Degradation
after 30 days was reduced in the 3 h cross-linked HPCS nanofibers compared to the non-crosslinked HPCS nano-
fibers. Enhanced antibacterial activity was achieved against both Staphylococcus aureus and Escherichia coli upon
increasing the honey concentration. Changing the honey concentration and the extent of nanofiber crosslinking
can be used to adjust different parameters of the HPCS nanofibers to suit their applications inwound healing and
tissue engineering.
© 2016 Elsevier B.V. All rights reserved.
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1. Introduction
Electrospinning is a feasible and simple technique for production of
nanofibers [1–4]. The electrospun nanofibers exhibit increased surface
to volume ratio with improved and controlled porosity allowing their
use in various applications including tissue engineering, [5,6] drug de-
livery [7,8] wound healing, [9,10] filtration, energy storage, defense,
and security [11–13]. Among the different materials spun into nanofi-
bers, chitosan stands as one of the most advantageous biopolymers
due to its enhanced properties. Chitosan is well known for its biocom-
patibility, biodegradability, nontoxicity and non-immunogenicity [14].
Chitosan is also characterized by its cost-effectiveness as it is derived
from chitin the second most abundant polymer after cellulose [15].
This has also allowed chitosan to be an important candidate in a large
number of applications [16,17]. However, electrospinning of chitosan
into nanofibers is not an easy process particularly due to its high charge
and viscosity, in addition to the need to use toxic or highly acidic sol-
vents [18,19]. Residues of such solvents are not favorable in biomedical
applications. The optimum strategy to avoid this drawback is through
co-spinning of chitosanwith other easily spun polymers such as polyvi-
nyl alcohol and poly ethylene oxide [20–22]. Such strategy, however
allows the electrospinning of only small concentrations of chitosan.
Honey, a carbohydrate rich syrup has been used since ancient times
and is now rediscovered for its antibacterial andwound healing activity
[23–26]. Honey nanofibers are gaining increasing interest due to the en-
hanced activity realized upon combining the advantages of the
nanofibrous structure especially the increased surface to volume ratio
with the advantageous properties of honey. However, due to its low vis-
cosity honey was only electrospun in small concentrations [27,28].
Recently, we have managed to electrospun honey/polyvinyl alcohol/
chitosan combinations (HPCS) into nanofiberswith high concentrations
of chitosan (up to 5.5%w/w) and honey (up to 40%w/) via nontoxic sol-
vent (1% acetic acid) and the resulting HPCS nanofibers demonstrated
an enhanced nontoxicity and biocompatibility [29].
High concentration HPCS nanofibers represent promising candi-
dates for various biomedical applications due to their biodegradability,
biocompatibility and antibacterial effects [30,31]. However, such high
concentrations of honey included within the nanofibers is expected to
affect the crystallinity, porosity, thermal properties, and degradation be-
havior of the nanofibers, thus the effect of changing the honey concen-
tration on such properties will be evaluated in the present study along
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with the change in swelling and weight loss extents and antibacterial
abilities of the developed HPCS nanofibers.
2. Materials and methods
2.1. Materials
Chitosan (Mw, 240 kDa andDDAof 84%, Chitoclear, cg110, TM3728)
was provided by Primex, Siglufjordur, Iceland. Polyvinyl alcohol of Mw,
85 kDa, and glutaraldehyde (25% in H2O) were obtained from Sigma
Aldrich (St. Louis, USA). Glacial acetic acid of 99–100% purity was
purchased from Merck (Wadeville, South Africa). Nutrient broth and
Nutrient agar were obtained from Becton Dickinson and Company
(USA).
2.2. Electrospinning of honey/polyvinyl alcohol/chitosan (HPCS) mixtures
Various honey/polyvinyl alcohol/chitosan (HPCS) solutions with in-
creasing honey concentrations were prepared using the following
weight% ratios; 10:7:3.5, 20:7:3.5, and 30:7:3.5 of honey, polyvinyl alco-
hol, and chitosan, respectively dissolved in 1% acetic acid. Then, the
as-prepared solutions were allowed to age at room temperature for a
week. Afterwards, the conductivity of the as-prepared solutions were
measured using a conductivity meter (Ysi 3200). Subsequently, the
aged solutions were electrospun with the aid of an electrospinner
(E-spin, NanoTech, Kalyan-pur, India). In brief, a 5 ml plastic syringe
was loaded with the different solutions and was attached to the nozzle
that has outside and inner diameters of 1.3 and 0.7 mm respectively.
Then, different voltages (Gamma High Voltage Power Supply, USA)
were applied to the electrospun solutions, and the voltage required for
optimum collection of the nanofibers was selected. The distance be-
tween the collector and the tip of the nozzle was maintained at 15 cm
and the flow rate was maintained at 10 μl/min. All the samples were
collected on ground collector covered with an aluminum sheet. The
humidity and temperature were maintained at 30–35% and 32 °C, re-
spectively during electrospinning.
2.3. Characterization and measurements
The surface morphologies of the electrospun nanofibers were
observed using scanning electron microscopy (FESEM, Leo Supra 55,
Zeiss Inc., Oberkochen, Germany) and transmission electron microsco-
py (Jeol, Musashino, Akishima, Tokyo, Japan). Image-J software was
used for measurement of the diameters of the collected nanofibers.
From three different images 100 fibers were measured for each of the
developed nanofibrous mats. Subsequently, the average diameter and
diameter distribution were determined. The X-ray diffraction patterns
of the HPCS nanofibers with increasing honey concentrations were
obtained using an XRD diffractometer (Bruker 4040, Karlsruhe,
Germany) with a wavelength, λ= 0.154 nm at 40 kV, 150 mA, and at
a scan speed of 4° per minute in the 2θ range of 5°–80°. Porosity mea-
surements and pore size distribution of each of the electrospun HPCS
nanofibers were obtained using mercury porosimetry (PoreMaster®
mercury intrusion porosimeter, Quantachrome, Florida, USA). Thermal
behavior of the nanofibers was investigated using differential scanning
calorimetry (DSC 4000, PerkinElmer, Inc., Massachusetts, USA). The
nanofibrous mats were weighed and sealed in aluminum pans. Then,
the temperaturewas elevated from room temperature to 200 °C follow-
ed by cooling to room temperature and then heating again to 200 °C
with a heating rate of 10 °C/min. Moreover, thermogravimetric analysis
(TGA) of the nanofibers was performed (TGA Q50, TA Instruments).
Samples were heated in a platinum pan under nitrogen atmosphere
(60 ml/min) up to 700 °C, at a heating rate of 10 °C/min.
2.4. Assessment of swelling of the cross-linked HPCS nanofibers
The developed HPCS nanofibrous mats with increasing honey con-
centrations; 10:7:3.5, 20:7:3.5, and 30:7:3.5 (w%) were cross-linked
through exposure to glutaraldehyde (GA) vapours for 1 h and 3 h
followed by heating at 40 °C to enhance the crosslinking and remove
any unreacted GA. The cross-linked nanofibrous mats were then evalu-
ated for their swelling ability. The mats were placed in phosphate buff-
ered saline, PBS of a pH 7.4 at 37 °C, and their swelling ability was
determined at 1, 4 and 24 h with the aid of the following relationship:
Swellingdegree %ð Þ ¼ M−Mi=Mi½   100
WhereMi is the initial dry weight of the nanofibrous mats, andM is
the swollen weight of the nanofibrousmats after surface blottingwith a
filter paper.
2.5. Degradation rate of the cross-linked HPCS nanofibers
The degradation behavior of the developedHPCS nanofiberswith in-
creasing honey concentrations 10:7:3.5, 20:7:3.5, and 30:7:3.5 (w%)
was determined in PBS (pH 7.4) at 37 °C and 100 rpm after 30 days.
The degradation behavior of both the non-cross-linked (non CL) and
cross-linked samples via exposure to glutaraldehyde (GA) vapours for
3 h (3 h CL) followed by heating at 40 °Cwas determined. The degrada-
tion index (Di) was determined based on themass loss according to the
following equation:
Di ¼ W0−Wtð Þ=W0  100
whereW0 is the initial weight of the electrospun nanofibers, andWt is
the weight of the dried fibers after 30 days.
2.6. Antibacterial activity
The antibacterial activities for the obtained HPCS nanofibrous mats
with increasing honey concentrations; 10:7:3.5, 20:7:3.5, and 30:7:3.5
(w%) of honey, polyvinyl alcohol, and chitosan, respectively were
determined against Staphylococcus aureus and Escherichia coli. The
nanofibrous mats (0.05 g) after UV sterilization for 20 min were placed
in sterile vials containing 3 ml of Muller Hinton broth. A bacterial sus-
pension of each of the bacterial strainswas prepared from fresh colonies
after overnight incubation at 37 °C and the turbidity was adjusted to 0.5
McFarland standard (1× 108 CFU/ml). A 10 μl of that suspensionwas di-
luted in 9mlMuller Hinton broth to prepare (1 × 107 CFU/ml) bacterial
suspension. A 30 μl aliquot of each organism and from each bacterial
dilution was added to each vial containing the nanofibrous mats.
Then, the tubes containing the bacterial strains and the nanofibrous
mats as well as the controls were incubated at 37 °C with shaking at
100 rpm. After 24 h, samples of 10 μl were taken from the treated
bacterial broth and the controls. Serial dilution in nutrient broth was
performed for each sample from which 50 μl were spread on nutrient
agar plates that were subsequently incubated for 24 h at 37 °C. Follow-
ing the 24 h incubation, surviving colonies were counted. The dilution
that allowed counting 10 to 150 CFU were counted. The experiment
was repeated three times and the mean value of CFU was recorded.
3. Results and discussion
3.1. Electrospinning of increasing concentrations of honey within the HPCS
nanofibers
Prior to electrospinning, the conductivity of the aged polyvinyl
alcohol/chitosan solutions (7:3.5w%) with increasing honey concentra-
tions (10, 20, and 30 w%) was determined. It was observed that the
change in the honey concentration within the polyvinyl alcohol/
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chitosan solutions resulted in a small variation in the conductivity of the
solutions from 1510 uSwith the PCS solutions containing 30%H to 1480
and 1400 uS with the 20%H and 10% H, respectively. The conductivity of
a solution is related to its amount of ions. Thus, the decrease in the
honey concentration results in a decrease in the amount of ions present
in the solution and consequently led to a reduction in its conductivity.
Subsequently, the aged HPCS solutions with increasing honey concen-
trations were electrospun into nanofibers at a feed rate of 10 μl/min
and distance of 15 cm between the nozzle and the collector. Different
voltages ranging from 10 kV to 29 kV were applied to obtain the opti-
mum value which corresponds the lowest voltage that allowed collec-
tion of uniform nanofibers that were free of any beads, sticking or
clusters. For each applied voltage, a sample of nanofibers was collected
after five minutes of electrospinning followed by examining its mor-
phology under the SEM (data not shown). It was observed that 24 kV
is the minimum voltage that allowed for a uniform nanofiber deposi-
tion. As apparent fromFig. 1, it wasnoted that increasing the honey con-
centration led to increasing the diameter of the nanofibers. For instance,
theHPCS nanofiberswith 10% honey exhibited amean fiber diameter of
284±97nm(Fig. 1a & b)which increased to 371±110 nm, and 464±
185 nm upon increasing the honey concentration to 20% (Fig. 1c & d),
and 30% (Fig. 1e & f), respectively. Although the increase in conductivity
of a solution results in a reduction in the diameter size of electrospun
nanofibers, themain parameter affecting the diameter of the nanofibers
is the solution concentration [32]. And because of the high concentra-
tions of the honey loaded within the developed HPCS nanofibers, the
increase in the fiber diameter is a direct consequence for increasing
the amount of honey loaded within the nanofibers as can be observed
from Fig. 2a & b, where it is apparent that honey is embedded within
the chitosan/polyvinyl alcohol nanofibers. It was also observed
that the amount of honey loaded within the nanofibers influences the
fiber diameter distribution. As seen in Fig. 1d, addition of 20%
honey to the chitosan/polyvinyl alcohol nanofibers allowed for the
most focused fiber diameter distribution, as most of the nanofibers
exhibited diameters between 300 nm and 450 nm. Whereas, the
addition of 10% and 30% honey to the chitosan/polyvinyl alcohol nano-
fibers resulted in broad distribution of the diameters of the fibers
(Fig. 1b & f).
Fig. 1. SEM images of the electrospun honey/polyvinyl alcohol/chitosan (HPCS) nanofibrousmats with increasing concentrations of honey (a, c, e) and their diameter distribution (b, d, f):
(a, b) HPCS (10%:7%:3.5%), (c, d) HPCS (20%:7%:3.5%), and (e, f) HPCS (30%:7%:3.5%).
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Fig. 2. TEM (a) & SEM (b) images of honey/polyvinyl alcohol/chitosan (HPCS) nanofibers (30:7:3.5 w%) illustrating the inclusion of honey within the nanofibers.
Fig. 3.Mercury porosimetry results of pore diameter versus delta volume of intrudedmercury (a1, c, e), and pore diameter versus delta surface area (b, d, f) of the honey/polyvinyl alcohol/
chitosan (HPCS) nanofibrous mats with increasing honey concentrations; (a, b) HPCS (10%:7%:3.5%), (c, d) HPCS (20%:7%:3.5%) (e, f), and HPCS (30%:7%:3.5%).
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3.2. Effect of increasing the honey concentration on the porosity of the HPCS
nanofibers
In both tissue engineering and wound healing applications, the po-
rosity of the nanofibrous scaffolds will affect themigration and prolifer-
ation of cells, growth of the blood vessels and the exchange of thewaste
products and nutrients between the cells and their surrounding micro-
environment [33]. Mercury porosimetry is a well-known method for
measuring porosity of materials, and it is based on the fact that mercury
does not wet solid surfaces. The sample is completely surrounded with
mercury that does not intrude through the pores except after applying
pressure. As the pressure increases, mercury intrudes through the
large pores first, and by further increase in pressure, the mercury in-
trudes into the fine pores. After the pressure reaches to the maximum
the porosity and pore volume are calculated. It is of note that, mercury
porosimetrymeasures pore sizes between 0.0018 and 400 μm, however
pore sizes smaller than 0.0018 μm cannot be measured via mercury
porosimetry thus presenting a source of error in the mercury
porosimetry results [34,35]. As shown in Fig. 3, mercury porosimetry
was used for quantitative assessment of the pore size distribution and
porosity of the HPCS nanofibers with increasing honey concentrations
(10%, 20% and 30%). Increasing the honey concentration resulted in a
slight decrease in the overall porosity. In addition, it was noted that
the porosity of all theHPCS nanofibers developed in this study, irrespec-
tive the honey concentrations, have demonstrated enhanced porosity
compared to previously spun chitosan and chitosan/polyvinyl alcohol
nanofibers [36,37]. The developed HPCS nanofibers with 10% and 20%,
30% honey have demonstrated porosity of 97.8% and 95.1% respectively,
compared to 79.9% in previously spun non-sonicated chitosan nanofi-
bers [36].
Recently, it was reported that the increase in the overall porosity due
to increase in the pore size and fiber diameters enhances the viability of
cells. Whereas, increasing the overall porosity due to the simultaneous
reduction in fiber diameter and pore diameter could reduce the cell vi-
ability [38]. In our study, it was observed that the pore diameter was
greatly influenced by the change in the honey concentration within
the HPCS nanofibers. The HPCS nanofibers with 10% and 30% honey ex-
hibited wider distribution of pore diameter and most importantly
exhibited increased number of pores having large pore diameter
reaching to 140 μm (Fig. 3b & f). This was also observed in the volume
of mercury intruded through the fibers where most of the volume in-
truded was through pores having pore diameters between 35 μm and
138 μm (Fig. 3a & b). These results could be attributed to the relatively
large fiber diameter as well as the wide distribution of the diameters
of the nanofibers of the 10% and 30%honeyHPCSnanofibers, respective-
ly. Similar results were observed by Ryu et al., who observed that by in-
creasing the polymer concentration from 15 to 30%, the fiber diameter
increased from 90 to 480 nm and subsequently the porosity as deter-
mined by mercury porosimetry increased from 25% to 80% [39]. More-
over, Ko et al., have demonstrated that the porosity of SiO2-ZrO2
composite nanofibers ranged from 81.3% to 91.7% by increasing the
amount of ZrO2 from 10 to 20% due to an increase in the fiber diameter
with an increase in the ZrO2 content. Thus, a direct relation between the
increase in the fiber diameter and pore diameter and porosity was ver-
ified via different previous studies [40]. Such increased pore diameter
achieved in the 10% and 30%honey nanofibers is favorable in cell related
applications such as tissue engineering and wound healing [37]. Al-
though the 20% honey HPCS nanofibers showed large fiber diameter
of 371±110 nmbut they also exhibited a focused diameter distribution
(Fig. 1d), this in turn resulted in a more focused pore diameter distribu-
tion at less than 20 μm (Fig. 3d). However, a large volume of mercury
can still be seen intruded from the pores with pore diameters between
40 μmand 160 μm(Fig. 3c). This could be attributed to the fact that they
can allow much greater volume to be intruded through them due to
their larger surface area compared to the pores with small diameters
as less than 20 μm.
3.3. Effect of increasing the honey concentration on crystallization and ther-
mal properties of the HPCS nanofibers
The XRD diffraction patterns of pure polyvinyl alcohol and chitosan
have been previously reported [41,42]. Moreover, the XRD patterns of
polyvinyl alcohol/chitosan (PCS) nanofibers and films were reported
by Jia et al., who observed that nanofibers of the PCS exhibited deterio-
rated crystalline structure compared to the films [43].
Fig. 4, illustrates the XRD diffraction patterns of the prepared HPCS
nanofibers with increasing honey concentrations. The HPCS nanofibers
exhibited an amorphous microstructure with a single broad peek
around 2θ = 20°. Such XRD patterns are in coherence with those
observed for the previously prepared polyvinyl alcohol/chitosan nanofi-
bers [43]. Thus the addition of honey did not affect the diffractionmodel
of the polyvinyl alcohol/chitosan nanofibers and consequently the
increase in the honey concentration within the HPCS nanofibers had
no effect on their diffraction pattern.
Fig. 4.XRDdiffraction patterns of the honey/polyvinyl alcohol/chitosan (HPCS) nanofibers
with increasing honey concentrations. Theweight blending ratios of the electrospunmats
were 7% polyvinyl alcohol (P), 3.5% chitosan (CS), and increasing concentrations of honey
(H): 10%, 20%, and 30%.
Fig. 5. TGA (a) DSC (b) thermograms of the honey/polyvinyl alcohol/chitosan (HPCS)
nanofibers with increasing honey concentrations. The weight blending ratios of the
electrospun mats were 7% polyvinyl alcohol (P), 3.5% chitosan (CS), and increasing
concentrations of honey (H): 10%, 20%, and 30%.
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The deterioration of the crystalline structure of the electrospun
nanofibers was previously reported [44,45]. Such deterioration could
be attributed to the fast deposition and drying of the elongated
electrospun nanofibers thus hindering the crystallization [43].
TGA of the HPCS nanofibers with increasing honey concentrations
(10%, 20% and 30%)was performed. As observed in Fig. 5a, the examined
samples demonstrated similar thermal degradation process that takes
place in several steps. The first step of weight loss is attributed to mois-
ture elimination which resulted in loss of less than 10% of the weight of
the examined nanofibers below 120 °C.
It is of note that at 120 °C the HPCS nanofibers having 10% honey
exhibited the highest weight loss of ~8% whereas the weight loss de-
creased by increasing the amount of honey within the HPCS nanofibers
to ~6% and ~3%with the 20% and 30% honey, respectively. This indicates
that the HPCS nanofibers with higher honey concentrations exhibited
higher initial moisture content, which is a result of the hygroscopic na-
ture of honey. The second and major weight loss of approximately 50%
of theweight occurred after 120 °C till 400 °C and ismainly attributed to
the thermal decomposition of the polymer structure as well as the deg-
radation of the honey components followed by carbonization of the
honey contents. In the final step of the thermal decomposition at tem-
peratures above 500 °C, the polymer backbone has been ruptured in ad-
dition to the oxidation of the organic matter found in honey. These
observations are in agreement with what has been previously reported
[46,47]. TGA clearly demonstrates that the fabricated HPCS nanofibers
with different honey concentrations exhibit good thermal stability
below 120 °C.
The DSC thermograms of the HPCS nanofibers with increasing
concentrations of honey (10, 20, and 30 w%) are illustrated in Fig. 5b.
The three DSC thermograms showed no peaks. This further proves the
deteriorated crystalline structure of the developed HPCS nanofibers.
Moreover, it was previously proven that increasing the chitosan content
within the PCS nanofibers to ~1% resulted in further deterioration of the
crystallinity of the fibers [43,48]. Thus, in the present work the increase
in the chitosan concentrations to 3.5%within the developed HPCS nano-
fibers combined with the nanofibrous structure and the honey loaded
within the nanofibers resulted in a significant deterioration in the crys-
talline structure and development of the nanofibers in amorphous form
resulting in absence of any peaks in the DSC thermogram. Obviously,
increasing the honey concentration loaded within the nanofibers did
not affect the DSC thermograms of the obtained HPCS nanofibers.
3.4. Effect of increasing the honey concentration on the swelling of the HPCS
nanofibers
Honey and chitosan nanofibrous mats represent top candidates for
wound dressing applications and determining their swelling capabili-
ties would allow prediction of their exudate management ability [49].
Recently we have illustrated that the swelling capabilities of the
noncrosslinked HPCS nanofibrous mats with varying degrees of chito-
san and honey ranged from 46% to 197% [29]. Such values illustrate
the low swelling capability of the noncrosslinked HPCS nanofibrous
mats. In the present study the swelling capability of the crosslinked
fibers with increasing honey concentrations was investigated.
Crosslinking allowsmaintaining the nanofibrous structure of the de-
veloped HPCS nanofibrous mats in aqueous media, thus, allowing for
improved porosity. However, increasing the crosslinking degreewill de-
crease the swelling ability of the nanofibers due to the increased rigidity
of the network as a result of increasing both the inter- and intra-
molecular interactions [50]. Consequently, the effect of changing the
honey concentration was studied at two mild crosslinking degrees.
These include exposing the nanofibers to GA vapours for 1 h and 3 h
with subsequent heating at 40 °C to enhance crosslinking and
remove any residual GA. Such crosslinking treatments were selected
as they represent the shortest possible exposure to GA vapours that
allowed crosslinking, thus avoiding deteriorating the nontoxicity and
biocompatibility of the developed nanofibers upon excessive exposure
to theGA vapours.Moreover, theHPCS nanofibers thatwere crosslinked
via exposure to GA vapours for 3 h with subsequent heating were
proved nontoxic and biocompatible via MTT cytotoxicity evaluation
[29].
Increasing the honey concentrationwithin the nanofibers decreased
its swelling ability at both the tested crosslinking degrees (Fig. 6a & b). It
could be observed from the figures that the HPCS nanofibers with 10%
honey and 1 h of crosslinking with the GA vapours exhibited superior
swelling capabilities reaching to 520% at 1 h and 300% after 24 h
(Fig. 6a). On the other hand, the effect of the crosslinking time on the
swelling capabilities of theHPCS nanofibers varied according to their in-
corporated honey concentration. For the HPCS nanofibers with 10%
honey, increasing the crosslinking time from 1 h to 3 h decreased their
swelling capabilities noticeably from 520% to 273%. Whereas, HPCS
nanofibers with 20% honey exhibited increased swelling ability with
the increase in the crosslinking time from 1 h to 3 h. Noticeably, the
HPCS nanofibers with 30% honey demonstrated the lowest swelling
ability at both crosslinking times.
Although honey is known for its high water uptake ability [51], it
also has high water solubility. Such high water solubility results in
increasing the degradation rates of the nanofibers and consequently
losing their compact porous structure that can hold in water [52].
Thus, this eventually results in massive decrease in swelling ability.
This was observed by the very low swelling abilities of the HPCS nano-
fibers with 30% honey.
Fig. 6.% Swelling of the (a) 1 h cross-linked (CL) (b) 3 h cross-linked (CL), honey/polyvinyl
alcohol/chitosan (HPCS) nanofibers mats with increasing honey concentrations after
immersion in PBS (pH 7.4) for 1, 4, and 24 h. The weight blending ratios of the
electrospun mats were 7% polyvinyl alcohol (P), 3.5% chitosan (CS), and increasing
concentrations of honey (H) 10%, 20%, and 30%.
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Interestingly, the increase in the crosslinking efficiency by increasing
the exposure time to theGAvapours allows the nanofibers tomaintain a
more compact nanofibrous structure [53,54] thus, the percent of
released and solubilized honey decreases. This allows the honey to be
maintained within the nanofibers for longer periods of time, and thus
itswater uptake capabilities could be realized. On the other hand, the in-
crease in the crosslinking degree decreases the swelling ability as it hin-
ders the intermolecular motion and chain disentanglements within the
nanofibrous scaffold. These two opposite effects on the swelling abilities
of the nanofibrous scaffolds could be observed in the results presented
in Fig. 6a & b. In the HPCS nanofibers with 10% honey, the amount of
honey within the nanofibers is small thus the effect of the swelling hin-
dering due to crosslinkingwasmore pronounced than thewater uptake
ability of the maintained honey. Whereas, when the concentration of
honey increased to 20%, the water uptake ability of the maintained
honey in this case exceeded the hindering effect of crosslinking on
swelling which allowed the HPCS nanofibers with 20% honey to exhibit
a noticeable increase in swelling ability even at 24 h by increasing the
crosslinking time to 3h. The HPCS nanofibers with 30% honey however
showed slight decrease in the swelling ability at 24h with increasing
the crosslinking time. This is because at such high concentration of
honey such crosslinking treatments could not overcome the increased
solubility of theHPCSnanofiberswith 30%honeywhich affects the com-
pact structure of the nanofibrous scaffold. These results reveal the
importance of optimization of the crosslinking degree as well as the
honey concentrations within the developed HPCS nanofibers to adjust
the water uptake ability according to the desired application.
3.5. Effect of increasing the honey concentration on the degradation rates of
the HPCS nanofibers
The effect of increasing the honey concentration within the HPCS
nanofibers on the degradation behavior of both the noncrosslinked
and crosslinked nanofibers via exposure to GA vapours for 3 h followed
by heating at 40 °C for 24 h was studied.
As illustrated in Fig. 7, increasing the honey concentrationwithin the
HPCS nanofibers increased the degradation ability of the nanofibers
after 30 days of incubation in PBS at 37 °C and 100 rpm. This could be
attributed to the highwater solubility of honey. Thus, in theHPCS nano-
fibers with higher honey concentrations such effect could be realized
with an increase in the degradation behavior of the nanofibers.
Meanwhile, the crosslinked HPCS nanofibers at all honey concentra-
tions showed decreased degradation ability compared to the
noncrosslinked fibers. This is mainly because crosslinking the HPCS
nanofibers via exposure to GA for 3 h allows maintaining the
nanofibrous structure as was previously proven [29]. Exposure of the
HPCS nanofibers to GA allows chemical crosslinking of chitosan either
through formation of Michael-type adducts or Schiff's base structures
[55] and thus decreases their degradation rate.
3.6. Effect of increasing the honey concentration on the antibacterial
activity of the developed HPCS nanofibers
Both honey and chitosan exhibit antibacterial activity. Honey
exerts its antibacterial activity via its acidity, high sugar content as
well as its ability for hydrogen peroxide production [56]. Whereas, the
polycationic nature of chitosan allows it to interact with the negatively
chargedmembranes of bacteria leading to loss in the permeability of the
membrane with subsequent cell leakage and death [57].
Electrospun nanofibers allow enhancement of the antibacterial
activity of both chitosan and honey within the developed HPCS nanofi-
bers, mainly due to the increase in the surface to volume ratio [29].
It was previously shown that the antibacterial effect of HPCS nanofi-
bers with 30% honey are significantly affected by the change in the chi-
tosan concentrationswithin the nanofibers [29]. In the presentwork the
effect of changing the honey concentration within the HPCS nanofibers
was investigated as shown in Fig. 8. The increase in the honey concen-
tration within the HPCS nanofibers enhanced their antibacterial activi-
ties against both S. aureus and E. coli at 1 × 107 CFU/ml (Fig. 8a & b).
However, upon increasing the bacterial count to 1 × 108 CFU/ml the in-
crease in the honey concentration resulted in an increase in the antibac-
terial activity against S. aureus, whereas nearly no antibacterial effect
was realized against E.coli. These results agree with the previously
reported results of the HPCS nanofibers that demonstrated enhanced
antibacterial activity against gram positive S. aureus over the gram neg-
ative E.coli [29].
4. Conclusions
Different honey concentrations (10%, 20% and 30%) have been
electrospun within chitosan (3.5%)/polyvinyl alcohol (7%) nanofibers.
Fig. 7. % Degradation of the Non-cross-linked (Non CL) & 3 h cross-linked (CL),
honey/polyvinyl alcohol/chitosan (HPCS) nanofibers mats with increasing honey
concentrations after immersion in PBS (pH 7.4) for 30 days at 37 °C. The weight
blending ratios of the electrospun mats were 7% polyvinyl alcohol (P), 3.5% chitosan
(CS), and increasing concentrations of honey (H) 10%, 20%, and 30%.
Fig. 8. The antibacterial activity of the electrospun honey/polyvinyl alcohol/chitosan
(HPCS) nanofibrous mats against 1 × 108 CFU/ml and 1 × 107 CFU/ml of E. coli (a) and
S. aureus (b) represented by reduction in the log (CFU) after h. The weight blending
ratios of the electrospun mats were 7% polyvinyl alcohol (P), 3.5% chitosan (CS), and
increasing concentrations of honey (H); 10%, 20%, and 30%.
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The effect of increasing the honey concentration on the different prop-
erties of the electrospun nanofibers has been investigated. Increasing
the honey concentration resulted in an increase in the fiber diameter
from 284 ± 97 nm with 10% honey to 464 ± 185 nm with 30% honey,
whereas the porosity was slightly decreased from 97.8% with 10%
honey to 95.1% in the case of the nanofibers incorporating 20% and
30% honey. Interestingly, it was observed that both the HPCS combina-
tions with 10% honey and 30% honey exhibited an increased number of
pores with large pore diameter reaching to 140 μm which is advanta-
geous for tissue engineering andwoundhealing applications. The swell-
ing of the nanofibers was greatly influenced by the concentration of
incorporated honey and the degree of crosslinking. Highest swelling ex-
tent was observed with HPCS nanofibers having 10% honey, and the
least swelling was noted in the HPCS nanofibers having 30% honey.
However, the swelling ability of the nanofibers containing 20% honey
was noticeably enhanced with increasing the crosslinking degree. The
degradation ability of the nanofibers increased with increasing the
honey concentration within the HPCS nanofibers and decreased with
crosslinking of the fiber mats. The crystallization and thermal behavior
of the nanofibers on the other hand were not affected by changing the
honey concentration within the developed HPCS nanofibers, Increasing
the honey concentrationwithin theHPCSnanofibers enhanced their an-
tibacterial activity against both S. aureus and E.coli at 7 × 107 CFU/ml.
Whereas, at 7 × 108 CFU/ml nearly no antibacterial effect was realized
against E.coli at all honey concentrations included within the HPCS
nanofibers.
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Bacterial resistance is not only restricted to human infections but is also a major problem in
food. With the marked decrease in produced antimicrobials, the world is now reassessing
bacteriophages. In 2006, ListShield received the US FDA approval for using phage in food.
Nevertheless, regulatory approval of phage-based therapeutics is still facing many challenges.
This review highlights the use of bacteriophages as biocontrol agents in the food industry. It
also focuses on the challenges still facing the regulatory approval of phage-based therapeutics
and the proposed approaches to overcome such challenges.
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In 1917, the term bacteriophage was first intro-
duced by Felix d’Herelle who was also the first
to test phage therapy. d’Herelle applied bacter-
iophages against livestock infections and even
tested them on himself. It was then recognized
that the same phenomenon was described by
Twort in 1915 and by Hankin in 1896 in the
Ganges River against Vibrio cholerae [1–3]. It
was in the 1920s, when d’Herelle used bacter-
iophages for fighting different bacterial infec-
tions around the world that the discipline
known as ‘phage therapy’ was introduced.
Phage therapy rapidly developed globally and
was used as the major antibacterial in many
countries. Moreover, phage therapy also
attracted the attention of many pharmaceutical
companies including E.R. Squibb & Sons
(Princeton, NJ, USA), Eli Lilly (Indianapolis,
IN, USA) and Swan-Myers/Abbott laborato-
ries, which produced commercial phage prepa-
rations [4]. However, because phage properties
were poorly understood and well purified and
characterized preparations were lacking, phage
therapy resulted in variable outcomes and
many specialists questioned its efficacy. With
the introduction of antibiotics in the 1940s,
bacteriophages were unable to stand against the
miracle antibiotics [4]. However, during the
past two decades, which witnessed the continu-
ous rise in bacterial resistance together with
alarming decrease in the production of new
antibiotics, the Western world is actively revis-
iting the world of bacteriophages in different
practical applications. An interest that has
resulted in several companies developing
phage-based products for food, agriculture,
diagnostics and therapeutics (TABLE 1).
Bacteriophages: brilliant antibacterials
Bacteriophages are the most abundant micro-
organisms with an estimated number of
1030–1032 phage particles. Humans are regu-
larly exposed to bacteriophages in water and
unprocessed food. Moreover, phages are pres-
ent in the intestinal tract, saliva and in dental
plaque. One milliliter of unpolluted water
contains 2  108 phage particles [5,6].
Bacteriophages infect bacteria via two possi-
ble lifecycles: the lysogenic and the lytic. The
infection begins with the adsorption of the
bacteriophage onto the surface of the bacteria
then the viral genetic material is injected into
the cytoplasm. Lytic bacteriophages take
immediate control of the biochemical machin-
ery of the host cell to make new virions and
the growth cycle ends by killing the host
cell [7]. In contrast, temperate bacteriophages
insert their genome into the chromosome of
the host cell and remain in the dormant state
until the bacteria is exposed to certain stimuli,
which lead to initiation of the lytic cycle.
TABLE 2 illustrates attributes of bacteriophages
that make them attractive antibacterial thera-
peutics [8,9]. It is relatively easy and inexpensive
to find new phages against bacterial resistance
compared with years and billions of dollars in
case of antibiotic. Moreover, the ability of bac-
teriophages to kill pathogenic bacterial strains
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in situ through exponential growth of phage is significant for
the treatment of chronic bacterial infections [8,10].
Rediscovering bacteriophages
Since the discovery of penicillin, antibiotic production is esti-
mated at US$25 billion per year. The widespread and some-
times inappropriate use of antibiotics has contributed to the
increased incidence of bacterial resistance. The overuse of anti-
biotics in animal feed has also contributed to antibiotic resis-
tance. Many of the 17 antibiotic classes are used in animal
feed. Although Europe has banned the use of antibiotics for
promoting animal growth, it is still allowed in the USA [5].
In the USA, bacterial resistance costs the health-care system
over US$20 billion every year, leading to over 8 million extra
hospital days. Moreover, the social costs are over US$35 billion
every year. In the EU, multidrug-resistant bacteria result in the
death of nearly 25,000 patients annually and the associated
economical burdens are postulated to be nearly 1.5 billion
Euros annually [11].
Several antibiotic-resistant bacteria have been identified
including methicillin-resistant Staphylococcus aureus,
vancomycin-resistant S. aureus [8] and vancomycin-resistant
Enterococcus faecium [11]. In 2010, a serious Escherichia coli-
resistant strain was reported in India which carried a gene
called NDM1 (New Delhi metallo-b-lactamase). This was the
first report on spread of resistant strains in a community, as
such incidences were restricted to hospitals [12]. The problem of
bacterial resistance is further complicated with the marked
decrease in introducing new antimicrobials. Major decrease in
antibiotic development occurred over the past 25 years. From
2008 to 2012, only two antibiotics were under develop-
ment [13,14], and from 2003 to 2007, only five antibiotics were
underdevelopment compared with over 14 antibiotics back
between 1983 and 1987 [14].
Applications of bacteriophages
Although the focus of Western countries on bacteriophages as
an antibacterial has almost faded with the introduction of anti-
biotics, countries as the former Soviet Union with Georgia as
the epicenter continued their studies on bacteriophages to treat
serious and chronic infections [14].
In the 1980s, Smith and coworkers carried out several studies
to assess the effectiveness of phage therapeutics against E. coli
infections [15–17]. Many other reports evaluated bacteriophage
therapeutic efficacy against different bacterial infections as E. coli
[18], Pseudomonas aeruginosa [19], Acinetobacter baumanii [20],
Klebsiella pneumoniae [21], Vibrio vulnificus [22], as well as Salmo-
nella [23] in animal models. Other studies revealed phage thera-
peutic effectiveness against drug-resistant strains of bacteria, such
as vancomycin-resistant E. faecium [24] and methicillin-resistant
S. aureus [25]. More remarkably, phages were able to reach intra-
cellular bacteria, such as Mycobacterium tuberculosis [26].
Another important property of bacteriophages is their abil-
ity to disperse biofilms, although it was observed that antibi-
otic use at subminimal concentrations could end in induction
of biofilm formation [27,28]. Biofilms represent aggregation of
cells either eukaryotic or prokaryotic. Such cells are sur-
rounded by a matrix of extracellular polymeric substance. Bac-
teria found within biofilms possess increased resistance to
antibiotics and biocides, where it may require 1000-times
more of such agents to eradicate biofilm bacteria compared
with free-living bacteria [28]. Bacteriophages, however, have
proven ability to infect bacteria within biofilms [28]. Phage
replication within the bacterial cells results in localized ampli-
fication in phage numbers. Phages then spread within the bio-
film eradicating the bacteria producing the extracellular
polymeric substance. Moreover, some bacteriophages have the
ability to express or carry depolymerizing enzymes that can
degrade extracellular polymeric substance [28]. Unfortunately,
the chance of isolating a natural phage that shows both advan-
tages is low. Thus, researchers are now engineering phages to
express biofilm degrading enzymes [29]. Phage dispersing bio-
films show strong potential not only on the therapeutic front
but also at the industrial scale, where biofilms represent a con-
tinuous source of bacteria on different surfaces. It was shown
also that phages and antibiotics are not mutually exclusive
instead they could be synergistic, especially for managing bio-
film infections [30,31].
Table 1. List of some bacteriophage-based
companies.
Company Established Ref.
Omnilytics (USA) 1954 [98]
Exponential Biotherapies (USA) 1994 [99]
Biophage Pharma (Canada) 1995 [100]
PhageTech (Canada) 1997 [101]
Intralytix (USA) 1998 [102]
Hexal Gentech (Germany) 1998 [103]
Phage Biotech (Israel) 2000 [104]
GangaGen
(Bangalore, India; San Francisco,
CA; Ottawa, Canada)
2000 [105]
PhageGen
(Las Vegas, NV; previously Regma
Bio Technologies of London)
2000 [106]
Phico Therapeutics (UK) 2000 [107]
Phage-Therapy (Tbilisi, Georgia) 2002 [108]
Ampliphi biosciences (Australia) 2002 [109]
Novolytics (UK) 2002 [110]
Technophage (Portugal) 2002 [111]
Enzobiotics/New Horizons
Diagnostics (USA)
2003 [112]
Pherecydespharma (France) 2006 [113]
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Many studies were done on the use of phage as a microbial
control in food, including meat, poultry, fish, fruits and vegeta-
bles, both in the preharvest and postharvest (fresh and pack-
aged foods) stages. Studies have been conducted on different
stages in the food production chain, including also livestock
decontamination, and sanitation of contact surfaces and equip-
ment to control some of the most persistent foodborne patho-
gens in poultry including Campylobacter jejuni [32] and
Salmonella typhimurium [33]. Phage was also applied in cattle
and sheep against E. coli O157:H7 [34]. However, more studies
are required to enhance the in vivo biotherapeutic effects of
phages, including better understanding of the interactions
between phage and bacteria in the gut and alimentary system
of live animals [35].
Since the regulatory approval of ListShieldTM as the first
phage-based product for control of Listeria in products of meat
and poultry, studies for phages targeting food (meat, fruits,
vegetables, processed ready to eat [RTE] food, cheese, pasteur-
ized milk, powdered infant formulas, etc.) in the postharvest
stage have increased [36]. Guenther et al. (2009 and 2012) stud-
ied the effect of bacteriophages against Listeria monocytogenes
and S. typhimurium in RTE foods, respectively [37,38].
Kim et al. (2007) reported the use of a phage cocktail against
Cronobacter sakazakii in reconstituted infant formula [39].
Anany et al. (2011) immobilized anionic heads of phages on
cationic cellulose membranes leaving the tails to catch and kill
both L. monocytogenes and E. coli O157:H7 in RTE and raw
meat [40].
Bacteriophages were also used as biocontrol agents in vegeta-
bles and fruits. Leverentz et al. (2001) used phage alone or in
combination with bacteriocin to reduce Salmonella contamina-
tion in fresh cut fruits [41]. Whereas, Viazis et al. (2010)
showed complete inactivation of E. coli O157:H7 strains in let-
tuce and spinach using a combination of phage mixture and
trans-cinnamaldehyde oil [42]. In 2013, the combined use of
bacteriophages with modified atmosphere packaging improved
the effect of bacteriophages [43].
Several reviews have addressed successful bacteriophage appli-
cations in human therapy [44–46] and in food either in the pre-
harvest or postharvest stages [47].
Phages approved as biocontrol agents in the food
industry
The market of food and beverage was valued at US$5.7 trillion
worldwide in 2008 and is expected to reach US$7 trillion in
2014 [5]. Food poisoning and spoilage due to bacterial contam-
ination represent a major burden on health and food industry.
The Centers for Disease Control estimated about 9.4 million
cases of foodborne illnesses in addition to about 56,000 hospi-
talizations, and over 1350 deaths in the USA annually [48].
Moreover, microbial contamination is the major cause of food
spoilage, which results in loss of 25% of food produced each
year [49].
Due to the increase in bacterial resistance, together with the
progress achieved in understanding phage biology and its appli-
cations, numerous companies worldwide are currently investing
in developing phage-based products as food biocontrol agents,
decontamination, sanitation and diagnostics.
In 2005, the US Environmental Protection Agency approved
AgriphageTM (OmniLytics Inc., Sandy, UT) [50] for treating
bacterial spots in different crops. In 2006, the FDA approved
ListShieldTM to be applied directly on RTE meat and poultry
to control L. monocytogenes [51]. Thus, bacteriophages were for
the first time considered generally recognized as safe
(GRAS) [29]. TABLE 3 presents selected examples of using
approved phage products in food.
In 2007, FDA approved phage-based preparations produced
by Omnilytics to decontaminate live animals from E. coli and
Salmonella [52]. Now, several products are commercially avail-
able including Finalyse spray against E. coli O157:H7 in cattle
and Armament against Salmonella in poultry [47].
The future of phage-based products in the food industry
shows tremendous promise, especially with the number of com-
panies as well as research institutes actively engaged in phage
Table 2. Comparison between phages and antibiotics as antibacterials.
Bacteriophages Antibiotics
Very specific affecting only the targeted bacterial species with no
disruption of normal flora therefore minimizing the possibility of
secondary infections
Target both pathogenic microorganisms and normal microflora
which may lead to serious secondary infections
Autodosing through replication at the site of infection (repeated
administration may not be needed)
Metabolized and eliminated and do not accumulate at the site
of infection
No serious side effects have been described
Minor side effects may be due to the liberation of endotoxins
from bacteria lysed in vivo by the phages
Multiple side effects, including allergies, intestinal disorders,
secondary infections, adverse effects on the kidney and the liver
Phage-resistant bacteria are not resistant to other phages having
a similar target range
Resistance to antibiotics extends over targeted bacteria
Finding new phages against developed bacterial resistance can
be achieved in days
Developing a new antibiotic against antibiotic-
resistant bacteria is a very lengthy and expensive process
Ability to clear biofilms Limited ability of biofilm clearance
Challenges facing phage therapy Review
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research. However, this is not the case for phage therapy in
humans, where a number of challenges still impede its
approval.
Phages not approved as therapeutics; challenges still in
the way
Despite the long history of phage therapy in addition to its
safety record, phages are still not approved by the FDA to be
used as therapeutics. Back in the 1970s, 1980s and 1990s, the
FDA revised the usage of phage preparations as therapeutics in
human. At the time, phage phiX174 was applied via intrave-
nous administration to patients with immunodeficiency such as
those infected with HIV. In the 1970s, after the inclusion of
phages in several vaccines, the FDA performed a safety review
on phages and concluded that bacteriophages are safe and
allowed the continued usage of the vaccines [7].
In 2008, the first phage Phase I clinical trial was approved
by the FDA. The study evaluated the use of a phage prepara-
tion of eight phages against venous leg ulcers. The trial verified
the safety of the phage cocktail preparation [53].
Despite the documented safety of bacteriophages, however,
regulatory bodies have not approved its use as a therapeutic,
although recently approving it in food. Such approval confirms
that phage is safe for human consumption and thus represents
a major step towards its approval as a therapeutic. Challenges
that currently hinder regulatory approval of phage as human
therapeutics as well as possible approaches to overcome them
will be discussed (FIGURE 1).
Immunogenicity
Phage immunogenicity is a major challenge facing phage ther-
apy, mainly because of its effects on phage pharmacokinetics
and also because of the possible side effects, such as
anaphylactic shocks. Phages are recognized as foreign antigens
by mammalian hosts [54].
It was initially reported that the reticulo-endothelial system
was responsible for the decrease in the concentrations of bacter-
iophages in the blood of mice [55]. Decades later it was proven
that the liver played the major role in phage elimination with
over 99% of the phages present in the circulatory system were
phagocytosed by the liver [56]. Such elimination of phage by
the reticulo-endothelial system, coinciding with lack of infor-
mation on phage pharmacokinetics, has resulted in majority of
phage applications being administered orally [57]. Consequently,
despite the advantageous therapeutic effects of phages on sys-
temic diseases, most studies to date were concerned with the
treatment of non-systemic diseases, such as gastrointestinal, ear
and wound infections [58]. Merril et al. [59] serially passed
phages in animals to isolate mutants that were capable of stay-
ing longer in circulation and allowing enhanced systemic
administration [59].
In addition to the interaction with the innate immune sys-
tem, bacteriophages also stimulate the adaptive immune system
and consequently the production of antibodies [60]. Less anti-
genic bacteriophages may be developed through phage display-
ing certain peptide ligands; Sokoloff and coworkers injected a
T7-phage peptide display library in rats, and observed that
phage displaying peptides with arginine or carboxy-terminal
lysine residues protected against the complement-mediated
inactivation of the bacteriophage by binding C-reactive protein,
whereas human serum phages that displayed C-terminal tyro-
sine residues were resistant to inactivation [61].
Within this context, Kim et al. were the first to introduce
PEGylation to bacteriophages to increase bacteriophages sur-
vival and efficacy [62]. Consistent with this, Molenaar et al.
have shown that the incorporation of targeting ligands
Table 3. FDA approved phage-based products for use in ready to eat food.
Product Regulatory approval Applications Ref.
ListShield Intralytix, Inc.
USA
US FDA (2006) and USDA for direct application
onto foods (21 CFR 172.785.) EPA (EPA
registration 74234-1)
– Ready to eat food: salami, sausage,
basterami, etc.
– Sea food
– Food contact surfaces and enviroments
[114]
EcoShield Intralytix, Inc.
USA
FDA (2011) cleared as ‘Food Contact Notification’
or FCN, (FCN No. 1018). FSIS Directive
7120.1 (safe and suitable antimicrobial)
– Red meat parts and trim intended to be ground [115]
SalmoFresh Intralytix, Inc.
USA
FDA (GRAS Notice No. GRN 000435),
FSIS Directive the Star K-certified Kosher and
IFANCA-certified Halal product.
OMRI-listed suitable in the production of organic
foods
– Poultry
– Fish and shellfish
– Fresh and processed fruits and vegetables
[116]
LISTEX Micreos EBI
Food Safety
Netherlands
In 2006 approved by the FDA as GRAS, and by
the USDA in 2007 and by the EFSA, Health
Canada, BAG (Switzerland) and FSANZ (Food
Standards Australia New Zealand)
– Meat
– Ready to eat meat
– Fish
– Cheese
[117]
Agriphage Omnilytics
USA
EPA 2005 for use in agriculture – In agriculture on fruits and vegetables [118]
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increased the efficient delivery and specificity of the
M13 phage to liver Kupffer and parenchymal cells [63].
S-radiolabeled M13 bacteriophage was chemically modified by
conjugation of either succinate groups or galactose to the phage
coat protein to facilitate the uptake of the phages by scavenger
receptors and hepatic receptors, respectively. Although the main
purpose of this study was to increase efficiency of in vivo pan-
ning of phage libraries, the same principle could be used for
targeting other organs for therapeutic purposes [63].
Pharmacokinetics
The pharmacokinetic behavior of phages was only weakly
addressed. Efficient pharmacokinetic data are required to sup-
port phage delivery via the bloodstream to achieve systemic
effects. Phages replicate exponentially, interact and show differ-
ent phenomena completely different from the chemical kinetics
of conventional drugs [64]. Consequently, studying the pharma-
cokinetics of bacteriophages as antibacterial therapeutics necessi-
tates knowledge of the infected host, the bacteriophage and the
infecting bacteria as well as their complex interactions. Interest-
ingly, through the process of infection and phage therapy, the
growth of bacteria would lead to exponential growth of phages,
unlike the conventional use of antibiotics [64]. Along this line,
Dubos and coworkers treated mice that were infected intracere-
brally with Shigella dysenteriae by administering phage into the
peritoneal cavity [65]. Similar studies by Smith and Huggins
demonstrated that mice infected either intracerebrally or intra-
muscularly with E. coli were rescued with phages via intramus-
cular administration [15]. In both the studies, the levels of the
bacteriophages were highest in the infected tissues but then
decreased as the bacterial levels decreased. On the other hand,
phage levels in the blood of the control animals were in accor-
dance with the phage dilution in the total blood of the animal.
These data were used as the basis for mathematical models pre-
dicting the kinetic behavior of phages [64,66]. Several parameters
should be considered to achieve effective phage therapeutics.
These include the route and timing of administration and the
required dose [64].
Systemic side effects
Lytic phages are the only phages that are used in therapy. First
because they are more potent than the temperate phages, and
second because temperate phages have the risk of transferring
fragments of the DNA of the host to other bacterial species,
thus posing the risk of producing virulent strains if such frag-
ments were toxin encoding or antibiotic-resistant genes.
No reports have been recorded of serious complications
accompanying phage therapy. Moreover, humans are in contin-
uous exposure to bacteriophages, as they are so common in the
environment. For example, unpolluted water contains ca. 2 
108 (phage/ml), and phages are continuously consumed in
foods [44].
Safety of bacteriophages was proved through different studies
where bacteriophage did not cause adverse effects in
humans [67,68]. However, there are concerns that any lytic
bacterial treatment will generate endotoxins and superantigens
that may be released during the massive and fast destruction of
bacteria in vivo [58]. Although this possibility may be low, engi-
neered phages that are either lysis deficient or non-replicative
have been developed. For example, filamentous phages were
engineered to express certain toxic genes in E. coli leading to
bacterial toxicity but not their lysis, thus overcoming the prob-
lem of endotoxins [69]. Non-lytic and non-replicative phages
were also designed against P. aeruginosa [70]. Interestingly, in
both the studies, it was observed that the non-lytic phages
increased the survival of treated infected mice compared with
lytic phages, which may have been caused by reduced
inflammation.
It is also important to ensure that bacteriophages for ther-
apy do not carry gene sequences that possess significant simi-
larity with antibiotic-resistance genes, genes for other bacterial
virulence factors and genes for phage-encoded toxins. More-
over, phages should be also incapable of generalized transduc-
tion [47]. A number of quality assurance and quality control
measures to consider are described in Merabishvili et al.
(2009) [71].
Narrow host range
Each phage strain infects only one type of bacteria. The down-
side of such narrow host range is the limited applicability in
cases where the identification of the specific bacterial host can-
not be achieved [7]. However, with the tremendous develop-
ments of rapid diagnostics, identifying the specific bacterial
host is easily achieved. In most situations, however, bacterio-
phage cocktails are used to broaden the host range and increase
the overall therapeutic efficiency. It is unlikely, however, to
achieve 100% therapeutic efficiency [7,58]. Thus, the use of sin-
gle phages versus cocktails of phages has to be further studied
and optimized as both regimens may lead to the development
of resistance [72]. Nevertheless, as will be discussed later,
approval of phage cocktails is problematic, thus other methods
have also to be developed. Using broad host spectrum bacterio-
phages, such as Listeria P100 or S. aureus phi812 was pro-
posed [73,74]. Also, broad host range could be achieved via
Regulatory
approval
Bacterial
resistance
Immunogenicity
Manufacturing
Challenges
facing phage
therapy
Systemic side
effects Patentability
Narrow host
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Figure 1. Challenges facing phage therapy.
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grafting the g3p phage protein of one filamentous bacterio-
phage to another [75,76]. Such an approach, however, although
would broaden the host range of the engineered bacteriophage
and would facilitate its patentability, may also complicate its
regulatory approval. Moreover, safety of such engineered
phages has not been thoroughly studied, especially that such
engineered phages may increase the probability of phage-
mediated transfer of genetic sequences among bacterial
species [77].
Developing clinical diagnostics to allow rapid identification
of the infective bacterial pathogen as well as their phage suscep-
tibility may be necessary to allow the use of the required phage
instead of phage cocktails. These phage-based diagnostics
should be fast and reliable [78].
Along this line, Loessner and coworkers [78] developed lucif-
erase reporter bacteriophages for the sensitive and fast detection
of viable cells of Listeria. In addition, diagnostic tests that uti-
lized phage enzyme lysins have been developed allowing rapid
bacterial identification and have resulted in commercialized
products (Enzobiotics; Columbia, MD, USA) [9].
Bacterial resistance
Bacteriophages are the most abundant and diverse microorgan-
isms on the planet. Such diversity is due to the continuous
adaptation to different pressures. Bacteriophages have evolved
different mechanisms that enable it to avoid, withstand and get
over different mechanisms of bacterial resistance [79]. It was
found that in monoculture studies performed in vitro, phage
resistance can evolve within hours or days [58]. However, it was
observed that bacteria develop phage resistance in vitro more
rapidly than in vivo [80]. Thus, the correlation between the rate
of resistance development in vivo and in vitro is an area that
requires further study.
The exposure of a certain bacterial strain to a single bacterio-
phage is suggested to aid in the emergence of phage-resistant
strains of the bacteria. On the other hand, several studies report
that phage cocktails help control or delay the evolution of
phage-resistant strains [72,81,82]. Reduction of appearance of
resistant bacterial strains can be achieved using new techniques,
such as using combinations of bacteriophages with other anti-
microbials (such as antibiotics or antimicrobial herbal extracts),
cycling bacteria through mixtures of different phages and tar-
geting phage-resistance mechanism by genetically engineered
bacteriophages [58].
In this context, additional studies are needed to identify
phage receptors and understanding the interaction of bacterio-
phages with the receptors on the host surface. Until now,
except for E. coli, very few phage receptors have been identi-
fied [79]. Moreover, the evolution of phages in response to the
mutations in the host surface receptors needs to be investi-
gated. Finally, the environment in which phage-resistance
mechanisms are studied need to be translated from a closed
laboratory environment with single phage at a time to a more
real complex environment containing multiple anti-phage
barriers [79].
Manufacturing; (safety & efficacy)
In the past, and in Russia until now, phages have been admin-
istered to humans: orally, either in tablets or liquid formula-
tions (105 to 1011 PFU/dose); locally to the skin, ear or eye in
the form of creams, tampons and rinses; rectally; as aerosols; as
intrapleural injections; and intravenously [45]. Still, there are
two critical factors that need to be standardized during bacteri-
ophage manufacturing, which are safety and efficacy. Inability
to optimize these factors may have been responsible for the
recorded negative results of phage therapy. Efficacy of the
phage preparation reflects the presence of sufficient virulent
phages, especially against the target bacteria [83]. Poor viability
and/or stability of phage preparations may result from
improper manufacturing techniques. Therefore, in some early
commercial phage preparations, mercurials and oxidizing agents
as well as heat treatments were used to ensure bacterial sterility.
Nevertheless, such treatments may result in ineffective prepara-
tions due to phage inactivation. However, advanced
manufacturing techniques are now utilized for phage purifica-
tion. Moreover, determination of the phage titer and viability
is essential [83].
Safety on the other hand is a very important parameter, as
issues related to the presence of exotoxins and pyrogens released
during bacterial lysis by bacteriophages have always raised seri-
ous safety concerns. Consequently, bacteriophage manufacturing
for clinical use must be optimized to eliminate bacterial exotox-
ins and pyrogens [60]. Early therapeutic phage preparations suf-
fered from inefficient purification resulting in crude lysates of
the host bacteria in the preparation [84]. Efficient purification
can be achieved by ammonium sulfate precipitation and also by
CsCl gradient centrifugation [84]. Ultrafiltration and two-step
chromatography were also used [84]. However, the purification
procedures have witnessed considerable evolution in the past few
years. Recently, Kramberger and coworkers [85] utilized methac-
rylate monoliths columns in S. aureus phage purification from a
lysate of bacterial cells. This method resulted in recovery of
60% of viable phages in a single purification step [85]. In this
context, Gill and Haymen, published an interesting review
exploring the different available methods for bacteriophage puri-
fication as well as the different levels of purification required for
different applications together with the current protocols utilized
in the commercial production of different products of phage
therapy [83]. Standard purification techniques should be devel-
oped to achieve clinical grade bacteriophage preparations.
Regulatory approval
Despite the successful application of phage therapy for decades
in some eastern countries such as Poland and the former Soviet
republics, especially Georgia and Russia [86], their clinical data
failed to gain regulatory approval because such data were not
developed under the regulatory authorities frameworks.
A major hurdle in the way of phage becoming part of the
mainstream medicine is the absence of well-defined guidelines
for regulatory approval of phage. Instead, phage is regulated
according to existing guidelines developed for typical
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antibacterials [7], meaning that every component of the thera-
peutic cocktail of phages must undergo individual clinical trials
and that the composition of the approved phage cocktail can-
not be changed without re-approval. Such regulations do not
take into consideration the differences between phages and
antibiotics. Fortunately, there exists a regulatory framework
that could be applied for phage therapy, which is that of the
influenza live-virus vaccine. Such a vaccine is formulated from
a cocktail of three or four influenza strains that the FDA has
approved to be reformulated annually according to the circulat-
ing flu strain [7].
However, with the recent approval of different phage prepara-
tions in food and agriculture together with the approval of some
clinical trials, the situation may be improving. Recently some
Phase I studies have been carried out and published [87], whereas
others are being conducted but to date have not been pub-
lished [53]. In 2009, Biocontrol Ltd Company (Nottingham,
UK) has completed randomized, double-blind, placebo-con-
trolled, fully regulated Phase II clinical trial for phage therapy
against Pseudomonas infections in the western world [54]. Another
FDA-approved Phase I clinical trial in 2008 used phage to target
P. aeruginosa, E. coli, and S. aureus in venous ulcers [87].
An important approach that should be considered by the
regulatory authorities is regulating phages for the ‘pharmacy
approach’. The approach allows phage cocktails to be custom
made by licensed hospital pharmacists from current Good
Manufacturing Practice phage preparations instead of all hospi-
tals using the same preparations [7].
In Europe, and pending resolution of regulatory issues, phage
therapy is used under the supervision and responsibility of medi-
cal ethical committees within the approval of the World Medical
Association Declaration of Helsinki [88,89]. This is only a tempo-
rary solution that will not result in efficient introduction of
phage therapy into the western or the rest of the world [53].
Patentability
Recently, a patent by Heo and coworkers was granted and was
based on bacteriophage MPK6, a novel bacteriophage belong-
ing to the order Caudovirales, and its pharmaceutical composi-
tion for treating P. aeruginosa [90,91]. The issue of phage
patentability resembles that of patenting monoclonal antibod-
ies, where in both cases a wide array of potential targets exist
and the methodology for their discovery is common knowl-
edge. Individual bacteriophages are patentable where they can
be put under the Budapest treaty in an approved collection [92].
However, in both the cases, there are always other agents
(either antibodies or phages) that can be discovered, isolated
and optimized to formulate even more efficient bacteriophage
preparations [53]. The European patent laws allow patenting of
known phages provided that the use of these phages has not
been disclosed [93]. Moreover, the new phage formula can be
patented [53]. The European patent office necessitates a certain
technical intervention for isolating phage from its natural envi-
ronment, as well as proper characterization of the isolated
phage. For the US Patent and Trademark Office, however,
only genetically engineered bacteriophages can meet the patent
regulations. Several patents, however, have been granted by the
US patent office, including a patent for reduction of sepsis
with a pharmaceutical preparation including bacteriophages, as
well as other patents approved for using phage in the food sec-
tor. A detailed discussion of patent issues related to therapeutic
use of phage is described elsewhere [93–95].
Expert review
The regulatory approval of phage consumption in food pro-
vides a validation for its safety for humans. Thus, the main
hurdles still facing the regulatory approval of phage as thera-
peutics include the need for more clinical evidence for its thera-
peutic efficacy as well as new or modified regulatory guidelines.
Such clinical evidence must be supported by detailed data on
phage immunogenicity, pharmacokinetics and formulations.’
Some approaches for overcoming the challenges that hinder
the approval of such an important therapeutic are discussed
below.
. Bacteriophages act as exogenous antigens inducing a humoral
reaction due to the presence of immunogenic epitopes in
phage proteins [64]. Masking or modifying these recognition
epitopes is needed to improve phage blood circulation and
decrease immunogenic response. Chemical modification
through PEGylation of the bacteriophages and/or addition of
biocompatible moieties can be used to improve phage phar-
macokinetics and decrease its immunogenicity [61,63].
. Phage pharmacokinetics. The basic kinetic principles of self-
replicating phages have been recently addressed in a number
of important studies [7,64] which will allow better experimen-
tal design and data interpretation. There is still a need to
develop kinetic models describing the density dependent bac-
teria–phage interactions [8].
. Optimization of the formulation and long-term stability. A
small-scale quality controlled production of defined bacterio-
phage cocktail for use in human was developed and resulted
in approved clinical trials [71].
. The approval of phage in food (TABLE 1) should motivate
researchers and the pharmaceutical industry to pursue more
clinical evidence for its therapeutic efficacy and to work with
the regulatory agencies to develop new guidelines for phage
therapy. This is now important with the alarming rise of bac-
terial resistance and the low number of new antibiotics
introduced [86].
Five-year view
The application of bacteriophages in different food sectors is
expected to increase supported by the regulatory approval of
different phage products (TABLE 1).
With the alarming increase in bacterial resistance together
with the decreased number of new antibiotics, the current regu-
latory guidelines may be modified in favor of phage therapy.
Developing specific and simple tests that allow rapid identifi-
cation of the causative bacterial strain as well as their phage
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susceptibility is one of the major areas that will aid in phage
adoption as therapeutics. Along this line, nano-based tests will
be one of the fast developing areas in the upcoming years [96].
It is expected that stable phage formulations alone or with
other antibiotics or natural antibacterials may be developed
with the aid of novel nanomaterials [97].
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Key issues
. In 2011, the WHO has made the call ‘No action today, no cure tomorrow’ raising the need for immediate solutions against the serious
problem of bacterial resistance.
. Phage holds a substantial antibacterial potential as a therapeutic and a bio-control agent in food.
. In 2006, US FDA approved the first phage product to be applied directly to ready-to-eat meat.
. Different challenges are still in the way for approval of phage therapy, such as: immunogenicity, pharmacokinetics, systemic side
effects, narrow host range, bacterial resistance, manufacturing safety and efficacy, regulatory approval and patentability.
. The regulatory approval for phage consumption in food should motivate the pharmaceutical industry and scientific community for
developing bacteriophage therapeutics.
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